Role of Cannabinoid Type 1 Receptor in Locus Coeruleus Activity: Implications for Therapeutic Intervention in Stress-Induced Psychiatric Disorders by Wyrofsky, Ryan Rudolph
	   	  
 
 
 
 
 
ROLE OF CANNABINOID TYPE 1 RECEPTOR IN LOCUS COERULEUS 
ACTIVITY: IMPLICATIONS FOR THERAPEUTIC INTERVENTION IN 
STRESS-INDUCED PSYCHIATRIC DISORDERS 
 
 
A Thesis 
Submitted to the Faculty 
of 
Drexel University College of Medicine 
by 
Ryan Rudolph Wyrofsky 
in partial fulfillment of the 
requirements for the degree 
of 
Doctor of Philosophy 
March 2018 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
	   ii	  	  
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
 
 
 
 I would like to express my extreme gratitude towards Dr. Elisabeth Van 
Bockstaele for accepting me into her lab as her first student upon transferring to Drexel 
University College of Medicine.  Her mentorship has taught me how to write, think, and 
present like a scientist, and she has opened many exciting doors and provided me with 
tremendous opportunities to advance my research and career.  Another key person in the 
Van Bockstaele lab is Dr. Beverly Reyes, to whom I am also beyond thankful.  Her 
constant encouragement and eagerness to teach has made such a positive impact on me, 
both scholastically and personally.  A large portion of this thesis would not have been 
possible without Dr. Lynn Kirby, who I had the privilege to work with at Temple 
University.  Through her guidance and support, the once daunting electrophysiology is 
now a technique that I both understand and enjoy.  I would be amiss to not also thank 
several members of the Kirby lab who have helped train me throughout my time there, 
including Dr. Chen Li, Daniel Kalamarides, Dr. Jonathan Palma, and Dr. Linnet Ramos.  
I appreciate the time and energy Dr. Paul McGonigle, Dr. Ole Mortensen, and Dr. Wei 
Du have spent with me discussing my project both in and out of committee meetings, and 
providing their insight, expert opinions, and encouragement.  And to Carolann Imbesi, 
Carmen Cruz-Adames, and Elizabeth Kopen – thank you for assisting me with anything I 
have needed over the past five years, from help with grant submissions to a little gossip 
	   iii	  	  
and laughter.  Finally, Dr. Olympia Meucci (and former chair Dr. Jim Barrett), I am very 
lucky to have joined such a positive and collaborative department, which I believe is 
largely accredited to your efforts and constant drive to make our floor the best that it can 
be. 
 Without my family and friends, this would have been a much more arduous 
journey, and one that I doubt I would have completed.  Whenever I stumbled or faltered, 
your constant support, encouragement, and love pushed me through.  To Cat Theisen, 
Melissa Urquhart, Tara Retson, and all other labmates past and present, especially Jenn 
Ross, who has been a constant in my research life for over three years – thank you for the 
good times, coffee chats, and putting up with my eclectic taste in music.  Continue 
inspiring those around you, as you have done for me. 
 Most importantly, to my parents, Kathy and Rod, my sister, Tara, and my 
grandparents, Loretta and Charles – your love has been a constant throughout my life.  I 
most certainly would not be the person I am today if it were not for your guidance, 
support, and the values that you have instilled in me. 
 To those aforementioned and the many others who have influenced my research 
and life over the past five years, from the bottom of my heart, thank you. 
 
 
 
 
 
 
 
 
 
 
 
 
	   iv	  	  
 
 
 
 
 
TABLE OF CONTENTS 
 
 
 
 
INTRODUCTION……………………………………………………………………….1 
     The Endocannabinoid System………………………………………………………….2 
     eCB, Mood, and Psychiatric Disorders………………………………………………..6 
     Targeting the eCB system……………………………………………………………...8 
     eCB and the Locus Coeruleus………………………………………………………...14 
     Effect of eCB on Stress Response……………………………………………………..17 
     Sex Differences………………………………………………………………………..20 
     Goals of Thesis………………………………………………………………………..23 
 
CHAPTER 1 
Effect of cannabinoid type 1 receptor deletion on locus coeruleus-norepinephrine 
neurons and corticotropin releasing factor-mediated responses………………………..25 
     Abstract……………………………………………………………………………….27 
     Introduction…………………………………………………………………………...28 
     Methods……………………………………………………………………………….31 
          Animals……………………………………………………………………………31 
          Drug preparation and administration…………………………………………….32 
          Electrophysiology…………………………………………………………………33 
          Data analysis for electrophysiology………………………………………………36 
          Protein extraction…………………………………………………………………36 
          Western blot analysis……………………………………………………………...37 
          ELISA……………………………………………………………………………...39 
          Data analysis for Western blot and ELISA………………………………………..40 
     Results………………………………………………………………………………...41 
	   v	  	  
          Heightened LC-NE activity in male CB1r-KO mice………………………………41 
          Sex differences in cellular adaptations following cannabinoid receptor deletion..49 
          Loss of CRF-induced increases in LC-NE excitability In CB1r-KO mice………...53 
     Discussion…………………………………………………………………………….60 
          Methodological considerations……………………………………………………61 
          CB1r-KO increases in LC-NE excitability in males but not females……………...63 
          Loss of CRF-mediated responses in CB1r-KO mice………………………………68 
          Implications for pharmacotherapies………………………………………………71 
     Acknowledgements……………………………………………………………………73 
     References…………………………………………………………………………….74 
 
CHAPTER 2 
Co-localization of the cannabinoid type 1 receptor with corticotropin releasing factor 
containing afferents in the noradrenergic nucleus locus coeruleus: implications for the 
cognitive limb of the stress response…………………………………………………….80 
     Abstract……………………………………………………………………………….82 
     Introduction…………………………………………………………………………...83 
     Methods……………………………………………………………………………….86 
          Animals……………………………………………………………………………86 
          Immunofluorescense………………………………………………………………87 
          Anterograde transport…………………………………………………………….90 
          Electron microscopy………………………………………………………………93 
          Controls and data analysis………………………………………………………..95 
          Identification of immunogold-silver labeling in profiles………………………….96 
     Results………………………………………………………………………………...97 
          CB1r localization in LC: co-existence with CRF…………………………………97 
          Ultrastructural localization of CRF and CB1r in the LC………………………..103 
          CRF and CB1r co-localization and inhibitory and excitatory synapses in LC….104 
          CB1r and CRF co-localize in amygdalar projections to the LC………………...112 
     Discussion…………………………………………………………………………...115 
          Methodological considerations…………………………………………………..116 
	   vi	  	  
          CRF regulation of LC neurons: implications for modulation by CB1r………….117 
          Functional implications………………………………………………………….123 
     References…………………………………………………………………………...126 
 
CHAPTER 3 
Effect of social stress on the endocannabinoid system in the locus coeruleus…………139 
     Abstract……………………………………………………………………………...140 
     Introduction………………………………………………………………………….141 
     Methods……………………………………………………………………………...143 
          Resident-intruder paradigm……………………………………………………...143 
          Protein extraction and quantification……………………………………………144 
          Western blot analysis…………………………………………………………….145 
          Data analysis…………………………………………………………………….146 
     Results……………………………………………………………………………….146 
          Effect of social stress on eCB protein expression in the LC……………………..146 
          Effect of social stress on CRFr1 expression in the LC…………………………..151 
     Discussion…………………………………………………………………………...152 
          Differences in DGL expression across phenotypes……………………………...152 
          Functional consequences………………………………………………………...154 
     Acknowledgements………………………………………………………………......155 
     References…………………………………………………………………………...156 
 
DISCUSSION………………………………………………………………………….160 
     Overall Conclusions…………………………………………………………………161 
     Research implications across studies……………………………………………….162 
          Role of eCB system in LC-NE activity…………………………………………...163 
          Working model of eCB regulation of LC-NE activity……………………………167 
          Sex differences in eCB regulation of LC-NE activity…………………………….170 
     Future directions…………………………………………………………………….172 
     Practical applications……………………………………………………………….173 
          Effects of cannabinoids on fear and PTSD………………………………………173 
	   vii	  	  
          Therapeutic potential for the treatment of psychiatric disorders………………..177 
 
REFERENCES………………………………………………………………………...183 
 
APPENDICES…………………………………………………………………………207 
 Appendix A: Permission for Reuse from Taylor & Francis………………….....208 
 Appendix B: Permission for Reuse from Springer Nature……………………...209 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   viii	  	  
 
 
 
 
 
LIST OF TABLES 
 
 
 
 
Table I:  Summary of drugs and compounds that are known to target the eCB 
                    system………………………………………………………………………...9 
 
Table II:  Summary of the clinical progression of endocannabinoid-based drugs tested 
                     for the treatment of psychiatric disorders………………………………….13 
 
Table I.I:  Characterization of the primary antibodies used for immunofluorescence 
                      microscopy (IF) and Western blotting (WB) ……………………………...38 
 
Table I.II:  Action potential and after-hyperpolarization characteristics of LC-NE  
                        neurons before and after 300 nM CRF bath application in wild type (WT) 
                        and CB1r-knock out (KO) male and female mice………………………..57 
 
Table II.I:  Characterization of the primary antibodies used for immunofluorescence  
                        microscopy (IF) and electron microscopy (EM) ………………………...88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   ix	  	  
 
 
 
 
 
 
 
 
 
 
LIST OF ILLUSTRATIONS 
 
 
 
 
Figure 1:  The endocannabinoid system………………………………………………….4 
 
Figure 2:  Parallel engagement of stress responses……………………………………...21 
 
Figure 1.1:  CB1r deletion causes an increase in LC-NE excitability in male mice……42 
 
Figure 1.2:  Confirming electrophysiological data in obtained from NE producing cells 
                          within the LC…………………………………………………………...45 
 
Figure 1.3:  Western blot and ELISA analyses of NE indices in the LC and mPFC of 
                          male and female WT and CB1r/CB2r-KO mice………………………..47 
 
Figure 1.4:  Western blot analysis of α2-adrenoreceptor (α2-AR), corticotropin releasing 
                          factor (CRF), and norepinephrine transporter (NET) expression in the LC 
                          and mPFC in male and female WT and CB1r/CB2r-KO mice…………50 
 
Figure 1.5:  CB1r deletion disrupts CRF-induced increases in LC-NE excitability in male 
                          and female mice………………………………………………………...54 
 
Figure 1.6:  Sex, genotype, and CRF treatment affect the after-hyperpolarization (AHP) 
                          duration of LC-NE neurons…………………………………………….58 
 
Figure 1.7:  Schematic depicting the effects of CB1r deletion on LC-NE indicies.…….65 
 
Figure 2.1:  Secondary antibodies show no cross-reactivity……………………………91 
 
Figure 2.2:  CB1r is localized presynaptically in the LC………………………………..98 
 
Figure 2.3:  CB1r is co-localized with CRF in the LC………………………………...100 
 
Figure 2.4:  CRF-containing afferents co-localize with CB1r in the LC………………105 
	   x	  	  
 
Figure 2.5:  CB1r and CRF co-localize with GAD in the LC…………………………108 
 
Figure 2.6:  CB1r and CRF co-localize with VGlut in the LC………………………...110 
 
Figure 2.7:  CB1r and CRF co-localize in PHAL-labeled amygdalar afferents to 
                          the LC………………………………………………………………….113 
 
Figure 2.8:  Functional consequences of eCB modulation of CRF afferents………….118 
 
Figure 3.1:  Western blot analysis of diacylglycerol lipase α (DGL) and fatty acid 
                         amide hydrolysis (FAAH) in male and female rats following 5 days 
 of social stress………………………………………………………….147 
 
Figure 3.2:  Western blot analysis of corticotropin releasing factor type 1 receptor 
 (CRFr1) in male and female rats following 5 days of social stress……149 
 
Figure 3:  Schematic depicting alterations to LC-mPFC microcircuit in male CB1r-KO 
                      mice………………………………………………………………………165 
 
Figure 4:  Working model for eCB modulation of LC following chronic stress………168 
 
Figure 5:  Schematic diagram depicting cannabinoid-adrenergic interactions in stress- 
          integrative circuitry………………………………………………………175 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   xi	  	  
 
 
 
 
 
 
 
 
 
 
LIST OF SYMBOLS and ABBREVIATIONS 
 
 
 
 
µg     micrograms 
µm     micrometers 
2-AG     2-arachidonylglycerol 
4V     fourth ventricle 
ABC     avidin-biotin complex 
aCSF     artificial cerebrospinal fluid 
AEA     N-arachidonylethanolamide/anandamide 
AHP     afterhyperpolarization potential 
ANOVA    analysis of variance 
AP     action potential 
AR     adrenoceptor 
Bar     Barrington’s nucleus 
BLA     basolateral amygdala 
BNST     bed nucleus of the stria terminalis 
BSA      bovine serum albumin 
C     Celsius 
Ca2+     calcium 
cAMP     3’,5’-cyclic adenosine monophosphate 
CB     cannabinoid 
CBD     cannabidiol 
CBr     cannabinoid receptor 
CB1r     cannabinoid type 1 receptor 
CB2r     cannabinoid type 2 receptor 
CeA     central nucleus of the amygdala 
CNS      central nervous system  
CRF     corticotropin releasing factor 
CRFr     corticotropin releasing factor receptor 
CRFr1     corticotropin releasing factor receptor type 1 
DA     dopamine 
DAB     3,3’-diaminobenzidine tetrahydrochloride dihydrate 
DAPI     4’,6-diamibino-2-phenylindole 
	   xii	  	  
DAT     dopamine transporter 
eCB     endocannabinoid 
ELISA     enzyme-linked immunosorbent assay 
EM     electron microscopy 
FAAH     fatty acid amide hydrolase 
FITC     fluorescein isothiocyanate 
FST     forced swim test 
GABA     gamma-aminobutyric acid  
GAD     glutamic acid decarboxylase 
GAPDH    glyceraldehyde 3-phosphate dehydrogenase 
h     hours 
HPA     hypothalamic-pituitary adrenal (axis) 
IF     immunofluorescence 
k+     potassium 
kDa     kilodaltons 
KO     knockout 
KOR     κ-opioid receptor 
LC     locus coeruleus 
M     molar 
MAO     monoamine oxidase 
MGL     monoacylglycerol 
min     minutes 
mL     milliliters 
MΩ     megaohms 
MOR     µ-opioid receptor 
mPFC     medial prefrontal cortex 
mRNA     messenger ribonucleic acid 
ms     milliseconds 
mV     millivolts 
NAPE-PLD     n-acyl-phosphatidylethanolamine-hydrolyzing 
     phospholipase-D 
NE     norepinephrine 
NET     norepinephrine transporter 
NIH     National Institutes of Health 
nm     nanometers 
nM     nanomolar 
NPY     neuropeptide Y 
pA     picoamps 
PAG      periaqueductal gray 
PB     phosphate buffer 
PBS     phosphate buffer saline 
PC      Pearson’s coefficient 
PFC     prefrontal cortex 
pg     picograms 
PGi      paragigantocellularis 
PHAL     phaseolus vulgaris-leucoagglutinin 
	   xiii	  	  
PLCb     phospholipase C b 
POD      peroxidase 
PrH      nucleus prepositus hypoglossi 
PTSD     posttraumatic stress disorder 
PVDF     polyvinylidene 
PVN     paraventricular nucleus 
rpm     rotations per minute 
sec (s)     seconds 
SEM     standard error of means 
SN     substantia nigra 
SNARE    soluble NSF attachment protein receptor 
syn     synaptophysin 
TBS     tris buffered saline 
TH     tyrosine hydroxylase 
THC     Δ-9 tetrahydrocannabinol 
TMB      tetramethylbenzidine 
TRITC     tetramethylrhodamine 
TRPV1    transient receptor potential vanilloid receptor type 1 
TST     tail suspension test 
VGlut     vesicular glutamate transporter 
WB      Western blot 
WT     wild type 
Y1     neuropeptide Y receptor type 1 
Y2     neuropeptide Y receptor type 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   xiv	  	  
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
Role of cannabinoid type 1 receptor in locus coeruleus activity: 
Implications for therapeutic intervention in stress-induced psychiatric disorders 
Ryan Rudolph Wyrofsky 
Elisabeth Van Bockstaele 
 
 
 
 
Cannabinoids have profound effects on mood and behavior, in part through their 
modulation of the stress-integrative locus coeruleus (LC)-noradrenergic system.  
Cannabinoid type 1 receptor (CB1r) agonists are capable of increasing noradrenergic 
activity and anxiety-like behaviors; however, they can also decrease stress-induced 
anxiety.  In order to more closely examine the role of CB1r in regulating LC-
norepinephrine (NE) activity, whole-cell patch clamp electrophysiology was performed 
on LC-NE neurons from CB1r-knockout (KO) mice.  Since sex differences are found 
within the endocannabinoid (eCB) system, stress signaling, and the prevalence of 
psychiatric disorders, both males and females were examined.  CB1r deletion caused an 
increase in LC-NE excitability, input resistance, and NE levels in the prefrontal cortex in 
male mice, but not females.  Additionally, stress peptide corticotropin releasing factor 
(CRF)-induced increases in LC-NE excitability are lost in CB1r-KO mice.  Western blot 
analysis revealed an increase in CRF and tyrosine hydroxylase expression levels, and 
decrease in norepinephrine transporter expression in male CB1r-KO compared to WT in 
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the LC, and an increase in α2-adrenoceptor expression in female CB1r-KO compared to 
WT.  Next, immunoelectron and immunofluorescence microscopy determined the 
cellular localization of CB1r with respect to the CRF in the LC, showing co-localization 
of CB1r to CRF-containing amygdalar afferents.  Finally social stress, which leads to 
anxiety-like behaviors, differentially alters eCB system protein levels in the LC in 
resilient and non-resilient populations of rats across sexes.  These results expand the 
understanding of cannabinoid-CRF-adrenergic interactions, and how targeting CB1r 
could provide therapeutic relief for anxiety disorders.  
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INTRODUCTION 
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The Endocannabinoid System 
Cannabis sativa, or marijuana, is one of the most widely used illicit drugs, known 
to promote relaxation, euphoria, and a feeling of contentment (Velez et al., 1989, Green 
et al., 2003, Di Marzo et al., 2004).  Chronic use, however, can be accompanied by 
dysphoria, depressive mood, and increased anxiety (Reilly et al., 1998), with the severity 
of symptoms being exacerbated by exposure to greater concentrations and increased 
frequency of usage (Lee et al., 2009).  The first pharmacologically active compound 
identified in C. sativa, D-9 tetrahydrocannabinol (THC), was characterized in 1964 and 
has since been established as its primary psychoactive component (Gaoni and 
Mechoulam, 1964, Micale et al., 2013).  Since its discovery, over 100 additional active 
components of C. sativa have been identified (Micale et al., 2013). 
The first cannabinoid receptor, cannabinoid type 1 receptor (CB1r), was identified 
in 1988 and a second receptor, cannabinoid type 2 receptor (CB2r), was characterized in 
1993 (Devane et al., 1988, Di Marzo et al., 2004).  Both are Gi/o protein-coupled 
receptors with distinct distributions in the body (Castillo et al., 2012).  CB1r are one of 
the most abundant G-protein-coupled receptors in the brain and their activation most 
commonly results in the inhibition of neurotransmitter release (Herkenham et al., 1990, 
Castillo et al., 2012).  CB2r are most prevalent in the immune system (Van Sickle et al., 
2005, Castillo et al., 2012); however, recent studies suggest a presence in the CNS as 
well, showing CB2r localization in the hippocampus, substantia nigra (SN), 
periaqueductal gray matter, and parvocellular reticular nucleus (Brusco et al., 2008, 
Onaivi et al., 2008).  Following the identification of the cannabinoid receptors, 
endogenous cannabinoid ligands, or eCBs, were discovered.  The first was N-
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arachidonylethanolamide (AEA), which was named ‘anandamide’ after the Sanskrit word 
meaning ‘bliss’ (Devane et al., 1992, Di Marzo et al., 2004).  Another well-characterized 
eCB is 2-arachidonoylglycerol (2-AG), first isolated from canine intestines by 
Mechoulam et al. in 1995 (Mechoulam et al., 1995).  It is now generally accepted that 2-
AG is a full CB1r and CB2r agonist, whereas AEA, which is less potent, is a partial 
agonist (Sugiura, 2009).  Initially, the mechanism proposed for eCB release involved a 
depolarization-induced event followed by retrograde signaling and binding of the 
endogenous ligand to presynaptically distributed receptors (Castillo et al., 2012, Wang 
and Lupica, 2014).  New evidence suggests that eCB can regulate synaptic transmission 
via non-retrograde and autocrine mechanisms, with CB1r having been discovered 
postsynaptically (Bacci et al., 2004).  Furthermore, eCBs can bind and activate transient 
receptor potential vanilloid receptor type 1 (TRPV1) receptors (Castillo et al., 2012). 
The rate of eCB synthesis and degradation determines their signaling profiles.  
Two primary mechanisms are known to be responsible for 2-AG synthesis: increases in 
intracellular Ca2+ via postsynaptic depolarization and activation of phospholipase C β 
(PLCβ) via stimulation of group I metabotropic glutamate receptors.  PLCβ forms 
diacylglycerol from the hydrolysis of phosphatidylinositol, which diacylglycerol lipase α 
(DGL) then converts to 2-AG (Blankman et al., 2007, Castillo et al., 2012).  
Monoacylglycerol lipase (MGL) is the main enzyme responsible for breaking down 2-
AG, rendering it inactive and thus controlling the strength and duration of its modulatory 
activity (Craft et al., 2013).  The synthesis and degradation of AEA is more complex.  
Though it is known that increases in intracellular Ca2+ and postsynaptic depolarization 
stimulate AEA formation, the mechanism underlying this process has yet to be elucidated  
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Figure 1 
The endocannabinoid system. 
 
CB
1r 
	   5	  	  
Figure 1: The endocannabinoid system. This schematic illustrates the basic 
components of the endocannbinoid system. Postsynaptic depolarization and influx of 
Ca2+ stimulates eCB synthesis. N-acyl-phosphatidylethanolamine-hydrolyzing 
phospholipase-D (NAPE-PLD) is the main enzyme responsible for synthesizing 
anandamide (AEA), while diacylglycerol lipase (DGL) synthesizes 2-arachidonylglycerol 
(2-AG). These eCBs can then cross through the membrane and diffuse across the 
synapse, where they retrogradely activate presynaptic cannabinoid type 1 receptors 
(CB1r). Presynaptic monoacylglycerol (MGL) then metabolizes 2-AG, and fatty acid 
amide hydrolysis (FAAH) breaks down AEA. 
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(Di Marzo,2011).  N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase-D 
(NAPE-PLD) has been identified as a contributor to AEA synthesis, but other synthetic 
pathways have also been reported (Okamoto et al., 2007).  AEA is primarily degraded by 
fatty acid amide hydrolase (FAAH) and, similar to MGL for 2-AG, FAAH controls the 
spatiotemporal profile for AEA signaling (Castillo et al., 2012).  In contrast to the 
activity-dependent classical eCB signaling, tonic eCB release has been observed in 
several brain regions (Castillo et al., 2012).  A schematic summary of eCB synthesis and 
degradation can be found in figure 1. 
 
eCB, Mood, and Psychiatric Disorders 
According to the National Institute of Mental Health, within a given year, 
approximately 9.5% of the adult population within the United States (US) suffers from a 
form of depression and 18.1% from anxiety disorders.  The third largest cause of 
hospitalization for individuals aged 18-44 are Major Depressive Disorder and other mood 
disorders (Department of Health & Human Services, 2009), and the US spends circa 
$193.2 billion per year on serious mental illnesses (Insel, 2008).  These statistics clearly 
show the significant impact psychiatric disorders have on the US population. 
Recognition of the involvement of the eCB system in the regulation of mood and 
specifically its role in depression and anxiety arose, in part, from observations obtained 
from symptomatic individuals (Parolaro et al., 2010, Hauer et al., 2013).  A significant 
increase in CB1r density and efficacy was reported in the dorsolateral prefrontal cortex 
(PFC) of depressed suicide victims, suggesting that altered functioning of the eCB system 
in the PFC could contribute to depression (Hungund et al., 2004, Parolaro et al., 2010).  
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Several other studies examined dysregulation of the eCB system in individuals suffering 
from PTSD and discovered that PTSD patients had greater CB1r availability throughout 
the brain as well as a significant decrease in AEA plasma concentrations (Hauer et al., 
2013, Neumeister et al., 2013). 
Genetic manipulations of the eCB system in animal models, particularly CB1r 
knockout (KO) mice, have provided insight into how eCB signaling affects behavior. 
CB1r KO mice exhibit an increase in passive behaviors compared to wild-type (WT) 
mice in the forced swim test (FST), which is typically interpreted as a depressive 
phenotype (Steiner et al., 2008).  They also show an increase in immobility time 
compared to WT mice in another animal model of depression, the tail suspension test 
(TST) (Aso et al., 2008).  Additionally, when exposed to chronic mild stress, KO mice 
develop anhedonia at a faster rate than WT mice, suggesting an increase in vulnerability 
to chronic stress (Martin et al., 2002).  In behavioral paradigms measuring anxiety-like 
behaviors, such as the elevated plus-maze, open-field test and light-dark box, CB1r KO 
mice exhibited increased anxiety-like behaviors (Parolaro et al., 2010).  CB1r KO mice 
display hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis and higher levels 
of circulating corticosterone following stressor exposure, a response that is also 
commonly observed in depressed patients (Uriguen et al., 2004). 
Pharmacological approaches also support a role for the eCB system in mediating 
depression and anxiety.  Acute administration of CB1r agonists decreases the amount of 
behavioral despair observed in the FST, and similar antidepressant-like effects are 
observed in the FST and TST following chronic administration (Gobbi et al., 2005, 
Bambico et al., 2007).  In support of this, injection of CB1r agonists directly into brain 
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regions that are known to be involved with emotion reduces the depressive phenotype 
(Parolaro et al., 2010).  Consistent with these preclinical findings, Rimonabant, a CB1r 
antagonist originally intended as an antiobesity drug, was withdrawn from clinical trials 
due to significant undesirable side effects including depression and suicidal ideation 
(Nissen et al., 2008).  Concerns about mood-altering side effects resulted in the 
withdrawal of several other CBr antagonists from clinical trials, including Taranabant and 
Otenabant from Phase III trials and Ibipinabant and Surinabant from Phase II trials (Le 
Foll et al., 2009).  These results provide evidence for a potential protective role of the 
eCB system in the development and treatment of depression and anxiety. 
Moreover, the ability of the eCB system to more broadly affect monoaminergic 
neurotransmission may underlie, in part, cannabinoids’ effects on mood.  For example, 
FAAH inhibitors and CB1r agonists enhance serotonergic neurotransmission (Gobbi et 
al., 2005, Bambico et al., 2007), CB1r activation can stimulate the release of 
norepinephrine (NE), and cannabinoid receptor agonists stimulate dopamine (DA) efflux 
in the cortex (Gobbi et al., 2005).  Many traditional antidepressants function via targeting 
monoamines (Wyrofsky et al., 2015); therefore, these findings indicate that eCBs may be 
neuroprotectective against the development of psychiatric disorders.  
 
Targeting the eCB System 
There are a wide variety of ways in which the eCB system can be targeted and 
modulated (Table I).  The most direct method is by utilizing CB1r or CB2r agonists and 
antagonists to increase or decrease eCB signaling, respectively.  Numerous selective and  
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Table I:  Summary of drugs and compounds that are known to target the eCB system. 
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nonselective agonists and antagonists have been synthesized and characterized (Table I) 
and have been useful tools in elucidating the role of the eCB system.  Several of these 
compounds have advanced to clinical trials over the past decade or two, though 
predominantly they have been tested for the treatment of pain, inflammation, 
neurodegenerative disorders, nausea, obesity, and nicotine and alcohol dependence 
(Okamoto et al., 2007, Wyrofsky et al., 2015). 
eCB signaling can also be modified by targeting the synthetic and metabolic 
enzymes of AEA and 2-AG (Table I).  By inhibiting FAAH and MGL, eCB levels can be 
increased, allowing for greater signaling to occur.  Conversely, by inhibiting eCB 
synthesis, eCB levels are decreased resulting in less signaling.  Finally, the eCB 
degradative enzymes are located intracellularly, so by blocking eCB uptake into the pre- 
or postsynaptic cell, eCB levels will remain high and signaling will be increased (Di 
Marzo et al., 2004).  These methods allow more fine-tuning of the eCB system as 
opposed to the CB1r agonists and antagonists, and many of these approaches have also 
been utilized to test the effects of altered eCB signaling in preclinical models of 
psychiatric disorders.  More recently, eCB-based drugs have begun clinical testing for the 
treatment of various psychiatric disorders, including schizophrenia, post-traumatic stress 
disorder (PTSD), and depression (Table II). 
Recently, allosteric CB1r agonists have been identified, which has important 
implications for drug discovery, as allosteric compounds allow for the modulation of 
signaling without completely inducing or blocking receptor responses as traditional 
agonists and antagonists would do (May et al., 2007).  Price et al. identified the first 
allosteric CB1r modulators in 2005.  They discovered three Organon compounds that all 
	   13	  	  
Table II:  Summary of the clinical progression of endocannabinoid-based drugs tested 
for the treatment of psychiatric disorders. 
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enhanced agonist affinity for the CB1r; however, they function as insurmountable 
antagonists, decreasing the Emax value for CB1r agonists and increasing the length of 
time it takes for the agonists to dissociate from the receptor (Price et al., 2005).  
Subsequent research has shown that Org-27569 might in fact function as a biased ligand, 
decreasing coupling to cAMP and β-arrestin signaling while increasing Gα-independent 
ERK phosphorylation and stimulating receptor internalization (Ahn et al., 2012).  This 
compound was tested in several in vivo rodent studies but failed to alter CB1-mediated 
effects of AEA, CP 55,940 (a CB1r agonist), and THC in anti-nociception, catalepsy, and 
hypothermia (Gamage et al., 2014); however, other eCBs were not tested in conjunction 
with Org-27569, nor were psychiatric effects evaluated.  PSNCBAM-1 appears to have a 
similar profile to Org-27596, functioning as a negative allosteric CB1r modulator.  In 
vivo studies, though, have shown it to be effective in an acute food-intake model 
(Horswill et al., 2007).  Additionally, several positive allosteric modulators of CB1r 
activity have been identified and in particular, carbozamides have been found to 
selectively enhance CB1r activity (Piscitelli et al., 2012).  Lipoxin A4 enhances AEA-
induced nociception and catalepsy in various mouse models (Pamplona et al., 2012, 
Pertwee, 2012).  Finally, RTI-371, a selective DAT inhibitor, has also been found to 
increase CP 55940 signaling in vitro in a concentration-dependent fashion (Navarro et al., 
2009). 
 
eCB and the Locus Coeruleus 
It is known that the noradrenergic system plays a key role in the modulation of 
emotional states, mood, and arousal (Carvalho and Van Bockstaele, 2012).  The locus 
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coeruleus (LC), a dense region of noradrenergic neurons located off of the fourth 
ventricle in the brainstem, innervates many regions of the neuraxis and provides the sole 
source of NE to the medial prefrontal cortex (mPFC) (Sara, 2009).  Dysregulation of NE 
in the mPFC and other terminal regions can result in the development of many 
psychiatric disorders (Carvalho and Van Bockstaele, 2012).  High levels of NE have been 
correlated with an increased duration of remission in previously depressed patients, 
implicating a potentially protective role of NE (Johnston et al., 1999, Carvalho and Van 
Bockstaele, 2012).  It is well accepted that NE signaling is important in the 
pathophysiology of depression (Carvalho and Van Bockstaele, 2012) and compounds that 
increase NE levels, such as serotonin-norepinephrine reuptake inhibitors, tricyclic 
antidepressants, and monoamine oxidase (MAO) inhibitors, are effective antidepressants, 
suggesting that low levels of NE can cause depressive symptoms (Carvalho and Van 
Bockstaele, 2012).  Conversely, other studies have shown that increased noradrenergic 
signaling following stressors plays a role in the pathophysiology of anxiety, PTSD, and 
cognitive deficits associated with depression (Birnbaum et al., 1999, Southwick et al., 
1999, Goddard et al., 2010).  This biphasic effect of NE is not only found in its ability to 
regulate mood, but also alertness and arousal.  Low tonic-low phasic firing of LC-NE 
neurons results in disengagement while high tonic-low phasic firing results in extreme 
arousal but difficulty sustaining attention on a given task.  The optimal LC discharge rate 
for focused attention is in between the two, where phasic and coupled firing occurs 
(Berridge and Waterhouse, 2003).  Interestingly, stress is one factor that can push the LC-
NE discharge rate into the high tonic-low phasic state resulting in both increased arousal 
and increased pathophysiology of psychological disorders. 
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High-resolution neuroanatomical studies have demonstrated coexistence of CB1r 
with noradrenergic axon terminals in this brain region (Carvalho and Van Bockstaele, 
2012).  CB1r are localized both pre- and postsynaptically in the LC (Scavone et al., 
2010).  Most of the presynaptic CB1r were localized to symmetric synapses, indicating 
that they are most likely regulating GABAergic transmission (Carvalho and Van 
Bockstaele, 2012).  The presence of CB1r in noradrenergic neurons (Scavone et al., 
2010) further suggests that the eCB system may modulate noradrenergic activity directly 
without presynaptic modulation of amino acid signaling (Carvalho and Van Bockstaele, 
2012), potentially acting as a subsequent brake on LC activation.  The opposing effects of 
CB1r on noradrenergic terminals decreasing NE release versus CB1r on GABAergic and 
serotonergic terminals increasing NE release also demonstrate the importance of local 
eCB levels in alteration of monoamine neurotransmission (Kirilly et al., 2013). 
Additional studies support eCB regulation of NE signaling.  CB1r agonists 
CP55940 and WIN 55,212-2 increase spontaneous firing and stimulate immediate early 
gene c-Fos expression in LC-NE neurons (Patel and Hillard, 2003, Muntoni et al., 2006).  
Additionally, an increase in Fos expression was observed in dopaminergic neurons 
following treatment with CBr agonists; however, this increase was blocked by co-
treatment with either an α1-adrenoceptor (AR) antagonist or an a2-AR agonist, indicating 
that the CB agonist-induced increase in dopaminergic activation is likely due to LC-NE 
activation (Patel and Hillard, 2003, Carvalho and Van Bockstaele, 2012).  The dose-
dependent increase in LC-NE firing observed after both systemic and central CB agonist 
administration is blocked by co-administration with SR141716A, a CB1r antagonist 
(Mendiguren and Pineda, 2006, Muntoni et al., 2006).  Interestingly, SR141716A 
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administration by itself results in a decrease in LC activity, suggesting that tonic eCB 
production controls the LC under basal conditions (Carvalho and Van Bockstaele, 2012).  
Also, administration of a FAAH inhibitor increases the spontaneous firing rate of LC-NE 
neurons, supporting the notion of tonic eCB regulation of LC neurons (Gobbi et al., 
2005). 
Following CB exposure, increases in NE levels have been observed and may 
involve mechanisms other than disinhibition of LC noradrenergic neurons (Jentsch et al., 
1997).  For example, in vitro studies have shown that CBs can inhibit MAO (Fisar, 
2010). MAO metabolizes monoamine neurotransmitters, so inhibition would produce 
increased NE levels.  CB-induced decreases in α2-AR expression in the LC have been 
observed, which would result in an increase in NE release at postsynaptic targets 
(Carvalho and Van Bockstaele, 2012).  Increases in NE efflux in the PFC have been 
observed following acute and chronic CB administration and pretreatment with 
SR141716A blocks CB-induced increases in NE levels (Oropeza et al., 2005, Page et al., 
2007).  Taken together, these data illustrate alterations in NE signaling following CB 
administration in regions where dysregulation is associated with stress and depressive- 
and anxiety-like effects. 
 
Effect of eCB on Stress Response 
HPA axis hyperactivity is very common in individuals suffering from depression 
and anxiety (Patel et al., 2004, Uriguen et al., 2004).  While glucocorticoid release is 
initially beneficial, priming the body physiologically and metabolically to deal with 
threats, long-term secretion can result in maladaptive cardiovascular, metabolic, and even 
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neurological conditions (McEwen, 2008).  There are negative feedback mechanisms in 
place, allowing glucocorticoids to attenuate HPA axis activity, and studies have shown 
the PFC to be the critical site for this termination (Hill et al., 2011).  
Immunohistochemical data and electron microscopy provide evidence that CB1r in layer 
V of the prelimbic PFC region are found on GABAergic terminals (Hill et al., 2011).  
Genetic deletion of CB1r and injection of CB1r antagonists directly into the PFC produce 
an increase in the stress response and corticosterone levels, further implicating the 
importance of the eCB system in the negative feedback mechanisms on the HPA axis 
(Hill et al., 2011).  Activation of the GABAergic circuits located in either the prelimbic 
PFC or the bed nucleus of the stria terminalis (BNST) results in a decrease in CRF 
release from the PVN (Herman et al., 2005). 
In vivo rat studies have demonstrated that peripheral injection of corticosterone 
causes a swift escalation of eCB levels in the PVN, indicating that stress up-regulates 
hypothalamic eCB levels via a glucocorticoid-mediated mechanism (Hill and McEwen, 
2009).  This has led Hill et al. to propose a model for the influence of the eCB system on 
the temporal phases observed in glucocorticoid feedback.  It is known that stress causes 
the production and release of glucocorticoids into the circulation.  According to the 
model, rapid attenuation of the HPA axis occurs via an increase in eCB synthesis and 
release in the PVN, resulting in the suppression of glutamatergic signaling on CRF-
releasing neurons (Hill et al., 2011).  A longer, time-delayed feedback loop centers on 
eCB production in the mPFC. Circulating glucocorticoids stimulate 2-AG synthesis and 
release in the prelimbic PFC, which then binds to CB1r on GABAergic neurons.  This 
results in the disinhibition of projection neurons that synapse with GABAergic neurons in 
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the BNST, ultimately causing a decrease in signals projecting to the PVN and a 
subsequent decrease in CRF release (Hill et al., 2011).  While it appears that eCBs are 
produced on demand in the above pathways, it has been proposed that tonic AEA 
signaling in the basolateral amygdala (BLA) occurs (Hill and McEwen, 2009).  This is 
the basis for a gatekeeper function, in which tonic eCB tone results in basal inhibition of 
the HPA axis (Hill et al., 2010b).  During acute stress, there is an increase in FAAH 
activity, resulting in a decrease in AEA levels (Hill and McEwen, 2009).  This causes a 
disinhibition of the principal neurons located in the BLA, subsequently leading to an 
increased amygdalar output to various regions including the PVN, stimulating the HPA 
axis (Hill and McEwen, 2009). 
The amygdala is a key structure involved in the regulation of fear and emotional 
memory, and the eCB system plays a role in regulating the amygdala’s response to stress.  
As previously mentioned, stress causes a rapid decrease in AEA levels within the 
amygdala; however, when stress is absent and corticosterone is administered, an increase 
in AEA levels within the amygdala is observed (Hill and McEwen, 2009, Hill et al., 
2010b).  While this might seem contradictory, such a mechanism may be adaptive.  
Activation of the HPA axis is important for escaping and managing an acute stress; 
however, problems arise from overactivation of the HPA axis.  Therefore, though stress 
initially causes a decrease in amygdalar AEA levels via a glucocorticoid-independent 
pathway, the subsequent glucocorticoid release caused by HPA axis stimulation feeds 
back to increase amygdalar AEA levels, attenuating the HPA axis activity (Hill et al., 
2010b).  While acute stressors only affect the production of AEA in the amygdala, 
repeated chronic stressors can increase amygdalar 2-AG signaling temporarily, with 
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levels beginning to return to normal 1 h after the stressful event (Patel et al., 2009).  
Therefore, elevated levels of 2-AG following repeated stressors represent another 
mechanism by which eCBs protect from HPA axis overactivation.  Consistent with this 
hypothesis, injection of a CB1r antagonist locally into the BLA reverses this stress 
habituation (Hill et al., 2010a). 
The LC plays a key role in the cognitive limb of the stress response, which is 
initiated in parallel with the HPA axis via CRF release from amygdalar afferents (Fig. 2) 
(Van Bockstaele et al., 1998, Valentino and Van Bockstaele, 2008).  NE-containing LC 
neurons express CRF receptor 1 (CRFr1), and chronic stress and the resulting release of 
CRF can lead to inappropriate increases in the firing of these neurons (Curtis et al., 1996, 
Reyes et al., 2008b).  Again, this dysregulated NE release in limbic and cortical areas 
contributes to the debilitating symptoms of depression and anxiety (Morilak and Frazer, 
2004, Leonard and Myint, 2009).  Just as the eCB system has been shown to modulate 
regions involved in the HPA axis and stress response, this anti-stress system also affects 
the cognitive limb and LC directly. 
 
Sex Differences 
Considering the known bias in susceptibility to psychiatric disorders between the sexes, 
understanding interactions between the eCB system, stress, and the LC-NE system across 
the sexes is of paramount importance.  Males are more prone to drug abuse, while 
females are about twice as likely to develop stress-induced disorders such as depression   
and anxiety (Kendler et al., 1995, Marcus et al., 2005).  Stress also affects both sexes 
differently; females are more sensitive to low levels of CRF due to both augmented CRF 
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Figure 2 
Parallel engagement of stress responses. 
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Figure 2: Parallel engagement of stress responses.  Corticotropin releasing factor 
(CRF) is responsible for coordinative activation of both the hypothalamic-pituitary-
adrenal axis (on the left) and the locus coeruleus (LC)-norepinephrine (NE) system (on 
the right).  CRF from the hypothalamus stimulates the anterior pituitary to secrete 
adrenocorticotropic hormone (ACTH), which then causes the adrenal cortex to release 
corticosterone (cort).  Cort then plays a role in the negative feedback loop for the HPA 
axis, with the help of endocannabinoids.  LC-NE activation is a key component in the 
cognitive limb of the stress response, causing a robust increase in NE in the medial 
prefrontal cortex and all throughout the neuraxis. 
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receptor (CRFr) signaling and diminished CRFr internalization after exposure to stress 
when compared to males (Bangasser et al., 2010).  In males, CRF binding to its receptor 
shows biased signaling towards the recruitment of β-arrestin and receptor internalization, 
but in females, CRF binding causes a biased response for Gs signaling (Valentino et al., 
2013).  Additionally, following stressors, female rats have increased dendritic extension 
into the peri-LC, the region surrounding the LC nucleus where a majority of limbic CRF 
afferents terminate (Bangasser and Valentino, 2012, Valentino et al., 2013).  Females 
have heightened HPA axis activity, coupled with slower negative feedback of the HPA 
axis (Handa et al., 1994, Handa and Weiser, 2014).  All of these discoveries lead to the 
generalized conclusion that females have heightened stress signaling within the LC 
compared to males. 
Also, differences across sexes are observed in the eCB system, both anatomically 
and behaviorally.  Females have a greater sensitivity to cannabinoid abuse, dependence, 
withdrawal, and relapse (Craft et al., 2013).  Females also have decreased CB1r density 
in certain brain regions, including the amygdala and cingulate areas 1 and 3 (Castelli et 
al., 2014).  Additionally, in human depressed patients, while both sexes show a rise in 
serum AEA, only females show a decrease in 2-AG (Reich et al., 2009).  Therefore, it is 
important to look at both males and females when designing experiments investigating 
stress and endocannabinoid systems, since sex differences exist in both systems. 
 
Goals of Thesis 
While the effect of exogenous cannabinoids on LC-NE activity has been 
examined, less is known about how the endogenous cannabinoid system and CB1r 
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deletion affects LC-NE activity.  Additionally, the eCB system is capable of modulating 
stress responses in many brain regions; however, its direct effect on the stress response 
within the LC is unknown.  Therefore, the goals of this project are as follows: 1) to 
examine the functional consequences of CB1r deletion on LC-NE activity and 
noradrenergic indices across sexes via whole-cell patch-clamp electrophysiology and 
Western blotting, 2) to determine how CB1r deletion alters CRF-induced effects on LC-
NE neurons via whole-cell patch-clamp electrophysiology, and 3) to test the hypothesis 
that CB1r are positioned to modulate CRF-containing afferents within the LC by using 
immunofluorescence and electron microscopy.  Taken together, the proposed work will 
elucidate mechanisms of action of eCB signaling and CRF on the stress-integrative NE-
mPFC circuitry and how they converge to regulate behavioral responses to stress across 
the sexes. 
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Abstract 
Cannabinoids are capable of modulating mood, arousal, cognition, and behavior, in part 
via their effects on the noradrenergic nucleus locus coeruleus (LC).  Dysregulation of LC 
signaling and norepinephrine (NE) efflux in the medial prefrontal cortex (mPFC) can lead 
to the development of psychiatric disorders, and CB1r deletion results in alterations of 
α2- and β1-adrenoceptors in the mPFC, suggestive of increased LC activity. To 
determine how CB1r deletion alters LC signaling, whole-cell patch-clamp 
electrophysiology was conducted in LC-NE neurons of male and female wild type (WT) 
and CB1r-knock out (KO) mice. CB1r deletion caused a significant increase in LC-NE 
excitability and input resistance in male but not female mice when compared to WT.  
CB1r deletion also caused adaptations in several indices of noradrenergic function. 
CB1r/CB2r-KO male mice had a significant increase in cortical NE levels and tyrosine 
hydroxylase and CRF levels in the LC compared to WT males.  CB1r/CB2r-KO female 
mice showed a significant increase in LC α2-AR levels compared to WT females.  To 
further probe actions of the endocannabinoid system as an anti-stress neuromediator, the 
effect of CB1r deletion on CRF-induced responses in the LC was investigated. The 
increase in LC-NE excitability observed in male and female WT mice following CRF 
(300 nM) bath application was not observed in CB1r-KO mice. These results indicate that 
cellular adaptations following CB1r deletion cause a disruption in LC-NE signaling in 
males but not females, suggesting underlying sex differences in compensation 
mechanisms in KO mice as well as basal endocannabinoid regulation of LC-NE activity. 
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Introduction 
The brainstem nucleus locus coeruleus (LC) plays an important role in regulating 
mood, arousal, and emotional states (Aston-Jones and Cohen, 2005; Valentino and Van 
Bockstaele, 2008), and is the sole provider of norepinephrine (NE) to the medial 
prefrontal cortex (mPFC) (Sara, 2009).  Dysregulation of the LC-NE system resulting in 
subsequent alterations in mPFC NE levels has been shown to precipitate the development 
of psychiatric disorders (Mueller et al., 2008; Mueller and Cahill, 2010).  One of the most 
widely used recreational drugs in the world, cannabis, often causes feelings of relaxation 
and euphoria (Velez et al., 1989; Green et al., 2003; Di Marzo et al., 2004); however, 
chronic usage can be anxiogenic and produce dysphoria (Reilly et al., 1998).  Via 
activation of cannabinoid type 1 receptors (CB1r), cannabinoids are known to affect 
attention and anxiety (Witkin et al., 2005; Pattij et al., 2008; Hill and Gorzalka, 2009), in 
part via actions on noradrenergic circuitry (Carvalho et al., 2010; Carvalho and Van 
Bockstaele, 2012; Wyrofsky et al., 2017).  There are, however, some discrepancies within 
the cannabinoid field.  While some studies find anxiolytic effects and therapeutic promise 
in cannabinoid treatments, others show that CB1r agonists can have a negative impact 
and promote anxiogenesis, and the exact dosage and experimental conditions can have a 
profound effect on whether targeting the endocannabinoid system could be beneficial (Di 
Marzo, 2008; Wyrofsky et al., 2015).  Further investigation of how the eCB system 
targets neurotransmitter systems, like norepinephrine, can provide further insight into the 
differential effects of cannabinoid agonism.  
Immunofluorescence and immunoelectron microscopy studies have provided 
direct anatomical evidence for CB1r co-localization to noradrenergic terminals in the 
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mPFC and localization to TH-containing neurons in the LC (Carvalho et al., 2010; 
Wyrofsky et al., 2017).  Several studies have also shown that CB1r activation increases 
NE release.  CB1r agonists WIN 55,212-2, tetrahydrocannabinol (THC), and CP 55940 
dose-dependently increase the spontaneous firing rate of LC neurons (Mendiguren and 
Pineda, 2006; Muntoni et al., 2006).  Both systemic and local administration of CB1r 
agonist WIN 55,212-2 increases c-Fos expression in LC-NE neurons and NE efflux in the 
rat mPFC (Oropeza et al., 2005; Page et al., 2008), as does inhibition of eCB catabolism 
with a fatty acid amide hydrolase (FAAH) inhibitor (Gobbi et al., 2005).  Additionally, 
administration of the CB1r antagonist SR141716A causes a decrease in LC activity, 
suggesting that during basal conditions (Muntoni et al., 2006), the LC is under tonic eCB 
regulation (Carvalho and Van Bockstaele, 2012; Wyrofsky et al., 2015).  Conversely, 
systemic administration of a CB1r antagonist rimonabant causes an increase in mPFC and 
hypothalamic NE levels (Tzavara et al., 2001; Tzavara et al., 2003), and low levels of 
THC can reduce NE release from synaptosomes (Poddar and Dewey, 1980).  These 
anatomical and functional studies provide evidence that the eCB system can modulate the 
LC-NE system.  
The eCB system is considered an “anti-stress” neuromediator (Viveros et al., 
2007; Cota, 2008), playing a role in the hypothalamic pituitary adrenal (HPA) axis 
negative feedback loop as well as initiating the stress response in the amygdala (Hill and 
McEwen, 2009; Hill et al., 2010a; Hill et al., 2010b).  The LC-NE system is involved in 
the cognitive limb of the stress response, and is activated in parallel with the HPA axis 
via corticotropin releasing factor (CRF), the pro-stress neuropeptide (Valentino and Van 
Bockstaele, 2008).  Following a stressor, CRF is released from limbic and autonomic 
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afferent sources such as the paraventricular nucleus of the hypothalamus, central nucleus 
of the amygdala, and bed nucleus of the stria terminalis (Van Bockstaele et al., 1996; Van 
Bockstaele et al., 1999; Van Bockstaele et al., 2001; Valentino and Van Bockstaele, 
2008), and can lead to increases in LC-NE firing and dysregulation of NE release in 
target regions, including the mPFC (Curtis et al., 1996).  We have recently shown that 
CB1r are positioned both pre- and post-synaptically with respect to CRF-containing 
afferents within the LC, providing a neural substrate for eCB modulation of CRF in this 
noradrenergic nucleus (Wyrofsky et al., 2017).   
Research examining male CB1r-knockout (KO) mice show that CB1r deletion 
increases anxiety and depressive-like behaviors in CB1r KO mice compared to wild type 
(WT) controls (Aso et al., 2008; Steiner et al., 2008; Parolaro et al., 2010; Wyrofsky et 
al., 2015). Additionally, CB1r-KO mice have increased plasma levels of 
adrenocorticotropin and corticosterone (Uriguen et al., 2004), and increased CRF mRNA 
expression in the hypothalamus, suggesting heightened HPA activity (Cota, 2008).  We 
have also demonstrated that CB1r-KO mice have reduced basal mPFC neuronal 
excitability due to desensitization of the normally excitatory mPFC α2-adrenoceptors 
(ARs) (Reyes et al., 2017).  These KO studies suggest that CB1r-KO mice have increased 
LC-NE release, which desensitized mPFC α2-ARs, resulting in decreased mPFC output 
(Reyes et al., 2017). 
In the present study, we used two strains of cannabinoid receptor KO mice to 
define electrophysiological properties of LC-NE neurons as well as effects on CRF-
mediated responses, and cellular adaptions that occur in absence of the cannabinoid 
receptors: CB1r-KO mice for in vitro slice electrophysiology studies and dual 
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CB1r/CB2r-KO mice for Western and ELISA experiments.  First, whole-cell patch clamp 
electrophysiological recordings were conducted in WT and CB1r-KO mice to measure 
basal properties of LC-NE neurons and their excitability.  Next, we used Western blot 
analysis to measure expression levels of the catecholamine synthesizing enzyme tyrosine 
hydroxylase (TH) in the LC and assessed cortical NE levels via ELISA in CB1r/CB2r-
KO mice.  We also investigated expression levels of CRF, α2-AR, and NET in the 
coeruleo-cortical pathway.  Finally, the effect of CRF administration on LC-NE activity 
in CB1r-KO mice was assessed using whole-cell patch-clamp recordings. Considering 
previous reports showing female rodents are more sensitive to the reinforcing effects of 
cannabinoids and are more likely to self-administer WIN 55,212-2 than males (Barna et 
al., 2004; Fattore et al., 2007; Roberts et al., 2014) and sex differences in CRF signaling 
within the LC, with female rodents having increased sensitivity to CRF following a 
stressor compared to males (Bangasser et al., 2010; Valentino et al., 2013), we included 
both male and female mice in the study.  These experiments help address the current gap 
in our understanding of how CB1r-KO differentially affects the LC-NE and stress 
systems across sexes. 
 
Methods 
Animals 
For all electrophysiology experiments, male and female wild-type (WT) and CB1r 
KO mice (9-12 weeks old) were housed four per cage in a controlled environment (12-
hour light schedule, temperature at 20oC).  Data was obtained from N=5 LC cells from 5 
WT male mice, N=4 cells from 4 WT female mice, N=6 cells from 5 KO male mice, and 
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N=7 cells from 4 KO female mice.  For Western blot and ELISA analysis, male and 
female WT and CB1r/CB2r dual KO mice (9-18 weeks old) were used.  Both CB1r and 
CB1r/CB2r KO mice were originally generated on a C57Bl/6 background by Zimmer et 
al. (Zimmer et al., 1999) at the National Institutes of Health.  Heterozygous breeding 
pairs were generously donated by Dr. Carl Lupica at the National Institutes of Health and 
were bred and genotyped at Temple University to obtain CB1r and CB1r/CB2r KO mice 
and WT littermates.  Food and water were provided ad libitum.  For Western blot 
analysis, data represents N=3 WT male mice, N=6 KO male mice, N=3 WT female mice, 
and N=6 KO female mice.  For ELISA analysis, data represents N=3 WT male mice, 
N=5 KO male mice, N=3 WT female mice, and N=5 KO female mice. 
The care and use of animals were approved by the Institutional Animal Care and 
Use Committee of both Drexel University and Temple University, and were conducted in 
accordance with the National Institutes of Health’s Guide for the Care and Use of 
Laboratory Animals (1996), the Health Research Extension Act (1985), and the PHS 
Policy on Humane Care and Use of Laboratory Animals (1986).  All efforts were made to 
utilize only the minimum number of animals necessary to produce reliable scientific data, 
and experiments were designed to minimize any animal distress. 
 
Drug preparation and administration 
Ovine CRF, generously provided by Dr. Jean Rivier (Clayton Foundation 
Laboratories for Peptide Biology, The Salk Institute, La Jolla, CA),	   was dissolved in 
water to make a 1 mg/mL solution and separated into 10 µL aliquots, which were 
concentrated using a Savant Speed Vac concentrator.  Aliquots were stored at -80oC until 
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the day of the experiment, when they were then reconstituted in aCSF and added to the 
perfusion bath at a final concentration of 300 nM CRF.  300 nM CRF was established as 
the optimal concentration based on a concentration-response curve (100-400 nM) tested 
in brain slices from male WT mice (data not shown).  Additionally, this dose matches 
with previous sources confirming that 300 nM CRF produces maximal increases in LC-
NE excitability (Jedema and Grace, 2004). 
 
Electrophysiology 
All electrophysiology procedures were conducted as described previously (Reyes 
et al., 2012; Cathel et al., 2014).  Male and female CB1r KO and WT mice were rapidly 
decapitated and brains rapidly extracted and placed in ice-cold artificial cerebrospinal 
fluid (aCSF), in which sucrose (248 mM) was substituted for NaCl. The brains were 
trimmed down to isolate the brainstem, and 250µm horizontal slices containing the LC 
were cut on a Vibratome 3000 Plus (Vibratome, St. Louis, MO, USA).  Slices were then 
incubated for 1h in aCSF at 35oC, and bubbled with 95% O2/5% CO2.  Slices were then 
maintained at aCSF at room temperature and bubbled with 95% O2/5% CO2.  The aCSF 
was composed of the following: 124 mM NaCl, 2.5 mM KCl, 2 mM NaH2PO4, 2.5 mM 
CaCl2, 2 mM MgSO4, 10 mM dextrose, and 26 mM NaHCO3. 
Slices were transferred to a recording chamber (Warner Instruments, Hamden, 
CT, USA) and continuously perfused with aCSF at a rate of 1.5-2.0 mL/min at a 
temperature of 34oC, maintained by an inline solution heater (TC-324; Warner 
Instruments, Hamden, CT, USA).  Data were obtained from one to two neurons per 
mouse; however, only one neuron was recorded per brain slice.  Neurons in the LC were 
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visualized using a Nikon E600 upright microscope fitted with a 40x water immersion 
objective, differential interference contrast and infrared filter (Optical Apparatus, 
Ardmore, PA, USA).  The microscope was connected to a CCD camera and computer 
monitor.  LC-NE cells were tentatively identified by their morphology and 
electrophysiological characteristics (Williams et al., 1984), using the fourth ventricle as a 
marker for the location of the LC nucleus.  Whole-cell recording pipettes were made with 
borosilicate glass capillary tubing (1.2 mm outer diameter, 0.69 mm inner diameter; 
Warner Instruments) on a P-97 micropipette puller (Sutter Instruments, Novato, CA, 
USA).  Electrodes were pulled to a resistance of 4-8 MΩ when filled with an intracellular 
solution containing 120 mM K-gluconate, 10 mM KCl, 1 mM MgCl2, 10 mM EGTA, 10 
mM HEPES, 2 mM MgATP, 0.5 mM Na2GTP, 10 mM Na phosphocreatinine, and 0.1% 
biocytin, pH 7.3.  Cells were approached with the electrode until a GΩ seal was 
established, and the cell membrane ruptured to obtain a whole-cell recording using 
HEKA patch-clamp EPC-10 amplifier (HEKA Elecktronik, Pfalz, Germany) under 
current clamp conditions (I = 0 pA).  The series resistance was monitored throughout the 
experiment, and if it appeared unstable or exceeded four times the electrode resistance, 
the cell was discarded.  Signals were stored on-line using Pulse software, filtered at 1 
kHz and digitized at 10 kHz.  The liquid junction potential was approximately 9 mV 
between the pipette solution and the aCSF, and was not subtracted from the data 
obtained. 
At baseline, membrane potential was recorded and input resistance calculated by 
averaging the voltage change that occurred during a 300pA current pulse and using the 
current/voltage relationship.  Neuronal excitability was assessed in each cell by injecting 
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a series of current pulses (0-180 pA, 30 pA increments), and the number of action 
potential per pulse was determined.  Additionally membrane characteristics were 
recorded, including action potential (AP) amplitude, AP duration, AP threshold, 
afterhyperpolarization potential (AHP) duration, and AHP amplitude.  After baseline 
recordings were performed, 300 nM CRF was bath applied, and membrane potential, 
input resistance, neuronal excitability, and membrane characteristics were re-assessed 6 
minutes after drug application. 
 Following electrophysiological experiments, dual fluorescence 
immunohistochemistry techniques were used to confirm that recordings were performed 
in LC-NE cells.  Slices that were used for recordings were post-fixed in 4% 
formaldehyde solution on 0.1 M phosphate buffer (PB; pH 7.4) for 72 hours. Biocytin-
filled (recorded) neurons were visualized using an Alexa Fluor 488-conjugated 
streptavidin antibody (1:500, ThermoFisher Scientific, Waltham, MA, USA).  Tyrosine 
hydroxylase (TH) was visualized using a primary TH antibody raised in mouse (1:1000, 
48 h incubation, Immunostar, Hudson, WI) followed by Alexa Fluor 647-conjugated 
mouse secondary antibody (1:400, Jackson ImmunoResearch, West Grove, PA, USA).  
Images were examined using an Olympus IX81 inverted microscope (Olympus, 
Hatagaya, Shibuya-Ku, Tokyo, Japan) equipped with lasers (Helium Neon laser and 
Argon laser; models GLG 7000; GLS 5414A and GLG 3135, Showa Optronics Co., 
Tokyo, Japan) with the excitation wavelength of 488, 543, and 635.  Data from recorded 
cells that were not co-stained with TH were excluded. 
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Data analysis for electrophysiology 
Electrophysiological recordings were analyzed using Clampfit 9.2 (Axon 
Instruments, Foster City, CA, USA).  The effect of genotype on input resistance and 
membrane characteristics across males and females was tested using two-way ANOVA 
(sex vs. genotype) followed by post-hoc Tukey’s multiple comparison adjustments.  
These statistics were performed using GraphPad Prism 7.03 (GraphPad Software, San 
Diego, CA, USA).  The effect of sex and genotype on neuronal excitability was tested 
using a three-way repeated measure ANOVA/mixed-effects regression model (with sex, 
genotype, and injected current as covariates, along with a random effect for repeated 
measures from injected current), while the effect of CRF on neuronal excitability was 
tested by using a second mixed-effects regression model (with sex, genotype, injected 
current, and drug treatment as covariates, along with a random effect for repeated 
measures from injected current and drug treatment), both followed by post-hoc Tukey’s 
multiple comparison adjustments when appropriate.  Statistical analyses for neuronal 
excitability were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).  
Results are presented as mean +/- SEM.  P-values less than 0.05 were considered 
statistically significant. 
 
Protein extraction 
Brain tissue from male and female WT and CB1r/CB2r KO mice was rapidly 
removed from each animal on ice.  Using a trephine, the LC and mPFC brain regions 
were microdissected from each animal.  Tissue punches were homogenized with a pestle, 
sonicated, and extracted in radioimmunoprecipitation assay lysis buffer with a protease 
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inhibitor cocktail (Santa Cruz Biotechnology, Santa Cruz, CA, USA) on ice for 20 min.  
Lysates were cleared by centrifugation at 13,000 rpm for 12 min at 4oC, and supernatants 
were extracted.  Protein concentrations were quantified using the bicinchoninic acid 
protein assay reagent (Pierce, Rockford, IL, USA). 
 
Western blot analysis 
Protein extracts were diluted with an equal volume of Novex 2© tris glycine 
sodium dodecyl sulfate sample buffer (Invitrogen, Carlsbad, CA, USA) containing 
dithiothreitol (Sigma-Aldrich Inc., St. Louis, MO, USA).  Cell lysates containing equal 
amounts of protein (30 µg per condition) were separated on 10% tris-glysine 
polyacrylamide gels and then electrophoretically transferred to Immobilon-P 
polyvinylidene fluoride membranes (Millipore, Bedford, MA, USA).  Membranes were 
blocked with Odyssey buffer (1 h, diluted in 0.01M PBS 1:1) and incubated in the 
various combinations of the following primary antibodies overnight at room temperature 
(Table I): mouse anti-tyrosine hydroxylase (TH; 1:1000, Immunostar Inc., Hudson, WI), 
rabbit anti-α2-adrenoceptor (α2-AR; 1:500; Millipore Sigma, Billerica, MA, USA), 
guinea-pig anti-CRF (1:2000, Peninsula Laboratories, San Carlos, CA, USA), mouse 
anti-norepinephrine transporter (NET; 1:1000, Millipore Sigma, Billerica, MA, USA).  
Mouse anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:2000, ProteinTech 
Group, Inc., Rosemont, IL, USA) was used as a loading control, to account for potential 
variability in amount of sample loaded.  Membranes were then rinsed and incubated with 
infrared fluorescent secondary antibodies (Licor, Lincoln, NE, USA) for 1 h: donkey 
anti-rabbit IRDye 800CW (1:15,000), donkey anti-guinea-pig IRDye800 CW (1:15000),  
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Table I.I: Characterization of the primary antibodies used for immunofluorescence 
microscopy (IF) and Western blotting (WB). 
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goat anti-mouse IRDye680LT (1:20,000).  Membranes were scanned using the Odyssey 
Infrared Imaging System (Licor, Lincoln, NE, USA), and protein quantification was 
determined using Odyssey Infrared Imaging software.  Protein quantification was 
normalized to the loading control, and all data is presented as a ratio of sample protein 
level to GAPDH level, to allow for comparison between groups. 
Additionally, Chameleon Duo Pre-stained Protein Ladder (Licor, Lincoln, NE, 
USA) was used to determine the molecular weights of protein bands observed: GAPDH – 
~37 kDa, CRF – ~25 kDa, α2-AR - ~45 kDa, TH - ~60 kDa, NET - ~80 kDa.  Only 
proteins that did not fall around the same molecular weight were probed for at the same 
time.  After imaging, membranes were stripped with NewBlot PVDF 5x Stripping Buffer 
(Licor, Lincold, NE, USA) mixed with four parts DiH2O for 20 min at room temperature.  
Blots were then rinsed and imaged to ensure removal of antibodies.  Then, the blot could 
be incubated again with other primary antibodies to detect additional proteins. 
 
ELISA 
Sandwich ELISA was conducted in accordance with the instructions provided in 
the High Sensitivity NE Kit (Eagle, Nashau, NH). Tissue lysates containing equal 
amounts of protein were dispensed into an extraction plate and incubated for 60 min in 
100 µl extraction buffer at room temperature on an orbital shaker.  The solution was then 
discarded and the extraction plates were washed before 200 µl acylation buffer was 
dispensed into each well of the extraction plate and left rotating at room temperature for 
20 min.  Liquid was then decanted and washed 3 times prior to the dispense of 125µl 
0.025 M hydrochloric acid into each well for an additional 20 min for elution.  Next, 100 
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µl eluent was transferred to the enzyme plate with 20 µl of freshly prepared enzyme mix 
(2 ml Catechol-O-methyltransferase with 0.3 ml S-adenosyl-L-methionine in 0.7 ml 
enzyme buffer) into all wells of the enzyme plate and left at room temperature for 90 
min.  Finally, 100 µl of the supernatant of each well was transferred to the NE ELISA 
with 20 µl of rabbit NE-antiserum and left overnight at 4°C.  The following day all wells 
were decanted and washed 3 times before incubation with 100 µl anti-rabbit IgG-POD-
conjugate for 60 min at room temperature on an orbital shaker.  The wells were 
subsequently washed 4 times and incubated with 100 µl of TMB solution for 40 min 
before 100 µl of stop solution was dispensed into the wells and the plate was read at 450 
nm within 15 min.  A standard curve was run for each replicate and was used to estimate 
the concentration of NE in each sample. 
 
Data analysis for Western blot and ELISA 
Differences in protein and NE levels were tested using two-way ANOVA/mixed-
effects regression model (sex vs. genotype) followed by post-hoc Tukey’s multiple 
comparison adjustments. Statistics for the Western blot and ELISA experiments were 
performed using GraphPad Prism 7.03 (GraphPad Software, San Diego, CA, USA).  
Results are presented as mean +/- SEM.  P-values less than 0.05 were considered 
statistically significant. 
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Results 
Heightened LC-NE activity in male CB1r-KO mice 
As previously stated, exogenous cannabinoids are known to increase LC-NE 
activity (Patel and Hillard, 2003; Muntoni et al., 2006).  Conversely, others studies have 
shown that the LC is under tonic eCB regulation and male CB1r-KO mice have decreased 
α2- and β1-adrenoceptor levels in the mPFC, suggestive of compensatory responses to 
heightened LC-NE activity (Reyes et al., 2017).  In order to elucidate the effect of CB1r-
KO on LC-NE signaling across sexes, whole-cell patch-clamp recordings from LC-NE 
neurons in 250um thick horizontal brain slices from CB1r-knock out (KO) mice and their 
wild type (WT) C57/Bl6 mice littermates were analyzed (Fig. 1.1). There was a 
significant effect of sex on input resistance (F1,15=5.865, p<0.05), genotype on input 
resistance (F1,15=14.54, p<0.01), and interaction between sex*genotype on input 
resistance (F1,15=4.771, p<0.05).  Tukey’s post-hoc analysis revealed that male CB1r-KO 
mice showed a significant increase in input resistance (393 ± 31 MΩ) when compared to 
male WT mice (225 ± 17 MΩ; p<0.01), female WT mice (213 ± 39 MΩ; p<0.01), and 
female KO mice (267 ± 25 MΩ; p<0.05), while there was no significant change in input 
resistance between female WT and KO mice (Fig. 1.1B).  A three-way repeated measures 
ANOVA/mixed effects regression model (genotype effect by sex*current pulse (repeated 
measure); sex effect by genotype*current pulse (repeated measure)) showed a significant 
effect of the following in the collected electrophysiology data: genotype (F1,18=11.41, 
p<0.01), current pulse (F6,104=75.78, p<0.0001), interaction between sex*genotype 
(F1,18=7.23, p<0.05), interaction between sex*genotype*current pulse (F5,104=2.72, 
p<0.05),  indicating all three factors were statistically significant  in the regression model.  
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Figure 1.1 
CB1r deletion causes an increase in LC-NE excitability in male mice. 
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Figure 1.1: CB1r deletion causes an increase in LC-NE excitability in male mice. a. 
Voltage responses to a 120 pA current pulse from representative WT and CB1r-KO male 
and female mice. b. LC-NE neurons from male CB1r-KO mice have a significantly larger 
input resistance compared to WT males and WT females. CB1r deletion does not cause a 
change in input resistance in female LC-NE cells. Panels c, d, and e summarize 
excitability data in the form of stimulus-response curves to a range of current pulses (0-
150 pA in 30 pA increments) in male and female WT and CB1r-KO mice. CB1r deletion 
results in a significant increase in excitability of LC-NE cells in male mice (leftward shift 
in c), which it does not affect LC-NE excitability in female mice (no shift in d). e. Female 
WT mice have a significant increase in LC-NE excitability compared to male WT mice.  
Data represent mean ± SEM. Astrisks indicate a significant difference between groups as 
determined by two-way and three-way repeated measure ANOVAs/mixed-effects 
regression model (* p < 0.05; ** p < 0.01, *** p < 0.001, **** p <0.0001). 
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Baseline membrane voltage was not different between CB1r KO and WT for male and 
female mice.  Further statistical examination of the data via Tukey post-hoc analysis 
revealed that genotype had a significant effect across all current pulses in male mice 
(p≤0.016), but not females (p≥0.24). Male CB1r-KO mice exhibited an increase in LC-
NE cell excitability compared to male WT mice [leftward shift of the stimulus-response 
curve; significantly increased excitability responses to 30 (p<0.05), 60 (p<0.001), 90 
(p=0.0001), 120 (p<0.0001), 150 (p<0.0001), and 180 pA (p<0.0001) current pulses] 
(Fig. 1.1C).  However, female CB1r-KO mice did not show a significant increase in 
excitability compared to female WT mice (Fig. 1.1D). Additionally, a significant effect of 
sex on WT mice across all current pulses was also observed. When comparing sexes, 
female WT mice showed a significant increase in LC-NE excitability compared to male 
WT mice [significantly increased excitability responses to 30 (p<0.05), 60 (p<0.05), 90 
(p<0.001), 120 (p<0.001), 150 (p<0.001), and 180 pA (p<0.001).  No significant effect of 
sex was observed between CB1r-KO mice at any of the current pulses. Representative 
traces from each group showing the number of spikes caused by 120pA current pulse: 
male WT – 11 spikes, male KO – 25, female WT – 25, female KO – 28 (Fig. 1.1A).  
Slices containing patched cells were processed for immunohistochemistry, to confirm 
that the data was collected from NE producing cells within the LC.  Only cells that were 
labeled with both tyrosine hydroxylase, a marker for NE production in the LC, and 
biocytin were included in the analyses (Fig. 1.2).  These data provide evidence that 
genetic deletion of CB1r increases LC-NE neuron excitability in males, increasing the 
ability of these male CB1r-KO LC-NE cells to respond to excitatory synaptic inputs. 
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Figure 1.2 
Confirming electrophysiological data is obtained from NE producing cells within the LC. 
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Figure 1.2: Confirming electrophysiological data is obtained from NE producing 
cells within the LC. Confocal fluorescence micrographs showing TH (red), biocytin 
(green), and co-localization (yellow) in the LC. a. TH was detected using an Alexa Fluor 
647-conjugated secondary antibody. b. Biocytin was detected using an Alexa Fluor 488-
conjugated streptavidin antibody. c. Arrow depicts co-localization between biocytin and 
TH, confirming that the patched cell was an LC-NE neuron. Single arrowheads indicate 
TH labeled cell bodies in the LC that were not patched.  Scale bar = 25µm. 
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Figure 1.3 
Western blot and ELISA analyses of NE indices in the LC and mPFC of male and female 
WT and CB1r/CB2r-KO mice. 
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Figure 1.3: Western blot and ELISA analyses of NE indices in the LC and mPFC of 
male and female WT and CB1r/CB2r-KO mice. Bands shown are representative of 
one sample obtained from one animal per group.  a. Western blot analysis for TH in 
protein extracts from the LC of male and female WT and CB1r/CB2r-KO mice. TH 
expression is significantly higher in male CB1r/CB2r-KO mice compared to male WT 
mice; however, there is no significant change in TH expression between female WT and 
CB1r/CB2r-KO. b. ELISA for NE in protein extracts from the mPFC of male and female 
WT and CB1r/CB2r-KO mice.  NE levels are significantly increased in male CB1r-KO 
mice compared male WT, female WT, and female CB1r/CB2r-KO mice.  CB1r deletion 
does not cause an increase in mPFC NE levels in female mice. c. Standard curve used to 
determine the NE concentration in LC protein extracts from each sample animal.  
Standards were run on the same plate as samples to avoid variability, and the R2 value for 
the curve equals 0.9904.  Data represent mean ± SEM. Asterisks indicate a significant 
difference between groups as determined by two-way ANOVAs/mixed-effects regression 
model (* p < 0.05). 	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Another way to assess alterations in LC-NE activity is to look at changes in NE 
production (Fig. 1.3).  Tyrosine hydroxylase (TH) is involved in the rate-limiting step in 
NE synthesis, and is used as a marker for NE production within the LC.  There was a 
significant effect of genotype on TH expression levels (F1,14=11.76, p<0.01).  Tukey’s 
post-hoc analysis revealed that WT male mice have significantly lower normalized levels 
of TH (0.314 ± 0.049) compared to CB1r/CB2r-KO males (0.741 ± 0.064; p<0.05) and 
KO females (0.751 ± 0.061; p<0.05), while no significant increase is observed between 
WT (0.539 ± 0.209) and KO females (0.751 ± 0.061; p>0.4) (Fig. 1.3A).  By using an 
ELISA, it is possible to more precisely determine changes in NE levels in the mPFC, 
representing a concrete endpoint for the effect of cannabinoid receptor deletion on LC-
NE activity.  Two-way ANOVA indicated a significant effect of genotype on NE levels 
(F1,11=9.752, p<0.01).  Male CB1r/CB2r-KO mice have significantly increased levels of 
NE in the mPFC (0.151 ± 0.032 pg/mL; p<0.05) compared to all other groups (Fig. 
1.3B): WT males (0.049 ± 0.008 pg/mL), WT females (0.039 ± 0.003 pg/mL; p<0.05), 
and KO females (0.071 ± 0.011 pg/mL; p<0.05).  The Western and ELISA data confirms 
that deletion of the CB1r causes a significant increase in NE indices in male but not 
female mice. 
 
Sex differences in cellular adaptations following cannabinoid receptor deletion 
In order to better understand what might be causing the increase in LC-NE 
activity in male CB1r-KO mice but not females, Western blot analyses were performed to 
determine what other changes in protein levels might be occurring (Fig. 1.4).  Within the 
LC,  the α2-AR  functions  to auto-inhibit  LC-NE neurons.   When examining changes in  
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Figure 1.4 
Western blot analysis of α2-adrenoreceptor (α2-AR), corticotropin-releasing factor 
(CRF), and norepinephrine transporter (NET) expression in the LC and mPFC in male 
and female WT and CB1r/CB2r-KO mice.	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Figure 1.4: Western blot analysis of α2-adrenoreceptor (α2-AR), corticotropin-
releasing factor (CRF), and norepinephrine transporter (NET) expression in the LC 
and mPFC in male and female WT and CB1r/CB2r-KO mice. Bands shown are 
representative of one sample obtained from one animal per group. a. Western blot 
analysis for α2-AR expression in protein extracts from the LC of male and female WT 
and CB1r/CB2r-KO mice. CB1r/CB2r deletion causes a significant increase in α2-AR 
expression compared to WT mice in females, but no change in males. b. Western blot 
analysis for CRF expression in protein extracts from the LC of male and female WT and 
CB1r/CB2r-KO mice. There is a significant increase in CRF levels in the LC of male 
CB1r/CB2r-KO mice compared to male WT mice, while no change occurs in female 
mice. c. Western blot analysis for NET expression in protein extracts from the LC of 
male and female WT and CB1r/CB2r-KO mice. Male WT mice have significantly greater 
NET levels in the LC compared to male CB1r/CB2r-KO, female WT, and female 
CB1r/CB2r-KO mice. d. Western blot analysis for NET expression in protein extracts 
from the mPFC of male and female WT and CB1r/CB2r-KO mice. No significant change 
in NET expression is observed across sexes or genotype. Data represent mean ± SEM. 
Asterisks indicate a significant difference between groups as determined by two-way 
ANOVAs/mixed-effects regression model ( * p < 0.05). 	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normalized α2-AR protein levels following CB1r/CB2r deletion (Fig. 1.4A), a two-way 
ANOVA determined a significant effect of genotype on α2-AR expression (F1,14=13.51, 
p<0.01).  Tukey’s post-hoc analysis showed no significant change between WT males 
(0.560 ± 0.027) and KO males (0.721 ± 0.054; p=0.365); however, KO females (0.484 ± 
0.009) showed a significant increase compared to WT females (0.720 ± 0.059; p<0.05).  
CB1r-KO mice have heightened HPA-activity and the LC is involved in the cognitive 
limb of the stress response; therefore, changes in CRF levels within the LC were also 
determined (Fig. 1.4B).  Two-way ANOVA revealed a significant effect of genotype on 
CRF expression (F1,14=8.888, p<0.01).  Tukey’s post-hoc analysis determined that 
CB1r/CB2r deletion resulted in a significant increase in normalized CRF levels in KO 
males (0.467 ± 0.088) compared to WT males (0.752 ± 0.062; p<0.05), but no significant 
change was observed between WT (0.581 ± 0.139) and KO females (0.715 ± 0.059; 
p=0.576).  Finally, changes in LC expression of the norepinephrine transporter (NET) 
were assessed (Fig. 1.4C).  Two-way ANOVA revealed a significant effect of sex 
(F1,13=12.8, p<0.01), genotype (F1,13=10.66, p<0.01), and interaction between sex* 
genotype (F1,13=9.595, p<0.01) on LC NET expression.  Tukey’s post-hoc analysis 
showed significantly greater expression of NET in WT male mice (0.893 ± 0.088) 
compared to all other groups: KO males (0.541 ± 0.048; p<0.01), WT females (0.522 ± 
0.071; p<0.01), and KO females (0.512 ± 0.041; p<0.001).  Within the mPFC, there were 
no significant changes in NET expression (Fig. 1.4D): WT males (0.842 ± 0.047), KO 
males (0.693 ± 0.070), WT females (0.756 ± 0.013), and KO females (0.819 ± 0.036).  
The increase in CRF expression in male KO mice compared to WT and α2-AR 
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expression in female KO mice compared to WT might provide some insight into why 
CB1r-deletion causes an increase in LC-NE excitability in males but not females. 
 
Loss of CRF-induced increases in LC-NE excitability in CB1r-KO mice 
We determined how CRF affects LC-NE excitability under conditions of CB1r 
deletion. After baseline measurements were recorded from male and female WT neurons, 
CRF (300 nM) was bath applied and the effect of drug treatment was then recorded.  This 
dose of CRF did not cause a significant increase in the input resistance of male (Fig. 
1.5B) or female (Fig. 1.5B’) WT and CB1r-KO mice when compared to baseline: male 
WT CRF (274 ± 29 MΩ), male KO CRF (417 ± 52 MΩ), female WT CRF (259 ± 43 
MΩ), and female KO CRF (282 ± 48 MΩ). Data for neuronal excitability was analyzed 
using a four-way repeated measure ANOVA/mixed-effects regression model (sex effect 
by genotype*current pulse, genotype effect by sex*current pulse, genotype effect by drug 
treatment*current pulse, drug effect by genotype*current pulse) and the following effects 
were found significant: drug treatment (F1,20=6.92, p<0.05), current pulse (F6,108=159.27, 
p<0.0001), interaction between sex*genotype (F1,18=10.55, p<0.01), interaction between 
genotype*current pulse (F6,108=4.85, p<0.001), interaction between sex*genotype*current 
pulse (F6,108=4.80, p<0.001), and interaction between genotype*drug treatment 
(F1,20=5.48, p<0.05), indicating all four factors were important predictors of neuronal 
excitability. CRF (300 nM) treatment caused a significant increase in LC-NE cell 
excitability in both male WT (Fig. 1.5C) and female WT (Fig. 1.5C’) mice, as expected.  
Tukey post-hoc analyses showed a significant drug treatment effect across WT male and 
female mice (p<0.0001 for 30, 60, 90, 120, and 150 pA current pulses; p<0.01 for 180 pA  
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Figure 1.5 
CB1r deletion disrupts CRF-induced increases in LC-NE excitability in male and female 
mice.	  
	   55	  	  
Figure 1.5: CB1r deletion disrupts CRF-induced increases in LC-NE excitability in 
male and female mice. Voltage responses to a 120 pA current pulse are shown from 
representative WT and CB1r-KO male (a) and female (a’) mice both at baseline and 
following CRF (300 nM) treatment. b. Bath application of CRF (300 nM) does not cause 
in increase in WT or CB1r-KO neuronal excitability in male or female (b’) mice. Panels 
c, c’, d, and d’ summarize excitability data in the form of stimulus-response curves to a 
range of current pulses (0-150 pA in 30 pA increments). Bath application of CRF (300 
nM) results in a significant increase in excitability of LC-NE cells in male WT mice 
(leftward shift in c) and female WT mice (leftward shift in c’); however, 300 nM CRF 
does not alter the excitability of LC-NE cells in male CB1r-KO mice (no shift in d) and 
female CB1r-KO mice (no shift in d’). Data represent mean ± SEM. Asterisks indicate a 
significant difference between groups as determined by two-way ANOVA (c and c’) and 
four-way repeated measure ANOVAs/mixed-effects regression model (d, d’, e, and e’; * 
p < 0.05; *** p <0.001). 	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current pulse).  Interestingly, CRF did not cause a significant increase in LC-NE cell 
excitability in male (Fig. 1.5D) and female (Fig. 1.5D’) CB1r-KO mice, as the post-hoc 
analyses showed no significant effect of drug treatment across KO male and female mice 
(p≥0.63).  Representative traces from each group showing the number of spikes caused 
by 120pA current pulse are provided in figure 5: male WT baseline – 11 spikes, male WT 
CRF – 16 spikes, male KO baseline – 25, male KO CRF – 28 (Fig. 1.5A), female WT 
baseline – 25 baseline, female WT CRF – 33, female KO baseline – 28, female KO CRF 
– 30 (Fig. 1.5A’).  These electrophysiological results suggest that while 300 nM CRF 
causes a significant increase in LC-NE cell excitability in WT male and female mice, it is 
not capable of producing the same effect in CB1r-KO mice. 
When examining single action potentials, CRF administration, sex, and genotype 
did not affect many of the analyzed characteristics (Table II).  Resting membrane 
potential remained constant among all groups, as did action potential threshold, duration, 
and after-hyperpolarization amplitude.  CRF bath application did cause a significant 
increase in action potential amplitude in WT females compared to baseline (p<0.05).  
Additionally, after-hyperpolarization duration was significantly reduced following CRF 
administration in WT males, KO males, and WT females (p<0.01; Fig. 1.6).  CB1r 
deletion also caused a significant reduction in after- hyperpolarization duration in males, 
but not in females. 
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Table II: Action potential and after-hyperpolarization characteristics of LC-NE neurons 
before and after 300 nM CRF bath application in wild type (WT) and CB1r-knock out 
(KO) male and female mice. Data represent mean ± SEM. Asterisks indicate a significant 
difference (p<0.05) between groups as determined by two-way ANOVAs/mixed-effects 
regression models (* : significant difference between CRF treatment and baseline; ✚ : 
significant difference between sex; ^	  : significant difference between genotype). 
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Figure 1.6 
Sex, genotype, and CRF treatment affect the after-hyperpolarization (AHP) duration of 
LC-NE neurons. 
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Figure 1.6: Sex, genotype, and CRF treatment affect the after-hyperpolarization 
(AHP) duration of LC-NE neurons.  a. LC-NE cells from female WT mice have a 
significantly shorter AHP duration compared to cells from WT males (p<0.05).  
Additionally, there is a sex difference in the effect of CB1r deletion, with neurons from 
male CB1r-KO mice having a shorter AHP duration compared to neurons male WT mice 
(p<0.05), but no difference between female CB1r-KO and WT cells. b and b’ show the 
effect of 300 nM CRF bath application on the AHP duration of LC-NE cells, separated by 
sex.  b. CRF causes a significant reduction in AHP duration in both male WT and male 
CB1r-KO neurons (p<0.05).  b’. CRF causes a significant  
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Discussion 
The present study highlights interesting sex differences in LC neurons following 
cannabinoid receptor deletion.  Electrophysiological studies conducted using an in vitro 
slice preparation show that CB1r deletion results in a significant increase in LC-NE 
excitability in male mice, but not in females.  Additionally, male CB1r-KO mice have a 
significant increase in TH expression in the LC and NE levels in the mPFC compared to 
WT males, which is not observed in females.  Via Western blot analysis, changes in 
protein expression across genotype and sex were observed.  Male CB1r/CB2r-KO mice 
exhibited an increase in CRF expression and a decrease in NET expression in the LC 
compared to male WT mice, and female CB1/CB2r-KO mice had an increase in α2-AR 
levels in the LC compared to female WT mice.  Finally, CB1r deletion affected CRF-
induced increases in LC-NE activity.  Bath application of CRF caused an increase in LC-
NE excitability in male and female WT mice; however, the effect of CRF was lost in 
CB1r-KO mice.  When examining individual membrane characteristics, LC-NE cells 
from male CB1r-KO mice showed a decrease in after-hyperpolarization duration.  
Additionally, CRF treatment caused a further decrease in after-hyperpolarization duration 
in LC-NE neurons from WT males and CB1r-KO males, and also a decrease in WT 
females.  These data further highlight the importance of the endocannabinoid system in 
maintaining normal brain adrenergic function, especially in male mice, where CB1r 
deletion had the most profound effect. 
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Methodological considerations 
 While electrophysiology experiments were carried out in CB1r-KO mice, Western 
blot and ELISA experiments were carried out in CB1r/CB2r-KO mice due to tissue 
availability.  Many immunohistochemical studies have identified CB1r as an abundant 
protein in the LC, both directly on the noradrenergic neurons as well as on presynaptic 
afferents synapsing onto LC-NE dendrites and cell bodies (Scavone et al., 2010; 
Wyrofsky et al., 2017).  While CB2r is traditionally thought to play a role in the 
periphery and immune responses (Castillo et al., 2012), growing accumulating evidence 
suggests that it does in fact play a role in neuronal signaling in some select brain regions 
(Van Sickle et al., 2005; Gong et al., 2006).  However, direct evidence of CB2r on LC-
NE neurons has not been shown.  Additionally, mixed CB1r/CB2r agonists such as THC, 
WIN 55,212-2, and CP 55,940 all dose-dependently increase LC-NE firing, and their 
effects are completely blocked by CB1r-selective antagonist SR141716A (Mendiguren & 
Pineda, 2006; Muntoni et al., 2006).  These studies suggest that there is a significantly 
greater influence of CB1r than CB2r on LC-NE neurons, providing indirect evidence for 
a minimal role of CB2r signaling in the LC.  Therefore, the effects of CB2r deletion in 
the LC should be less substantial than that of CB1r deletion, and the differences between 
CB1r-KO mice and CB1r/CB2r-KO mice should be minimal. However, the caveat exists 
that findings reported here are due to deletion of both receptor phenotypes. 
  Several studies have reported fluctuations in CB1r mRNA expression and eCB 
levels across the estrus cycle in several brain regions, including the anterior pituitary 
(Gonzales et al., 2000) and hypothalamus (Rodriguez de Fonseca et al., 1994), however 
the effect of ovarian hormones on CB1r and eCB levels in the LC has not been identified.  
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While estrogen might alter the endocannabinoid system, no effect of the estrus cycle was 
observed in preliminary studies examining the anti-depressant like behavioral effects of 
CB1r antagonism (Steiner et al., 2008).  Additionally, a study specifically examining the 
LC region controlled for the estrus cycle and found no notable effect of phase on female 
LC-NE excitability, firing rate, or CRFr1 compartmentalization in both WT and CRF-
overexpressing mice (Bangasser et al., 2013).  Since no direct effect of estrus cycle was 
has been found on baseline WT LC-NE excitability, and since the effect of circulating 
sex hormones on the eCB system is less relevant when CB1r are genetically deleted, we 
did not note the estrus cycle prior to our experiments, though the caveat exists that 
controlling for the estrus cycle could alter our results. 
 Some experimental caveats exist with Western blot and ELISA analysis, 
including the accuracy of tissue punches and equal protein quantities across various 
animals and groups.  In order to ensure that regions of interest were sampled accurately, 
one investigator preformed the micropunches for each animal.  Additionally, Western 
blots were probed with GAPDH as an internal standard to ensure equal protein loading 
for each sample.  Results were normalized to GAPDH expression, which was comparable 
across each animal group examined.  Finally, while Western blot analysis allows us to 
examine changes in protein expression levels, subsequent studies examining changes in 
mRNA levels could be conducted to further elucidate the effects of CB1r deletion on 
noradrenergic indices in the LC. 
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CB1r-KO increases LC-NE excitability in males but not females 
 One of the most interesting and surprising findings from this study is that CB1r 
deletion affected LC-NE excitability selectively in male subjects.  The changes observed 
in input resistance and after-hyperpolarization (AHP) duration across sex and genotype 
are consistent with the changes observed in LC-NE excitability.  All groups that had 
heightened LC-NE excitability also showed a decrease in AHP duration: CB1r-KO males 
and WT females compared to WT males, CRF treated WT males and females compared 
to baseline.  Additionally, CB1r-KO male and CRF treated WT males and females all had 
an increase in input resistance, suggesting a decrease in ion channel conductance.  
Neuronal increases in 3’,5’-cyclic adenosine monophosphate (cAMP) cause increased 
Ca2+ efflux.  Ca2+-mediated increases in K+ conductance occur in LC-NE cells, leading to 
more rapid repolarization (Adams et al., 1982; Osmanovic and Shefner, 1993; Nestler et 
al., 1999).  An increased repolarization rate corresponds with a shorter AHP duration, and 
suggests a general decrease in overall K+ ion conductance (Adams et al., 1982).  Results 
from the Western blot analysis provide further insight into why only certain groups had 
increased excitability. 
In males, a potential mechanism underlying increased LC-NE excitability 
involves differences in CRF expression. Interestingly, only male CB1r/CB2r-KO mice 
showed an increase in CRF expression in the LC when compared to WT and female 
subjects.  This was surprising initially, since many studies have shown that CB1-KO 
mice have heightened HPA axis activity and increased vulnerability to chronic stress 
(Martin et al., 2002; Uriguen et al., 2004), and female rodents are known to have 
increased susceptibility to stressors compared to males (Bangasser and Valentino, 2012; 
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Handa and Weiser, 2014).  However, more recent studies examining mice of both sexes 
report that females do not show HPA axis hyperactivity to the same degree as males 
following CB1r deletion or antagonism (Atkinson et al., 2010; Roberts et al., 2014).  
Thus, since the LC-NE cognitive limb of the stress response is engaged in parallel with 
the HPA axis (Van Bockstaele et al., 1998, Valentino and Van Bockstaele, 2008), it is 
tempting to speculate that female CB1r-KO mice might show less of an increase in CRF 
release in the LC compared to males.  CRF binds to its receptor, CRFr1, on LC-NE 
neurons and increases LC-NE firing rate (Curtis et al., 1996).  Both acute and chronic 
stress up-regulate the cAMP pathway (Nestler and Aghajanian, 1997), which, through 
downstream effects, increases neuronal re-polarization and decreases LC-NE AHP 
duration (Adams et al., 1982; Nestler et al., 1999).  Therefore, increased CRF expression 
represents one mechanism by which CB1r-KO males might have increased LC-NE 
excitability while female CB1r-KO mice do not (Fig. 1.7B). 
 Another potential mechanism underlying the observed sex differences in this 
study involves alterations in α2-AR expression between female CB1r/CB2r-KO and WT 
mice.  NE released from recurrent collaterals of LC neurons can bind to postsynaptic α2-
AR on the LC-NE dendrites resulting in auto-inhibition (Lee et al., 1998a, b).  In 
response, an increase in α2-AR would result in a decrease in cAMP and inhibition of LC-
NE neurons, which is characterized by an increase in AHP and decrease in input 
resistance (Korf et al., 1973).  While CB1r/CB2r deletion does not affect α2-AR levels in 
males, it does cause a significant increase in α2-AR expression in females.  This could 
represent a compensatory mechanism in females, where another inhibitory receptor, α2-
AR, is up-regulated to compensate for the loss of another inhibitory receptor, CB1r (Fig.  
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Figure 1.7 
Schematic depicting the effects of CB1r deletion on LC-NE indices. 
A 
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Figure 1.7: Schematic depicting the effects of CB1r deletion on LC-NE indices.  This 
schematic is contains a combination of results from electrophysiology studies performed 
in CB1r-KO mice with Western blot and ELISA analysis performed on CB1r/CB2r-KO 
tissue.  a. Our working model depicting how the endocannabinoid (eCB) system might 
modulate CRF-mediated responses within the LC.  (1) Stressors cause CRF to be released 
from excitatory amygdalar afferents into the LC.  (2) CRF binds to its postsynaptic CRF 
type 1 receptor (CRFr1), and subsequent post-synaptic depolarization and Ca2+ influx 
leads to increased LC-NE excitability and NE efflux in the mPFC.  (3) Increased 
intracellular Ca2+ levels stimulate eCB production, which then cross the synapse in a 
retrograde fashion to bind to their cannabinoid type 1 receptors (CB1r).  (4) CB1r 
activation leads to inhibition of pre-synaptic CRF and glutamate release, attenuating 
CRF-induced increases in LC-NE excitability and NE efflux in the mPFC.  b.  Male 
CB1r/CB2r-KO mice have increased CRF expression within the LC, which could be 
responsible for the heightened LC-NE excitability and subsequent NE efflux in the 
mPFC.  b’. Female CB1r/CB2r-KO mice do not have a significant increase in CRF 
levels, which corresponds with the lack of change in LC-NE excitability and NE efflux in 
the mPFC of CB1r-KO mice compared to wild type mice.  However, there is a significant 
increase in α2-adrenoceptor (α2-AR) expression in female CB1r/CB2r-KO mice 
compared to WT, while there is no significant change in α2-AR expression in males.  c. 
Bath application of ovine CRF (oCRF) causes a significant increase in male and female 
WT mice, but not in CB1r-KO mice.  In males, this might be due to saturation of CRFr1 
by the increased endogenous CRF levels.  c’. In females, the lack of oCRF-induced 
increases in LC-NE excitability could be attributed to the significant increase in α2-AR 
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expression.  oCRF could induce local NE release and subsequent auto-inhibition, 
preventing oCRF-induced increases in LC-NE activity. 
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1.7B’). This results in comparable excitability levels across LC-NE neurons, input 
resistance, and AHP duration in CB1r-KO and WT females. 
 It is important to note that while WT females have heightened excitability, this 
does not correlate to a heightened basal firing rate.  Previous studies by Bangasser et al. 
similarly found that female WT mice have increased LC-NE excitability compared to 
males, but the basal firing rate of these neurons is not significantly different across sexes 
(Bangasser et al., 2013).  In corroboration with Bangasser’s findings that male and female 
LC-NE neurons have similar firing rates, our study shows that there is no significant 
difference in NE levels in the mPFC across sexes – another endpoint for LC-NE firing.  
While we observe an increase in LC-NE excitability in male CB1r-KO mice, we did not 
examine the basal firing rates between male and female WT and CB1r-KO mice.  It 
would be tempting to postulate that CB1r-KO males would also have an increase in LC-
NE firing rate compared to the other groups, as they are the only group with increased 
mPFC NE levels.  Subsequent electrophysiology studies could further elucidate this 
hypothesis. 
  
Loss of CRF-mediated responses in CB1r-KO mice 
 Although CRF is known to modulate LC-NE neurons and increase their firing rate 
(Curtis et al., 1996; Valentino et al., 1997; Jedema and Grace, 2004), and this study 
confirmed that 300 nM CRF bath application is capable of doing so in LC neurons from 
WT males and females, this effect was not observed in CB1r-KO mice.  This loss of 
CRF-mediated increases in LC-NE excitability in male CB1r-KO mice could be due to 
the increased endogenous CRF levels saturating CRFr1, rendering the exogenous 
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application of oCRF ineffective (Fig. 1.7C).  In female CB1r-KO mice, the lack of CRF-
induced responses might be attributed to the increased α2-AR expression, causing local 
auto-inhibition and attenuation of LC-NE activity following oCRF administration (Fig. 
1.7C’). 
In addition to the eCB system, there are other endogenous anti-stress peptides that 
are known to suppress the stress response – several of which have been localized to the 
LC (Van Bockstaele et al., 2000; Tjoumakaris et al., 2003; Reyes et al., 2008).  The 
opioid system is capable of reducing the effects of stress throughout the brain, 
predominantly through the Gi-coupled µ-opioid receptor (MOR), which is abundantly 
expressed in the LC (Williams and North, 1984).  Within the LC, the endogenous opioid 
enkephalin is co-released with CRF, and by itself, enkephalin is capable of inhibiting LC-
NE activity (Curtis et al., 2001; Curtis et al., 2012).  Compensatory changes to the opioid 
system in CB1r-KO mice have been established in the striatum and other regions (Steiner 
et al., 1999; Befort, 2015), and CB1r-KO mice are less likely to self-administer 
morphine, illustrating the role of CB1r in the reinforcing effects of morphine (Cossu et 
al., 2001; Navarro et al., 2001).  Previous studies from our group have reported that MOR 
and CB1r co-exist in cellular profiles within the LC, providing a direct anatomical 
substrate for putative interactions (Scavone et al., 2010).  Therefore, it is tempting to 
speculate that CB1r deletion may modulate the endogenous opioid system in the LC.  If 
MOR were to be up-regulated as a compensation mechanism for the lack of CB1r 
inhibition, it could contribute to the lack of CRF-induced increases in LC-NE excitability 
in CB1r-KO neurons. More recently, neuropeptide Y (NPY) has emerged as an anti-stress 
peptide, capable of attenuating stress-induced anxiety and PTSD symptoms (Heilig, 
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2004; Cohen et al., 2012; Serova et al., 2013).  NPY and its two receptors, Y1 and Y2, 
are localized in the LC, and are also co-localized to synapses containing CRF-afferents 
(Warner et al., 2016).  Microinjection of NPY into the LC results in anxiolysis (Kask et 
al., 1998).  This anatomical positioning makes it possible for the NPY system to be 
altered to compensate for CB1r deletion.  Future studies and Western blot analyses could 
be performed to assess whether either the endogenous opioid or NPY systems are 
dysregulated in CB1r-KO mice. 
 Finally, chronic stress has been shown to alter CRFr1 trafficking in a sex 
dependent manner, with males exhibiting increased stress-induced internalization while 
females exhibit stress-induced recruitment to the plasma membrane (Bangasser et al., 
2010; Valentino et al., 2013).  It is possible that increased HPA hyperactivity (Uriguen et 
al., 2004) and a chronic increase in CRF levels in the LC of male CB1r-KO mice could 
lead to sustained de-sensitization of CRF receptors.  Immunoelectron microscopy 
experiments examining CRF receptor trafficking in LC-NE neurons of male and female 
CB1r-KO mice could provide further insight into changes in the stress circuitry following 
CB1r deletion.  Additionally, basal differences in CB1r expression and eCB signaling 
across sexes might be contributing to the findings observed in these studies.  Subsequent 
Western blot analyses investigating CB1r, FAAH, and other eCB metabolic proteins 
should be performed to determine their contribution to changes in LC-NE excitability 
across sexes and genotype. 
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Implications for pharmacotherapies 
 Dysregulation of NE is a key component in the development of anxiety and other 
stress-induced psychiatric disorders (Carvalho and Van Bockstaele, 2012). Furthermore, 
reduction in NET expression in the LC has been identified in individuals suffering from 
major depression and PTSD (Klimek et al., 1997; Pietrzak et al., 2013).  While acute 
stress does not affect NET levels, chronic and repeated stress exposure can lead to 
downregulation (Zafar et al., 1997).  Increased turnover and NE depletion, which can 
occur following a stressor (Korf et al., 1973), also leads to the downregulation of NET 
and upregulation of TH, and increased TH levels in the LC have also been correlated with 
the development of depression (Klimek et al., 1997).  Male CB1r/CB2r-KO mice exhibit 
a decrease in NET and an increase in TH expression, while no change was observed 
between female CB1r/CB2r-KO and WT mice.  These findings suggest that CB1r 
deletion or chronic antagonism may be more detrimental to males than females, creating 
a microenvironment in the LC of male KO mice that mimics conditions of chronic stress.  
In addition to cellular adaptations that occur following cannabinoid receptor 
deletion, the lack of increase in LC-NE excitability in female CB1r-KO mice could be 
due to less basal eCB signaling in females.  If the female LC is under less tonic regulation 
by eCBs, then removal of CB1r might have less profound of an effect.   In the amygdala, 
basal differences in the eCB system have been observed across sex, with males having 
greater levels of 2-AG and AEA, while females have increased expression of the 
enzymes responsible for their degradation (Krebs-Kraft et al., 2010; Craft et al., 2013).  A 
similar phenomenon might exist in the LC, and future Western blot and ELISA analyses 
of 2-AG, AEA, and their metabolic and synthesizing enzymes would provide further 
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insight into potential basal sex differences. 
We have demonstrated in previous studies that CB1r are localized to CRF-
containing afferents from the amygdala, and their presynaptic distribution in the peri-LC 
suggests that they might be capable of attenuating CRF release via activation by 
endogenous or exogenous cannabinoids.  A working model (Fig. 7A) is that CRF 
released from amygdalar afferents binds to postsynaptic CRFr1 on LC-NE neurons, 
causing membrane depolarization and increase in LC-NE excitability.  However, the 
influx of Ca2+ then stimulates the synthesis and release of eCBs, which in turn 
retrogradely traverse the synapse.  They then bind to presynaptic CB1r on CRF-
containing amygdalar axon terminals, aiding in the suppression of subsequent CRF 
release and helping return LC-NE activity back to baseline.  
CB1r antagonists and inverse agonists have been investigated for a variety of 
disorders ranging from obesity to schizophrenia (Wyrofsky et al., 2015).  Rimonabant, a 
CB1r antagonist originally used for the treatment of obesity, was discontinued due to 
adverse psychological side effects (Nissen et al., 2008).  Based on the results obtained in 
this study, CB1r antagonism might not cause an increase in LC-NE excitability to the 
same degree in females that it would in males, and the effects from CB1r antagonist 
treatment might be less significant in females, highlighting the importance of using both 
genders when performing pre-clinical trials.  Indeed, this would be in line with analyses 
performed on the adverse effects of rimonabant, which suggest that the odds ratio for 
developing depression after taking this CB1r antagonist was greatest in males aged 35-38 
(Pi-Sunyer et al., 2006; Nissen et al., 2008).  This study adds to the growing literature 
that dysregulation of the cannabinoid system can lead to the dysregulation of 
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noradrenergic signaling, especially in males, helping to advance our understanding of 
how these systems could be targeted for more effective treatment of psychological 
disorders. 
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Abstract 
The noradrenergic system has been shown to play a key role in the regulation of stress 
responses, arousal, mood, and emotional states. Corticotropin releasing factor (CRF) is a 
primary mediator of stress-induced activation of noradrenergic neurons in the nucleus 
locus coeruleus (LC). The endocannabinoid (eCB) system also plays a key role in 
modulating stress responses, acting as an “anti-stress” neuro-mediator. In the present 
study, we investigated the cellular sites for interactions between the cannabinoid receptor 
type 1 (CB1r) and CRF in the LC. Immunofluorescence and high-resolution 
immunoelectron microscopy showed co-localization of CB1r and CRF in both the core 
and peri-LC areas. Semi-quantitative analysis revealed that, 44% (208/468) of CRF-
containing axon terminals in the core and 35% (104/294) in the peri-LC expressed CB1r, 
while 18% (85/468) of CRF containing axon terminals in the core and 6.5% (19/294) in 
the peri-LC were presynaptic to CB1r-containing dendrites. In the LC core, CB1r + CRF 
axon terminals were more frequently of the symmetric (inhibitory) type; while in the 
peri-LC, a majority were of the asymmetric (excitatory) type. Triple label 
immunofluorescence results supported the ultrastructural analysis indicating that CB1r + 
CRF axon terminals contained either gamma amino butyric acid or glutamate. Finally, 
anterograde transport from the central nucleus of the amygdala (CeA) revealed that CRF-
amygdalar afferents projecting to the LC contain CB1r. Taken together, these results 
indicate that the eCB system is poised to directly modulate stress-integrative 
heterogeneous CRF afferents in the LC, some of which arise from limbic sources. 
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Introduction 
The stress response is characterized by a coordinated set of endocrine, 
physiological and cognitive responses to perceived threats in the environment (Ulrich-Lai 
and Herman 2009). A critical aspect of the endocrine stress response is the tight feedback 
regulation that serves to restrain and terminate the response (Keller-Wood and Dallman 
1984), which when dysregulated, contributes to the etiology of many stress-induced 
neuropsychiatric disorders (Plotsky et al. 1998; Wingenfeld and Wolf 2011). Feedback 
inhibition of the hypothalamic-pituitary-adrenal (HPA) axis by glucocorticoids is critical 
in terminating the endocrine limb of the stress response (Abou-Samra et al. 1986; Keller-
Wood and Dallman 1984). However, other neural circuits involved in the stress response 
are differentially regulated (Herman and Cullinan 1997; Ulrich-Lai and Herman 2009).  
Stressors that initiate the HPA response to stress also activate the brainstem locus 
coeruleus (LC)-norepinephrine (NE) system via the pro-stress neuropeptide, corticotropin 
releasing factor (CRF) (Vale et al. 1981; Valentino 1988). CRF-immunoreactive axon 
terminals synapse onto LC-NE dendrites and arise from multiple limbic-related and 
autonomic-related brain areas (Aston-Jones et al. 1991; Van Bockstaele et al. 1996a, b, 
1999). Stress-induced increases in CRF from these afferent sources can lead to 
inappropriate increases in the firing of LC-NE neurons and subsequent dysregulation of 
NE release in limbic and cortical areas (Curtis et al. 1996; Valentino et al. 2006; Van 
Bockstaele et al. 2010). The parallel engagement of the HPA and LC-NE systems serves 
to coordinate both endocrine and cognitive limbs of the stress response (Valentino and 
Van Bockstaele 2008a). One mechanism for counteracting stress responses in these 
neural circuits is through stress-elicited engagement of neuromodulators that act in 
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opposition to pro-stress systems, such as engagement of the endogenous opioid system 
(Heilig 2004; Reyes et al. 2008a, 2011; Tjoumakaris et al. 2003; Torner et al. 2001; 
Valentino and Van Bockstaele 2001; Van Bockstaele et al. 2000). Identifying 
mechanisms underlying counter-regulation of the stress response may better inform 
therapeutic strategies to prevent or treat stress-related neuropsychiatric diseases. 
The endocannabinoid (eCB) system is considered as an “anti-stress” 
neuromodulator that modulates pro-stress responses through effects on synaptic activity 
(Cota 2008; Viveros et al. 2007). Extracts of cannabis have been used as stress-reducing 
medicinals throughout history and by many cultures to reduce anxiety, pain, seizures, 
mania, and muscle spasms (Zuardi 2006). Modern research confirms certain benefits, 
with constituents of cannabis, ∆9-tetrahydrocannabinol (THC) and cannabidiol, being 
reported as effective anti-anxiety agents and stress-reducers (Bergamaschi et al. 2011; 
Tournier et al. 2003).  Emerging evidence also supports a role for the eCB system in the 
modulation of stress responses through effects on synaptic activity. The eCB ligands, N-
arachidonoylethanolamine/anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are 
primarily synthesized postsynaptically in response to increases in intracellular Ca2+ or 
activation of phospholipase C β (Castillo et al. 2012; Di Marzo et al. 2004).  Degradation 
of AEA and 2-AG occurs through the catabolic action of fatty acid amide hydrolase 
(FAAH) and monoacylglycerol lipase respectively (Castillo et al. 2012; Di Marzo et al. 
2004). Acting as retrograde messengers, AEA and 2-AG cross the synapse, where they 
primarily act through Gi-coupled cannabinoid CB1r localized to axon terminals (Castillo 
et al. 2012; Herkenham et al. 1990; Van Sickle et al. 2005), thereby inhibiting 
neurotransmitter release. By modulating glutamatergic and gamma amino butyric acid 
	   85	  	  
(GABA) ergic release, CB1r exert a profound effect on post-synaptic neuronal activity 
(Freund et al. 2003).   
CB1r protein and mRNA have been localized to the LC (Derbenev et al. 2004; 
Herkenham et al. 1991; Mailleux and Vanderhaeghen 1992; Matsuda et al. 1993). At the 
ultrastructural level, CB1rs in the LC have been shown to be localized both pre-
synaptically in axon terminals targeting NE-containing neurons as well as post-
synaptically in somatodendritic processes (Scavone et al. 2010).  Electron microscopy 
studies have shown that pre-synaptically distributed CB1r are localized to both excitatory 
and inhibitory type synapses (Scavone et al. 2010), which is consistent with 
electrophysiological studies. Systemic administration of CB1r agonists (Muntoni et al. 
2006) and fatty acid amide hydrolase (FAAH) inhibitors (Gobbi et al. 2005) increase the 
firing rate of un-stimulated noradrenergic neurons in the LC in a CB1r-dependent 
manner. CB1r agonists also increase cFos expression in the LC (Oropeza et al. 2005; 
Patel and Hillard 2003), enhance N-Methyl-D-aspartate (NMDA)-induced firing of LC 
neurons (Mendiguren and Pineda 2004), and increase NE synthesis (Moranta et al. 2009) 
and release (Oropeza et al. 2005) in terminal regions. WIN 55212-2 suppresses the 
inhibition of LC firing induced by activation of GABAergic afferents to the LC (Muntoni 
et al. 2006).  Taken together, these results are consistent with a mechanism by which 
activation of CB1r on excitatory or inhibitory type terminals in the LC result in increases 
in the firing of noradrenergic neurons. However, local administration of CB1r agonists 
into the LC does not alter the spontaneous firing of LC neurons (Mendiguren and Pineda 
2006) suggesting an indirect effect of CB1r agonists on LC firing, perhaps through 
increased afferent activity into the LC. 
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Convergent lines of evidence support a suppressive CB1r mechanism on CRF. 
CRF-induced activation of the sympathetic nervous system is inhibited by CB1r agonist 
administration and is potentiated by CB1r antagonists (Shimizu et al. 2010).  Activation 
of glucocorticoid receptors by cortisol causes an increase in eCB production, which then 
activates CB1r on presynaptic glutamatergic neurons within the paraventricular nucleus 
of the hypothalamus (PVN) resulting in a decrease in hypothalamic release of CRF (Hill 
et al. 2010).  Additionally, a longer feedback loop exists, where activation of CB1r on 
GABA neurons within the prelimbic medial prefrontal cortex (mPFC) causes a 
disinhibition of GABAergic neurons in the bed nucleus of the stria terminalis (BNST) 
which then project to the PVN, ultimately leading to a decrease in CRF release (Hill and 
McEwen 2009; Hill et al. 2010). Because of the complex interaction of the eCB system 
on stress-related circuitry and the localization of both CB1r and CRF-afferents within the 
LC, we sought to examine anatomical substrates for putative interactions between CB1r 
and CRF in the LC. Therefore, the present study used light microscopy, confocal 
fluorescence microscopy, and high-resolution immunoelectron microscopy to define how 
CB1r may be positioned to regulate CRF afferents in the LC.  
 
Methods 
Animals 
 For all experiments, male Sprague-Dawley rats between 200 and 300 g (Jackson 
Laboratory, Sacramento, CA) were used. They were housed two per cage, under standard 
conditions (25oC temperatures) and a 12 hour light/dark cycle (lights turned on at 
7:00am).  Ad libitum access to food and water was provided, and animal protocols were 
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approved by the Drexel University College of Medicine Institutional Animal Care and 
Use Committee in accordance with the revised Guide for the Care and Use of Laboratory 
Animals (1996).  All efforts were made to utilize only the minimum number of animals 
necessary to produce reliable scientific data.   
 
Immunofluorescence 
 Rats were deeply anesthetized via isoflurane exposure (Vedco, Inc., St. Joseph, 
MO) in a holding cage. Once a sufficient level of anesthesia was achieved, rats were then 
transcardially perfused via the ascending aorta with heparin followed by a 4% 
formaldehyde solution in 0.1 M phosphate buffer (PB; pH 7.4). Brains were then 
dissected, post-fixed in the formaldehyde solution for 24 h, and placed in 30% sucrose 
and 0.1 M PB solution before sectioning. Forty-micrometer sections through the 
rostrocaudal extent of each brain were collected using a cryostat (Microm HM 50, 
Microm International GmbH, Walldorf, Germany). Serial sections through the LC were 
placed in 1% sodium borohydride in 0.1 M PB for 30 min to remove any aldehydes 
remaining from the perfusion, followed by a 30min incubation in 0.5% bovine serum 
albumin (BSA) in 0.1 M Tris buffered saline (TBS; pH 7.6). Following extensive rinsing 
in 0.1 M TBS, tissues were incubated overnight in a mixture of primary antibodies 
including (Table II.I): CRF peptide raised in guinea-pig (1:7000, Peninsula Laboratories, 
San Carlos, CA), CB1r raised in rabbit (1:1000, kindly provided by Dr. Ken Mackie, 
Indiana University, IN), vesicular glutamate transporter (VGlut) raised in mouse (1:4000, 
Synaptic Systems, Gottingen, Germany), glutamate decarboxylase (GAD) raised in goat  
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Table II.I: Characterization of the primary antibodies used for immunofluorescence 
microscopy (IF) and electron microscopy (EM). 
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(1:700, Santa Cruz, Santa Cruz, CA), synaptophysin (Syn) raised in mouse (1:500, Merck 
Millipore, Billerica, MA), tyrosine hydroxylase (TH) raised in mouse (1:5000, 
Immunostar, Hudson, WI), unconjugated Phaseolus Vulgaris Leucoagglutinin (PHAL) 
raised in goat (1:5,000, Vector Laboratories, Burlingame, CA). For the primary 
antibodies that have not been previously characterized by our laboratory (VGlut, GAD, 
PHAL, and Syn), serial dilutions were performed to determine the optimal antibody 
concentration for the experiments. To visualize proteins, the following secondary 
antibodies were used, all at a concentration of 1:400 (Jackson ImmunoResearch): 
rhodamine isothiocyanate (TRITC) conjugated donkey anti-rabbit, fluorescein 
isothiocyanate (FITC) conjugated donkey anti-mouse, FITC conjugated donkey anti-goat, 
Alexafluor 647 conjugated donkey anti-guinea-pig, and Alexafluor 647 conjugated 
donkey anti-mouse. Additionally, some tissue sections were also incubated with 4’,6-
diamidino-2-phenylindole (DAPI; EMD Millipore, Billerica, MA) at 1:10,000 for 5 
minutes and washed 3 times with 0.05 M PB. The tissue sections were then examined 
using a Olympus IX81 inverted microscope (Olympus, Hatagaya, Shibuya-Ku, Tokyo, 
Japan) equipped with lasers (Helium Neon laser and Argon laser; models GLG 7000; 
GLS 5414A and GLG 3135, Showa Optronics Co., Tokyo, Japan) with the excitation 
wavelength of 488, 543 and 635. The microscope is also equipped with filters (DM 405-
44; BA 505-605; and BA 560-660) and with Olympus Fluoview ASW FV1000 program 
(Olympus, Hatagaya, Shibuya-Ku, Tokyo, Japan). Analysis of co-localization of profiles 
were obtained from dually labeled immunofluorescence images of CB1r and CRF taken 
from alternate LC sections of three rats (n=3) via the Coloc2 plug-in on FIJI ImageJ 
software. CRF (green) was set to channel 1 and CB1r (red) was set to channel 2, so the 
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Pearson’s coefficients obtained are representative of the likelihood that CB1r is co-
localized with respect to CRF. In order to best visualize co-localization in fluorescence 
micrographs, CB1r was always pseudocolored red, CRF and Syn, pseudocolored green, 
and glutamic acid decarboxylase (GAD) and vesicular glutamate transporter (VGlut) 
were pseudocolored cyan. Two sets of control tissues were processed in parallel, one with 
the omission of primary antibodies and the other with the omission of secondary 
antibodies. As an additional control, rabbit anti-CB1r was processed with both TRITC 
conjugated donkey anti-rabbit and Alexafluor 647 conjugated donkey anti-guinea-pig, 
and guinea-pig anti-CRF was also processed with both TRITC conjugated donkey anti-
rabbit and Alexafluor 647 conjugated donkey anti-guinea-pig (Figure 2.1). Since 
secondary antibody fluorescence was only observed when the corresponding primary 
antibody was used, there is no detectable cross-reactivity between the antibodies. 
 
Anterograde transport 
Surgery was performed on male Sprague-Dawley rats (n=3).  Animals injected with 
PHAL into the central nucleus of the amygdala (CeA) were initially anesthetized with a 
cocktail of ketamine hydroxide (100mg/kg; Phoenix Pharmaceutical, Inc., St. Joseph, 
MO) and xylazine (2 mg/kg; Phoenix Pharmaceutical, Inc., St. Joseph, MO) in saline 
intraperitoneally (i.p.) and placed in a stereotaxic apparatus for surgery. Anesthesia was 
supplemented with isoflurane (Abbott Laboratories, North Chicago, IL; 0.5-1.0%, in air) 
via a specialized nose cone affixed to the incisor bar of the stereotaxic frame (Stoelting 
Corp., Wood Dale, IL). Glass micropipettes (Kwik-Fil, 1.2mm outer diameter; World  
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Figure 2.1 
Secondary antibodies show no cross-reactivity. 
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Figure 2.1: Secondary antibodies show no cross-reactivity. Confocal fluorescence 
micrographs of control experiments that were performed to examine rhodamine 
isothiocyanate (TRITC)- and Alexafluor 647- conjugated secondary antibody specificity. 
a-c. Tissue was processed with guinea-pig anti-CRF primary antibody, then both 
Alexafluor 647 conjugated donkey anti-guinea-pig and TRITC conjugated donkey anti-
rabbit secondary antibodies. d-f. Tissue was processed with rabbit anti-CB1r primary 
antibody, then both TRITC conjugated donkey anti-rabbit and Alexafluor 647 conjugated 
donkey anti-guinea-pig secondary antibodies. a. With the absence of rabbit anti-CB1r 
primary antibody, TRITC does not fluoresce. b. CRF (green) peptide is visualized by 
Alexafluor 647 fluorescence. c. Merging of TRITC and Alexafluor 647 channels. d. CB1r 
(red) is visualized by TRITC fluorescence. e. With the absence of guinea-pig anti-CRF 
primary antibody, Alexafluor 647 does not fluoresce. f. Merging of TRITC and 
Alexafluor 647 channels. In a and e, minimal non-specific background labeling is 
observed. This demonstrates the specificity of both TRITC and Alexafluor secondary 
antibodies for their respective primary antibodies, and do not show any cross-reactivity. 
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Precision Instruments, Inc., Sarasota, FL) with tip diameters of 15-20µm were filled with 
2.5% PHAL (Vector Laboratories, Burlingame, CA).  The tips of the glass micropipettes 
were positioned in the CeA using the following coordinates; 2.3 mm posterior from 
Bregma and 4.2mm medial/lateral based on the rat brain atlas of Paxinos and Watson 
(1997).  The glass micropipettes were lowered targeting the appropriate coordinates for 
placement of PHAL into the CeA (6.7mm ventral from the top of the skull), and PHAL 
was injected using a Picospritzer (General Valve Corporation, Fairfield, NJ) at 24-26 psi, 
10ms duration and 0.2 Hz. Injection of PHAL was done unilaterally into the CeA of each 
animal.  Pipettes were left at the site of injection for 5 min after tracer deposit to limit 
leakage of the tracer along the pipette track.  After 10 days, rats were anesthetized and 
perfused as described above, and tissue was processed for immunohistochemical 
detection of PHAL, CB1r, and CRF. 
 
Electron microscopy 
 Rats were anesthetized and perfused as described above, using a 2% 
formaldehyde and 3.75% acrolein (from Electron Microscopy Sciences) solution. Brains 
were post-fixed in the formaldehyde and acrolein solution for 24 h, and 40 um sections 
were cut on a vibratome (Pelco EasiSlicer, Ted Pella, Inc., Redding, CA). Tissues were 
processed as we previously described (Reyes et al. 2006a, 2008b; Scavone et al. 2011). 
Briefly, alternate sections through the LC were processed for CRF and CB1r (n=4). 
Tissues were placed in 1% sodium borohydride in 0.1 M PB (pH 7.4) for 30 min to 
remove any aldehydes remaining from the perfusion, followed by a 30- min incubation in 
0.5% BSA in 0.01 M TBS. They were then rinsed with TBS and incubated overnight with 
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CRF peptide antibody raised in guinea-pig (1:2000, Peninsula Laboratories) and CB1r 
antibody raised in rabbit (1:1000). CRF was then visualized with immunoperoxidase 
labeling via biotinylated donkey anti-guinea-pig antibodies (1:400) for 30 min, followed 
by an avidin–biotin incubation for 30 min (ABC kit, Vector Laboratories, Burlingame, 
CA), and visualization with a 5-min reaction in 3,3′-diaminobenzidine (DAB; Sigma-
Aldrich Inc., St. Louis, MO) and hydrogen peroxide in 0.1 TBS. 
CB1r was visualized through immunogold silver enhancement. Tissues were first 
washed extensively, then incubated in goat anti-rabbit IgG, conjugated to 1nm gold 
particles (Amersham Bioscience Corp., Piscataway, NJ) for 2 h. Next, tissues were 
washed in 0.2% gelatin-phosphate buffered saline (PBS) and 0.8% BSA buffer followed 
by 0.1M PBS, then incubated for 10 mins in 2% glutaraldehyde (Electron Microscopy 
Sciences, Hatfield, PA) in 0.01M PBS. After washing with 0.01M PBS and 0.2M sodium 
citrate buffer (pH 7.4) sequentially, silver enhancement of the gold particles was done 
using a silver enhancement kit (Amersham Bioscience Corp.). This process was 
optimized empirically to determine the optimal enhancement time, which ranged between 
5-8 mins. Tissues were then washed again in 0.2M citrate buffer and 0.1M PB, then 
incubated in 2% osmium tetroxide (Electron Microscopy Sciences) in 0.1M PB. After a 1 
h incubation, tissues were washed in 0.1M PB, dehydrated in ascending series of ethanol 
then propylene oxide, and flat embedded in Epon 812 between two sheets of aclar 
(Electron Microscopy Sciences). Sections were cut at 70nm on a Leica Ultracut (Leica 
Microsystems, Wien, Vienna, Austria) with a diamond knife (Diatome-US, Fort 
Washington, PA), collected on copper mesh grids, and examined with an electron 
microscope (Morgagni Fei Company, Hillsboro, OR), with digital images captured by an 
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AMT advantage HR/HR-B CCD camera system (Advance Microscopy Techniques Corp, 
Danvers, MA).  Tissue was processed with the reverse immunolabels for each primary 
antibody, with CRF immunolabeled with silver-intensified gold particles and CB1r with 
peroxidase. 
 
Controls and data analysis 
Tissue sections for electron microscopy were obtained from rats with the best 
immunohistochemical labeling and preservation of ultrastructural morphology. The semi-
quantitative approach used in the present study is well established and has been described 
previously (Reyes et al. 2006b, 2007; Van Bockstaele et al. 1996a, b). While acrolein 
fixation optimizes the preservation of ultrastructural morphology, the caveat of limited 
and or differential penetration of immunoreagents in thick tissue sections exists (Chan et 
al. 1990; Leranth and Pickel 1989). Consequently, the limited penetration of CB1r and 
CRF may result in an underestimation of the relative frequencies of their distribution. We 
mitigated this limitation by collecting the tissue sections exclusively near the tissue-Epon 
interface where penetration is maximal and profile were sampled only when all the 
markers were present in the surrounding neuropil included in the analysis. The cellular 
elements were identified based on the description of Peters and colleagues (Peters and 
Palay 1996). Somata contained a nucleus, Golgi apparatus and smooth endoplasmic 
reticulum. Proximal dendrites contained endoplasmic reticulum, were postsynaptic to 
axon terminals and were larger than 0.7 µm in diameter. A terminal was considered to 
form a synapse if it showed a junctional complex, a restricted zone of parallel membranes 
with slight enlargement of the intercellular space, and/or associated with postsynaptic 
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thickening. A synaptic specialization was only limited to the profiles that form clear 
morphological characteristics of either Type I or Type II (Gray 1959). Asymmetric 
synapses were identified by thick postsynaptic densities (Gray’s type I; Gray 1959). In 
contrast, symmetric synapses had thin densities (Gray’s type II; Gray 1959) both pre- and 
post-synaptically. An undefined synapse was defined as an axon terminal plasma 
membrane juxtaposed to that of a dendrite or soma devoid of recognizable membrane 
specializations and no intervening glial processes. Two individuals quantified the synapse 
distributions in all profiles analyzed, both reaching the same percentages. 
 
Identification of immunogold-silver labeling in profiles 
Selective immunogold-silver labeled profiles were identified by the presence, in 
single thin sections, of at least two immunogold-silver particles within a cellular 
compartment. As we previously reported (Reyes et al. 2006b, 2007; Van Bockstaele et al. 
1996a, b), single spurious immunogold-silver labeling can contribute to false positive 
labeling and can be detected on blood vessels, myelin or nuclei. Although minimal 
spurious labeling was identiﬁed in the present study, the criterion for considering an 
axon or dendrite immunogold-silver labeled was defined by the presence of at least two 
silver particles in a profile. Whenever possible, the more lightly labeled dendritic labeling 
for CRF was confirmed by detection in at least two adjacent sections. Profiles containing 
CRF-labeled axon terminals were counted and their association with CB1r receptors was 
determined.   
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Results 
CB1r localization in LC: co-existence with CRF 
The LC is a compact cluster of NE neurons in the dorsal pons that serves as the 
primary source of NE in forebrain regions such as the hippocampus and cortex that 
govern cognition, memory and complex behaviors. To examine the relationship of CB1r 
with pre-synaptic neural profiles, CB1r immunoreactivity was combined with 
immunolabeling of an axonal marker, synaptophysin (Syn). Syn is a SNARE protein that 
is localized to the plasma membrane of axonal terminals (Edelmann et al. 1995).  
Immunofluorescence microscopy was performed for CB1r and Syn in the LC and DAPI 
was used to denote the nuclei in the LC region (Figure 2.2). Consistent with its known 
localization, Syn appeared in varicose processes, some of which were co-localized with 
CB1r (Figure 2.2d) suggesting that CB1r is located pre-synaptically in axon terminals.  
There also existed areas of CB1r immunoreactivity lacking Syn immunoreactivity, 
suggesting that CB1r is associated with profiles other than axon terminals in the LC.  
Considering the pre-synaptic distribution of CB1r, we sought to test the hypothesis 
that the eCB system is positioned to directly modulate CRF-containing afferents within 
the LC using immunofluorescence detection of CRF and CB1r (Figure 2.3a-c). As 
previously described in independent studies (Scavone et al. 2010; Valentino et al. 1992; 
Van Bockstaele et al. 1996a, 1999), CB1r and CRF appeared in punctate varicose 
processes that were distributed in the LC. Triple immunofluorescence revealed co-
localization of CB1r and CRF immunoreactive processes adjacent to TH-immunoreactive 
neurons (Figure 2.3d-g).  These data also show the presence of CB1r in localization while 
arrowhead and thick arrow point to singly labeled CB1r or Syn, 
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Figure 2.2 
CB1r is localized presynaptically in the LC. 
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Figure 2.2: CB1r is localized presynaptically in the LC. Confocal fluorescence 
micrographs showing that CB1r (red) and synaptophysin (Syn; green) are co-localized 
within the LC. a. DAPI was used to detect nuclei in LC cell bodies, b-c. CB1r was 
detected using a rhodamine isothiocyanate-conjugated secondary antibody and Syn, an 
axonal marker, was detected using an Alexafluor 647-conjugated secondary antibody 
(pseudocolored in green). d. CB1r and Syn appear punctate throughout. Co-localization 
of CB1r and Syn (yellow) can be seen in panel d. Arrows point to CB1r and Syn co- 
respectively. Arrows indicate dorsal (D) and lateral (L) orientation. 4V, fourth ventricle. 
Scale bar = 25µm.  
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Figure 2.3 
CB1r is co-localized with CRF in the LC. 
	   101	  	  
Figure 2.3: CB1r is co-localized with CRF in the LC.  a-c: Confocal fluorescence 
micrographs showing that CB1r (red) and CRF (green) are co-localized in the LC. CB1r 
was detected using a rhodamine isothiocyanate-conjugated secondary antibody (a) and 
CRF was detected using an Alexafluor 647-conjugated secondary antibody 
(pseudocolored in green) (b). Co-localization of CB1r and CRF (yellow) is shown in a 
merged image in panel C Arrows denote CB1r and CRF co-localization while arrowhead 
and thick arrow point to singly labeled CB1r and CRF,respectively. d-g: TH, a marker for 
noradrenergic neurons, was detected using fluorescein isothiocyanate-conjugated 
secondary antibody  (pseudocolored in blue) and was used to show that co-existing CB1r 
and CRF axon terminals are present within the core of the LC. Also note that CB1r are 
localized to TH-containing neurons suggesting that CB1r are localized both pre- and 
post-synaptically in the LC. g. Insets show co-localization of CB1r and CRF, and are 
shown at a higher magnification. Arrows depict triple co-localization of CB1r, CRF, and 
TH. 4V, fourth ventricle. Scale bar = 25µm.   
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TH-containing neurons suggesting that CB1r is also found post-synaptically, confirming 
our previous studies demonstrating that CB1r is localized both pre- and post-synaptically, 
in the LC (Scavone et al. 2010). 
 The core of the LC consists of a dense cluster of noradrenergic neurons, with 
dendrites that extend into the surrounding area, known as the peri-LC (Shipley et al. 
1996). CRF afferent nuclei are known to topographically innervate the LC (Van 
Bockstaele et al. 2001). CRF afferents from limbic regions, such as the amygdala and bed 
nucleus of the stria terminalis, have been shown to provide topographic innervation of the 
rostrolateral peri-LC while medullary afferents have been shown to project primarily to 
the core (Valentino and Van Bockstaele 2008a; Van Bockstaele et al. 1996a, 1999). In 
order to determine if there is differential distribution between the eCB regulation of CRF 
afferents in the core vs. peri-LC, confocal images of CB1r and CRF immunoreactivity 
were analyzed using the imageJ plug-in coloc2, and the average Pearson’s coefficient 
(PC) was determined: for the core, PC = 48.4 +/- 3.12; for the peri-LC, PC = 31.6 +/- 
3.78.  PC values represent the linear correlation of CB1r (red) signal intensity with 
respect to CRF (green) signal intensity at each pixel, and a PC > 1 signifies that the signal 
co-localization is greater than it would be at random, with a PC = 1 indicating perfect 
correlation (Adler & Parmryd 2010).  These values suggest that there is a correlation 
between CB1r and CRF in both the core and the peri-LC. Analysis of co-localization was 
further carried out using immunoelectron microscopy.  
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Ultrastructural localization of CRF and CB1r in the LC 
Immunoelectron microscopy was used to further determine the precise subcellular 
co-localization of CB1r in relation to CRF afferents in the LC (Figure 2.4). 
Immunoperoxidase labeling was used for the detection of CRF and immunogold-silver 
labeling was used for the detection of CB1r. These markers are routinely reversed and 
results showed a similar distribution irrespective of the seconday immunolabel of the 
primary antibody. The core of the LC consists of a dense cluster of noradrenergic 
neurons, with dendrites that extend into the surrounding area, known as the peri-LC 
(Shipley et al. 1996). CRF afferent nuclei are known to topographically innervate the LC 
(Van Bockstaele et al. 2001). CRF afferents from limbic regions, such as the amygdala 
and bed nucleus of the stria terminalis, have been shown to provide topographic 
innervation of the rostrolateral peri-LC while medullary afferents have been shown to 
project primarily to the core (Valentino and Van Bockstaele 2008a; Van Bockstaele et al. 
1996a, 1999). In order to determine if there is differential distribution between the eCB 
regulation of CRF afferents in the core vs. peri-LC, electron micrographs from the core 
and the peri-LC were quantified separately. 
For analysis of the LC core, a total of 468 profiles were analyzed from at least 5 
grids per LC section. At least three LC sections were collected from each Sprague-
Dawley rat (n=4).  Several interactions between CB1r and CRF-containing axon 
terminals were observed. One type of interaction demonstrated axon terminals containing 
both CB1r and CRF, suggesting an anatomical substrate for pre-synaptic modulation of 
CRF by CB1r (Figure 2.4a-d). It was also observed that CRF-containing afferents target 
dendrites expressing CB1r, providing a cellular substrate for potential post-synaptic 
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effects (Figure 10e). Of the 468 CRF-labeled axon terminals analyzed, 44.4% (208/468 
profiles) also contained CB1r, and of the 208 CRF+CB1r co-labeled axon terminals, 
12.5% (26/208 profiles) contacted dendrites that expressed CB1r postsynaptically. 
Additionally, 18.2% (85/468 profiles) of CRF axon terminals that did not express CB1r 
synapsed onto dendrites that contained CB1r. The remainder of CRF terminals did not 
exhibit CB1r or were not adjacent to profiles exhibiting CB1r immunoreactivity (37.4%; 
175/468 profiles).   
For peri-LC analysis, a total of 294 profiles were analyzed obtained from at least 
5 grids per LC section. At least three LC sections were collected from each Sprague-
Dawley rat (n=3). Of the 294 axon terminals analyzed that contained CRF, 35.37% 
(104/294 profiles) also contained CB1r, and of the 104 CRF+CB1r co-labeled axon 
terminals, 10.2% (30/104 profiles) contacted dendrites that expressed CB1r 
postsynaptically. Additionally, 6.46% (19/294 profiles) of CRF axon terminals that did 
not express CB1r synapsed onto dendrites that contained CB1r. The remainder of CRF 
terminals did not exhibit CB1r or were not adjacent to profiles exhibiting CB1r 
immunoreactivity (47.96%; 141/294 profiles). This provides compelling evidence for 
presynaptic regulation of CRF afferents by the eCB system in both the core and peri-LC 
areas. 
 
CRF and CB1r co-localize at inhibitory and excitatory synapses in LC 
 The type of synapses formed by CRF-labeled axon terminals that either contain 
CB1r or apposed to CB1r-containing dendrites were subsequently analyzed. In the LC  
 
	   105	  	  
 
 
 
 
 
 
Figure 2.4 
CRF-containing afferents co-localize with CB1r in the LC. 
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Figure 2.4: CRF-containing afferents co-localize with CB1r in the LC. a-f. 
Representative electron micrographs showing immunoperoxidase labeling for CRF-
containing axon terminals (CRF-t) and immunogold-silver labeling for CB1r 
(arrowheads) in the LC core (A-C) and peri-LC (D-E). a.  A CRF-labeled axon terminal 
containing CB1r forms is in direct contact (arrows) with an unlabeled dendrite (ud) in the 
LC core. b. A peroxidase-labeled CRF-t co-localizing CB1r (arrowheads) forms a 
symmetric type synapse (double arrows) with an unlabeled dendrite (ud) in the LC core. 
c.  An axon terminal containing both peroxidase- labeling for CRF and immunogold-
silver labeling for CB1r (arrowheads) forms an asymmetric type synapse (zig zag arrows) 
with an unlabeled dendrite (ud) in the LC core.  d. A CRF-labeled axon terminal 
containing CB1r (arrowheads) forms an asymmetric type synapse (zig zag arrows) with 
an unlabeled dendrite (ud) in the peri-LC. e. A peroxidase-labeled CRF axon terminal 
forming an asymmetric synapse (zig zag arrows) with a dendrite containing immunogold-
silver labeled CB1r (arrowheads)  f. A peroxidase-labeled CRF axon terminal can be seen 
in close proximity to a separate axon terminal containing immunogold-silver labeled 
CB1r. dcv, dense core vesicle. Scale bar = 0.5 µm.  
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core, of the dually labeled CRF- and CB1r axon terminals that formed synapses with 
unlabeled dendrites (10a-c), 72.0% (131/182 profiles) exhibited symmetric synapses 
(Figure 2.4b), 17.0% (31/182 profiles) formed asymmetric synapses (Figure 2.4c), and 
11.0% (20/182 profiles) formed undefined synapses (Figure 2.4a). For CRF-labeled axon 
terminals apposed to CB1r-labeled dendrites, 52.9% (45/85 profiles) formed symmetric 
synapses, 36.5% (31/85 profiles) formed asymmetric synapses, and 10.6% (9/85 profiles) 
formed undefined synapses. For dually labeled CRF- and CB1r axon terminals apposed 
to CB1r-labeled dendrites, 50.0% (13/26 profiles) formed symmetric synapses, 38.5% 
(10/26 profiles) formed asymmetric synapses, and 11.5% (3/26 profiles) formed 
undefined synapses. 
 In the peri-LC, of the dually labeled CRF- and CB1r axon terminals that formed 
synapses with unlabeled dendrites (Figure 2.4d), 21.15% (22/104 profiles) formed 
symmetric synapses, 53.84% (56/104 profiles) formed asymmetric synapses (Figure 
2.4d), and 28.85% (30/104 profiles) formed undefined synapses. For CRF-labeled axon 
terminals apposed to CB1r-labeled dendrites, 21.05% (4/19 profiles) formed symmetric 
synapses, 57.89% (11/19 profiles) formed asymmetric synapses, and 21.05% (4/19 
profiles) formed undefined synapses. For dual CRF- and CB1r-labeled terminals apposed 
to CB1r-labeled dendrites, 30.0% (9/30 profiles) formed symmetric synapses, 56.67% 
(17/30 profiles) formed asymmetric synapses, and 13.33% (4/30 profiles) formed 
undefined synapses. As compared to the core of the LC, where CB1r and CRF 
interactions exhibited primarily inhibitory-type synapses, the peri-LC showed a different 
synaptic organization with dually labeled terminals exhibiting primarily excitatory 
synapses. 
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Figure 2.5 
CB1r and CRF co-localize with GAD in the LC. 
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Figure 2.5: CB1r and CRF co-localize with GAD in the LC.  Confocal fluorescence 
micrographs showing CB1r (red), CRF (green), and GAD (cyan) co-localization in the 
LC.  a. CB1r was detected using a rhodamine isothiocyanate-conjugated secondary 
antibody. b. CRF was detected using an Alexafluor 647-conjugated secondary antibody 
(pseudocolored in green). c. GAD was detected using a fluorescein isothiocyanate-
conjugated secondary antibody (pseudocolored in cyan). d. Triple co-localization (pink) 
can be seen in the bottom row and is depicted by arrows.  The inset on the bottom left 
panel (d) is shown at a higher magnification on the bottom right (d’).  Additionally, co-
localization of CB1r and CRF without GAD (yellow, double arrow heads) and CB1r and 
GAD without CRF (white, asterisks) is observed. Single arrowheads point to singly 
labeled CB1r, CRF, and GAD. Scale bar = 30µm.  
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Figure 2.6 
CB1r and CRF co-localize with VGlut in the LC. 
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Figure 2.6: CB1r and CRF co-localize with VGlut in the LC.  Confocal fluorescence 
micrographs showing CB1r (red), CRF (green), and VGlut (cyan) co-localization in the 
LC. a. CB1r was detected using a rhodamine isothiocyanate-conjugated secondary 
antibody. b. CRF was detected using an Alexafluor 647-conjugated secondary antibody 
(pseudocolored in green). c. VGlut was detected using a fluorescein isothiocyanate-
conjugated secondary antibody (pseudocolored in cyan). d. Triple co-localization (pink) 
can be seen in the right panels and is depicted by arrows.  Additionally, co-localization of 
CB1r and CRF without VGlut (yellow, double arrow heads) and CB1r and VGlut without 
CRF (white, asterisks) is observed. Single arrowheads point to singly labeled CB1r, CRF, 
and GAD. Scale bar = 30µm. 
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The different morphological characteristics of dually labeled CRF and CB1r 
synaptic specializations in the core vs peri-LC suggested that CB1r modulation of either 
inhibitory or excitatory CRF afferents. To further explicate the neurochemical signature 
of dually labeled CRF and CB1r synapses, triple labeling immunofluorescence was 
performed. In addition to staining for CRF and CB1r, GAD, the enzyme responsible for 
GABA synthesis in axon terminals (Fonnum et al. 1970), was used as a marker for 
GABAergic neurons (Figure 2.5) and VGlut, a protein responsible for filling synaptic 
vesicles with glutamate (Fremeau et al. 2004), was used as a marker for glutamatergic 
neurons (Figure 2.6). Figures 2.5 and 2.6 demonstrate immunocytochemical evidence that 
CB1r, CRF, and GAD or VGlut are co-localized, suggesting that CB1r and CRF are 
expressed at both excitatory and inhibitory synapses. In addition, Figures 2.5 and 2.6 
show co-localization between CB1r and CRF in axon terminals lacking GAD or VGlut, 
respectively, as well as evidence for CB1r and GAD or VGlut in axon terminals lacking 
CRF.   
 
CB1r and CRF co-localize in amygdalar projections to the LC 
 CRF-afferents from both autonomic and limbic regions project to the LC, and the 
central nucleus of the amygdala (CeA) is one of the key limbic inputs involved in stress 
signaling (Aston-Jones et al. 1991; Van Bockstaele et al. 1996a, b, 1999).  Previous 
electron microscopy tracing studies have shown that within the rostrolateral peri-LC, 
approximately 35% of axon terminals from the amygdala co-localize with CRF, and 22% 
of CRF-labeled profiles originate from the amygdala (Van Bockstaele et al., 1998).  
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Figure 2.7 
CB1r and CRF co-localize in PHAL-labeled amygdalar afferents to the LC. 
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Figure 2.7: CB1r and CRF co-localize in PHAL-labeled amygdalar afferents to the 
LC.  The anterograde tracer PHAL was injected into the central nucleus of the amygdala 
(CeA) and immunofluorescence labeling was conducted for PHAL, CB1r and CRF in LC 
sections. a-d. Confocal fluorescence micrographs demonstrate triple co-colocalization of 
CB1r, CRF, and PHAL in the peri-LC. CB1r was detected using a rhodamine 
isothiocyanate-conjugated secondary antibody (a) and CRF was detected using an 
Alexafluor 647-conjugated secondary antibody (pseudocolored in green) (b) and PHAL 
was detected using fluorescein isothiocyanate-conjugated secondary antibody 
(pseudocolored in blue) (c). d. Triple co-localization (white) can be observed, and is 
depicted by arrows.  Double arrowheads point to dual co-localization of CB1r and CRF 
(yellow). Single arrowheads point to singly labeled CB1r, CRF, and PHAL. Scale bar = 
25µm. e. A schematic diagram adapted from the rat brain atlas of Paxinos and Watson 
(Paxinos and Watson 1997) depicting the location of the CeA. The box illustrates the 
region in which the lower image was taken.  This image showing an overlay of 
fluorescein isothiocyanate-labeled PHAL injection site with the same section stained with 
NIssl shows that the injection was positioned in the CeA. Opt: optic tract. Scale bar = 
.5mm. 
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Anterograde transport of PHAL from the CeA (Figure 2.7e) revealed that amygdalar 
projections to the LC that contain CRF also express CB1r (Figure 2.7a-d), suggesting that 
CB1r are positioned to modulate amygdalar CRF-release. 
 
Discussion 
While it is known that CRF and the eCB system independently regulate 
noradrenergic neurons in the LC, the present results demonstrate a direct interaction 
between the two by providing ultrastructural evidence for CB1r localization to CRF-
containing axon terminals in the LC. To our knowledge, these findings provide the first 
anatomical evidence that the eCB system is positioned to directly modulate CRF stress-
integrative circuitry within the LC-NE system. In addition, morphological analyses at the 
electron microscopic level revealed that dually labeled CB1r + CRF axon terminals 
exhibited Gray’s Type I (asymmetric or excitatory-type) and Gray’s Type II (symmetric 
or inhibitory type) synapses. Interestingly, to our knowledge, this is the first subcellular 
evidence that CB1r and CRF are co-localized within the LC. Type I synapses were more 
frequently found in the peri-LC, a known source of CRF limbic afferents, while Type II 
synapses were more frequently localized in the core of the LC, a known source or 
autonomic and visceroreceptive afferents. The ultrastructural data were confirmed by a 
triple immunofluorescence labeling approach showing that dually labeled CRF and CB1r 
afferents contain markers for either excitatory or inhibitory type amino acids. These 
results suggest that eCB modulation of CRF afferents will produce differential 
consequences on LC neuronal activity depending on whether distinct CRF afferents that 
contain co-existing excitatory or inhibitory amino acid transmitters are engaged, and 
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provide the first evidence that topographic distinctions occur between CB1r and CRF co-
localization with inhibitory and excitatory amino acids in the core and peri-LC, 
respectively. Finally, co-localization of CB1r, CRF, and PHAL in the LC demonstrates 
that CB1r are localized in CRF-containing afferents that arise from the amygdala. 
 
Methodological considerations 
 Dual labeling immunocytochemistry with peroxidase detection and immunogold-
silver labeling combined with electron microscopy makes it possible to identify the 
subcellular localization of receptors within a defined neuronal population. However, 
some limitations need to be considered when interpreting results from pre-embedding 
immunoelectron microscopy experiments. Often, there is limited and/or differential 
penetration of the primary and secondary antibodies, especially in thicker tissue sections 
(Chan et al. 1990; Leranth and Pickel 1989).  For example, antibodies directed against 
CRF or CB1r may not have penetrated the tissue section sufficiently, resulting in an 
underestimation of the number of CRF-containing afferents or CB1r in the LC. In order 
to minimize this caveat, only tissue sections where both markers could be detected near 
the tissue-Epon interface were analyzed (Leranth and Pickel 1989). Additionally, while 
classifying synapses as symmetric or asymmetric at the electron microscopic level is 
suggestive of inhibitory or excitatory type synapses (Gray 1959; Harris and Weinberg 
2012), it is not definitive. Therefore, triple immunofluorescence using GAD as a marker 
for GABAergic synapses and VGlut as a marker for glutamatergic synapses was used to 
unequivocally establish the presence of inhibitory or excitatory amino acids in dually 
labeled CRF + CB1r afferents. 
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CRF regulation of LC neurons: implications for modulation by CB1r  
The LC is a stress-integrative system that consists of a dense cluster of 
noradrenergic somata, defined as the core, with extensive dendritic processes extending 
from the core into surrounding portions of the neuropil, known as the peri-LC (Shipley et 
al. 1996). CRF fibers have been shown to prominently innervate peri-LC areas when 
compared to the core (Valentino et al. 2001; Van Bockstaele et al. 1996a, 1999). CRF-
containing afferents originating from the central nucleus of the amygdala (CeA; Van 
Bockstaele et al. 1998), Barrington’s nucleus (Bar; Valentino et al. 1996), the 
paraventricular nucleus of the hypothalamus (PVN; Reyes et al. 2005), and the nucleus 
paragigantocellularis (PGi; Van Bockstaele et al. 2001) form primarily asymmetric or 
excitatory-type synapses with LC dendrites. Additional CRF afferents arise from the 
BNST (Van Bockstaele et al. 1999), ventrolateral periaqueductal gray (PAG; Van 
Bockstaele et al. 2001), and the nucleus prepositus hypoglossi (PrH; Van Bockstaele et 
al. 2001) and form largely symmetric or inhibitory-type synapses (Figure 2.8a). CRF 
afferents also exhibit topographic innervation of the LC core and peri-LC areas, with the 
CeA and BNST projecting to the peri-LC, while Bar, the PVN, PGi, PAG, and PrH 
project to the core (Figure 2.8b) (Van Bockstaele et al. 2001). CRF exerts a primarily 
postsynaptic regulation of LC neurons where it acts upon CRF type 1 receptors that are 
prominently distributed within the LC (Curtis et al. 1999; Reyes et al. 2006a, 2008b).  
During stress, CRF is released to shift the activity of LC neurons to a high tonic 
state that promotes scanning of the environment and behavioral flexibility (Curtis et al. 
2001, 2002, 2012; Kreibich et al. 2008; Valentino et al. 2001; Valentino and Van 
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Figure 2.8 
Functional consequences of eCB modulation of CRF afferents 
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Figure 2.8:  Functional consequences of eCB modulation of CRF afferents.  a. Table 
showing known CRF projections to the LC, their putative co-localizing amino acid, and 
function. b. Schematic depicting the topographic innervation of the LC by CRF-afferents. 
Bar, PAG, PGi, PrH, and PVN are all known to project to the core of the LC, while the 
BNST and CNA project to the peri-LC. 
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Bockstaele 2005; Van Bockstaele et al. 2010; Xu et al. 2004). Previous neuroanatomical 
and electrophysiological studies demonstrated selective presynaptic inhibition of CRF 
afferent input by selective KOR agonists (Kreibich et al. 2008; Reyes et al. 2007). By 
allowing LC neurons to fire spontaneously, but attenuating information from excitatory 
afferents, pre-synaptic regulation of CRF by KOR may serve to protect the LC from 
over-activation (Kreibich et al. 2008). The present study reveals an additional component 
involved in the presynaptic regulation of CRF afferents in the LC, the CB1r. CB1r are 
known to be present in stress responsive circuits that are essential to the expression of 
stress-related behaviors (Hill et al. 2010; Shimizu et al. 2010). For example, the eCB 
system plays a critical role in glucocorticoid-mediated fast feedback inhibition of the 
HPA axis (Hill and McEwen 2009; Hill et al. 2010), and acute restraint stress has been 
shown to increase the synthesis of endogenous eCB in limbic forebrain areas (Haller et 
al. 2002; Martin et al. 2002; Patel et al. 2005). CB1r agonist administration has been 
shown to alter LC-neuronal discharge and NE release in target regions during basal and 
stress conditions (Herkenham et al. 1990; Oropeza et al. 2005; Page et al. 2007, 2008; 
Reyes et al. 2012). 
Ultrastructural analysis in the present study reveals that a majority of CRF and 
CB1r dual labeled afferents in the peri-LC form Type I or asymmetric synapses, 
suggesting that the eCB system may modulate release of CRF from limbic afferents, such 
as the amygdala, which was confirmed by combining anterograde labeling from the CeA 
with immunofluorescence detection of CRF and CB1r. eCB signaling within the 
amygdala is necessary for habituation and adaptation of fear related behaviors (Kamprath 
et al. 2006; Marsicano et al. 2002; Wyrofsky et al. 2015). It is tempting to speculate that 
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eCB modulation of the amygdalar CRF-afferents in the LC could also play a role in 
attenuating emotionally-charged stimuli. LC activation causes an increase in NE release 
in the mPFC, which plays a critical role in aversive memory extinction, and NE 
dysregulation can lead to the development of anxiety disorders (Wyrofsky et al. 2015; 
Mueller & Cahill 2010; Mueller et al. 2008). CRF release from the amygdala is known to 
increase LC activity. The co-localization of CB1r on amygdalar CRF-afferents provides a 
potential mechanism for the eCB system to modulate the stress response and attenuate 
stress-induced dysregulation of frontal cortical activity, which may result in enhancing 
traumatic memory extinction and diminish anxiety-like behaviors. 
A smaller percentage of, CRF-afferents co-expressing CB1r in the peri-LC 
formed Type II or symmetric synapses; therefore, the eCB system could also have an 
effect on CRF projections from the BNST. Unlike the peri-LC, a large majority of CB1r 
and CRF dual labeled synapses in the core region were of the inhibitory type (Type II 
synapses). GABA + CRF afferents originate in regions responsible for providing sensory 
and autonomic stimuli to the LC (Aston-Jones et al. 1991; Samuels and Szabadi 2008; 
Van Bockstaele et al. 2001). LC neuronal activity has a biphasic effect on arousal and 
attention: low tonic activity via involvement of GABA is associated with disengagement 
from the environment while phasic activity is optimal for sustained focused attention 
(Aston-Jones 1985; Aston-Jones and Cohen 2005). High tonic activity correlates with a 
shift towards scanning the environment and heightened arousal (Aston-Jones and Cohen 
2005; Berridge and Waterhouse 2003; Valentino and Van Bockstaele 2008b). While an 
initial shift to high tonic activity results in CRF-induced increases in behavioral 
engagement and scanning and is beneficial for adaptive responses to a stressor, chronic 
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high tonic activity disrupts focused attention (Aston-Jones and Cohen 2005; Valentino 
and Van Bockstaele 2008b). In this regard, eCB modulation of CRF could act to return 
LC activity to optimal phasic levels. 
 In other brain regions, such as the hippocampus and cerebellum, it has been 
shown that CB1r, can be located in the peri-synaptic region of both excitatory and 
GABAergic synapses (Kawamura et al. 2006; Nyiri et al. 2005). It is possible that further 
studies examining the regions adjacent to CRF afferents would reveal CB1r localization. 
Moreover, while CB1r is the predominant cannabinoid receptor in the brain (Scavone et 
al. 2010; Wyrofsky et al. 2015), eCBs can act at other receptors. Specifically, AEA has 
been shown to bind and activate transient receptor potential vanilloid type 1 receptors 
(TRPV1), resulting in long term depression within the dentate gyrus in a CB1r-
independent manner (Chavez et al. 2010; Ryskamp et al. 2014). TRPV1 expression has 
been reported in the LC (Caterina 2003; Toth et al. 2005). Future immunoelectron 
microscopy studies could examine the exact location of TRPV1 receptors, and if they are 
localized to excitatory CRF-containing terminals, they could represent another manner in 
which the eCB system could affect stress input from the PVN, Bar, and PGi. 
 Additionally, our data demonstrate CB1r labeling in somatodendritic processes, 
consistent with our previous reports (Scavone et al. 2010). It is not clear whether these 
CB1r are functional within the LC or whether these are CB1r being transported to 
noradrenergic axon terminals in the frontal cortex. We have previously demonstrated that 
noradrenergic axon terminals in the prefrontal cortex exhibit CB1r (Oropeza et al. 2007) 
and LC neurons express CB1r mRNA (Tsou et al. 1998; Matsuda et al. 1993). 
Interestingly, there is evidence for functional postsynaptically distributed CB1 receptors 
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in other brain regions. Cytoplasmic CB1r distribution has been observed within the rat 
caudate putamen nucleus (Rodriguez et al. 2001). Also, in HEK-293 cells transfected 
with CB1r, ~85% of CB1r are localized in intracellular vesicles (Leterrier et al. 2004), 
and the changes in subcellular localization seems to be attributed to activation-dependent 
internalization via endosomes during steady state conditions (Thibault et al. 2013).  
Ongoing slice physiology studies within the LC in our laboratory are exploring the 
functional significance of postsynaptically distributed CB1r (Wyrofsky et al. 2016). 
Therefore, future studies will provide critical information on the functional significance 
of pre- and post-synaptically distributed CB1r in the LC. 
 
Functional implications 
Targeting the eCB regulation of the LC-NE stress-integrative circuit could 
provide therapeutic relief for various stress-induced anxiety disorders (Wyrofsky et al. 
2015). For example, the inability to extinguish aversive and fearful memories coupled 
with repeated re-consolidation of these memories in limbic circuits underlies the 
pathophysiology of post-traumatic stress disorder (PTSD) and other anxiety disorders 
(Jovanovic and Ressler 2010; Lehner et al. 2009), and NE is involved in both processes.  
Consolidation of emotional memories involves LC-NE inputs to the amygdala (Ferry et 
al. 1999; McGaugh et al. 1996), while extinction of these memories involves LC-NE 
signaling in the mPFC (Mueller and Cahill 2010; Mueller et al. 2008). Several 
cannabinoid receptor ligands including THC (an active component in cannabis) and 
nabilone (a synthetic cannabinoid ligand) have shown promise in clinical studies at 
reducing the symptoms and flashbacks associated with PTSD (Fraser 2009; U.S. National 
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Institutes of Health 2012), and many individuals suffering from PTSD self-medicate with 
cannabis (Passie et al. 2012). 
Interestingly, cannabinoids are known to affect anxiety in a bi-directional and 
dose-dependent manner, with lower doses generally producing anxiolytic effects while 
higher doses result in anxiogenesis (Rey et al. 2012; Trezza and Vanderschuren 2008; 
Viveros et al. 2005). A recent study using CB1r conditional knock out mice showed that 
CB1r activation on GABAergic neurons in the forebrain is necessary for the anxiogenic 
effects of cannabinoids, while CB1r activation on cortical glutamatergic neurons is 
necessary for the anxiolytic effects (Rey et al. 2012). It is tempting to speculate that a 
similar mechanism applies to eCB modulation of CRF afferents in the LC. We have 
previously shown that CB1r is positioned to modulate at symmetric and asymmetric 
synapses (Scavone et al. 2010). Moreover, using single-unit extracellular recordings have 
demonstrated that CB1r activation can modulate synaptic transmission within the LC via 
the glutamatergic and GABAergic systems (Muntoni et al., 2006; Mendiguren & Pineda 
2004). While these data provide evidence of CB1r activation of LC through the excitatory 
and inhibitory neurotransmission, our present results is the first report illustrating the 
distribution and topography of CB1r modulation of glutamatergic and GABAergic CRF-
afferents not only at the immunofluorescence level but more importantly and 
interestingly at the ultrastructural level. In addition, this is the first report showing 
differential topography in synaptic signature of CB1r and CRF co-localization where 
asymmetric synapses indicative of excitatory transmission predominate in the peri-LC 
and symmetric synapse predominates in LC core indicative of inhibitory transmission. 
CRF-afferents co-localizing CB1r in the peri-LC and forming asymmetric synapses 
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suggest co-localization with glutamate (Van Bockstaele et al. 1996a, 1999), and we have 
shown CB1r and CRF co-localization within afferents originating from the amygdala, a 
brain region responsible for providing fear-related stimuli and emotional input (Davis 
1992; Kamprath et al. 2006; Walker et al. 2003). Blocking signaling from the amygdala 
via CB1r activation in the peri-LC could contribute to cannabinoid-induced anxiolytic 
effects. Because dysregulation of NE in the mPFC is known to contribute to the 
development of anxiety disorders (Anand and Charney 2000; Carvalho and Van 
Bockstaele 2012; Itoi and Sugimoto 2010; Nutt 2006; Southwick et al. 1999), targeting 
the eCB modulation of CRF afferents in the LC during stress may underlie the efficacy of 
nabilone in PTSD patients.  
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Abstract 
 
Social stress is a major contributor to the development of anxiety and psychological 
disorders, largely through the excitatory effects of corticotropin releasing factor (CRF) on 
locus coeruleus (LC)-norepinephrine (NE) system.  Increased NE efflux in the medial 
prefrontal cortex (mPFC) and hyperactivity of noradrenergic LC neurons contributes to 
the pathology of anxiety and depression.  However, not all exposed to social stress will 
develop such disorders, as different coping strategies and cellular adaptations exist 
between resilient and vulnerable individuals.  Rodents exposed to the resident-intruder 
model of social stress developed two distinct phenotypes based on the latency to assume 
a defeated posture: the resilient long latency rats and the vulnerable short latency rats.  
Previous studies have found that alterations to the opioid system underlie differences 
observed between both groups.  Given that the endocannabinoid (eCB) system modulates 
noradrenergic transmission and functions as an anti-stress neuromediator, it is possible 
that cellular adaptations to the eCB system might also contribute to the different coping 
strategies.  Therefore, the levels of diacylglycerol lipase (DGL), responsible for 
synthesizing eCBs, and fatty acid amide hydrolase (FAAH), responsible for degrading 
eCBs, were determined across sexes via Western blot analysis of LC from male and 
female following social defeat.  While no change in FAAH expression was observed, 
long latency rats had lower levels of DGL and short latency rats had heightened DGL 
expression.  Additionally, a significant decrease in CRF type 1 receptor expression was 
found in both males and females.  These cellular adaptations suggest that the eCB system 
might play a role in the different coping strategies. 
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Introduction 
 
 Chronic stress is known to contribute to the pathophysiology of psychological 
disorders (McEwen, 2008, Carvalho and Van Bockstaele, 2012).  In our current society, 
people experience social stressors – death of a family member, divorce, bullying, 
psychological abuse – more often than any other type (Kendler et al., 1995, Bjorkqvist, 
2001).  Each of these types of stressors has been correlated to an increased likelihood of 
developing depression or anxiety disorders (Kessler et al., 1994, Kendler et al., 1995).  
One of the most well established animal models for social stress is the resident-intruder 
paradigm, in which a smaller intruder rat is exposed to a more aggressive resident rat.  
Rats exposed to repeated social defeat by the larger resident rat develop increased 
depressive- and anxiety-like phenotypes as well as long lasting hyperactivation of stress 
signaling and the hypothalamic-pituitary-adrenal (HPA) axis (Wood et al., 2010, Wood 
and Bhatnagar, 2015). 
 While the type and severity of stressor bears importance on the development of 
psychiatric disorders, so does the individual’s ability to cope with the stress.  Active 
coping strategies center around behavioral responses in an attempt to minimize harm and 
reduce stress, and often lead to resilience from the anxiogenic effects of the social 
stressor (Veenema et al., 2003, Wood and Bhatnagar, 2015).  Passive coping strategies 
involve feelings of helplessness and immobility, which are associated with an increased 
susceptibility to depression and anxiety disorders (Billings and Moos, 1984, Wood and 
Bhatnagar, 2015).  These two coping strategies can be observed in the resident-intruder 
model by separating rats based on their average latency to assume a defeated posture. 
Rats belonging to the short latency group exhibit HPA axis dysregulation and depressive-
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like behaviors, while those in the long latency group show decreased efficacy of CRF and 
appear to be more resilient to the development of depressive-like behaviors (Wood et al., 
2010, Wood and Bhatnagar, 2015). 
 The stress-integrative locus coeruleus (LC) is responsible for providing 
norepinephrine (NE) throughout the entire neuraxis and medial prefrontal cortex (mPFC), 
where dysregulation in NE levels can lead to depression and anxiety (Valentino and Van 
Bockstaele, 2005, Carvalho and Van Bockstaele, 2012).  The LC is sensitive to social 
stressors (Chaijale et al., 2013), and the resident-intruder paradigm robustly increases 
sympathetic activation acutely compared to non-social stress paradigms (Sgoifo et al., 
1999).  Corticotropin releasing factor (CRF) is responsible for the increased LC-NE 
activity following a stressor via corticotropin releasing factor type 1 receptor (CRFr1) 
(Curtis et al., 1996, Curtis et al., 2012).  The endocannabionid (eCB) system modulates 
the stress response in many brain regions (Wyrofsky et al., 2015), and recent studies have 
localized the cannabinoid type 1 receptor (CB1r) to CRF-containing afferents in the LC, 
suggesting that the eCB system is positioned to modulate the stress response within this 
noradrenergic nucleus (Wyrofsky et al., 2017).  Previous studies investigating the effect 
of social stress on the LC in male rats have found a decrease in LC-NE activity following 
repeated stress, compared to an increase in activity after an acute stressor (Chaijale et al., 
2013).  Additionally, differences in cellular adaptations in the LC occur across 
phenotypes, with an increase in opioid signaling in long latency rats compared to short 
latency and control groups, suggesting one mechanism for combating chronic stress in 
the LC (Chaijale et al., 2013, Reyes et al., 2015). 
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 In order to determine whether differences in another anti-stress system - the eCB 
system - exist between the long and short latency groups, Western blot analysis was 
performed on LC micropunches from control, short latency, and long latency groups.  
Both male and female rats were tested, as sex differences in stress circuitry, the eCB 
system, and the prevalence of psychiatric disorders exist (Kendler et al., 1995, Marcus et 
al., 2005, Reich et al., 2009, Bangasser and Valentino, 2012, Craft et al., 2013).  The two 
most common eCBs, 2-arachidonoylglycerol (2-AG) and arachidonylethanolamide 
(AEA), are often up- and down-regulated following acute and chronic stress via their 
synthesis and degradation (Hill et al., 2010, Morena et al., 2016).  Fatty acid amide 
hydrolase (FAAH) is responsible for the degradation of AEA, and diacylglycerol lipase  
α (DGL) synthesizes 2-AG (Castillo et al., 2012).  Therefore, changes in both FAAH and 
DGL expression levels across phenotypes and sexes were examined. 
 
Methods 
Protein sample extracts from the LC were generously procured from Dr. Seema  
Bhatnagar’s laboratory at the Children’s Hospital of Pennsylvania.  The resident-intruder 
paradigm and protein extraction and quantification were performed by members of the 
Bhatnagar and Valentino Laboratories. 
 
Resident-intruder paradigm 
Male and female Sprague-Dawley rats (275-300g) were used as controls and 
intruders.  Larger male Long-Evans retired breeders (650-850g) and lactating female 
Long-Evans breeders were used as residents (Charles River, Wilmington, MA).  The 
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paradigm was based on the model established originally by Miczek (Miczek, 1979), and 
has been previously described (Wood et al., 2010).  For each social stress episode, the 
intruder rat was placed in the home cage of a novel aggressive resident rat.  Once the 
intruder rat assumed a subordinate defeated position for approximately 3 sec, the rats 
were separated by a wire mesh to prevent further physical contact between the two 
rodents.  Intruder rats remained in the wire mesh enclosure until the 30-minute session 
was complete, at which time they were returned to their own home cage.  Control rats 
were placed in a novel cage for 30 mins, in a wire mesh enclosure.  This procedure 
occurred for 5 consecutive days, and after the final session, rats were rapidly decapitated, 
brains extracted, and tissue was flash frozen for later use.  Intruder rats were separated 
into short or long latency groups based on the average time it took for them to reach 
subordination: short latency < 300s, long latency > 300s.  
 
Protein extraction and quantification 
The LC region was microdissected from male and female control, short latency, 
and long latency rats.  Tissue punches were homogenized with a pestle, sonicated, and 
extracted in radioimmunoprecipitation assay lysis buffer with a protease inhibitor cocktail 
on ice for 20 min.  Lysates were cleared by centrifugation at 13,000 rpm for 12 min at 
4oC, and supernatants were extracted.  Protein concentrations were quantified using the 
bicinchoninic acid protein assay reagent. 
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Western blot analysis 
Protein extracts were diluted with an equal volume of Novex 2© tris glycine 
sodium dodecyl sulfate sample buffer (Invitrogen, Carlsbad, CA, USA) containing 
dithiothreitol (Sigma-Aldrich Inc., St. Louis, MO, USA).  Cell lysates containing equal 
amounts of protein (30 µg per condition) were separated on 10% tris-glysine 
polyacrylamide gels and then electrophoretically transferred to Immobilon-P 
polyvinylidene fluoride membranes (Millipore, Bedford, MA, USA).  Membranes were 
blocked with Odyssey buffer (1 h, diluted in 0.01M PBS 1:1) and incubated in the 
various combinations of the following primary antibodies overnight at room temperature 
rabbit anti-diacylglycerol lipase α (DGL; 1:500) rabbit anti-fatty acid amide hydrolase 
(FAAH; 1:250), and rabbit anti-CRF receptor type 1 (CRFr1; 1:500).  Mouse anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:2000) was used as a loading 
control, to account for potential variability in amount of sample loaded.  Membranes 
were then rinsed and incubated with infrared fluorescent secondary antibodies (Licor, 
Lincoln, NE, USA) for 1 h: donkey anti-rabbit IRDye 800CW (1:15000), goat anti-mouse 
IRDye680LT (1:20000).  Membranes were scanned using the Odyssey Infrared Imaging 
System (Licor, Lincoln, NE, USA), and protein quantification was determined using 
Odyssey Infrared Imaging software. 
Protein quantification was normalized to the loading control, and all data is 
presented as a ratio of sample protein level to GAPDH level, to allow for comparison 
between groups.  Additionally, Chameleon Duo Pre-stained Protein Ladder (Licor, 
Lincoln, NE, USA) was used to determine the molecular weights of protein bands 
observed: GAPDH – ~37 kDa, CRFr1 – ~50 kDa, FAAH - ~63 kDa, DGL - ~110 kDa.  
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Data represents N=6 male control rats, N=7 male long latency rats, N=5 male short 
latency rats, N=6 female control rats, N=5 female long latency rats, N=6 female short 
latency rats. 
  
Data analysis 
Differences in protein expression levels were tested using two-way ANOVAs (sex 
vs. phenotype) followed by post-hoc Tukey’s multiple comparison adjustments. Statistics 
were performed using GraphPad Prism 7.03 (GraphPad Software, San Diego, CA, USA).  
Results are presented as mean +/- SEM. 
 
Results 
Effect of social stress on eCB protein expression in the LC 
Western blot analysis of LC tissue from various social defeat groups across sexes 
revealed differential expression of DGL levels (Fig. 3.1A). Analysis of control rats 
showed that under basal conditions, there is a sex difference in DGL levels in the LC: 
females (0.489 ± 0.092) had significantly lower expression compared to males (0.748 ± 
0.094; p<0.05). Regarding change in expression across phenotypes, males had a 
significant reduction in DGL expression in the long latency group (0.457 ± 0.046) 
compared to control (p<0.05), while no significant change between control and short 
latency groups (0.581 ± 0.033) was observed.  In females, no change between control and 
long latency groups (0.514 ± 0.063) was found; however, there was a significant increase 
in short latency females (0.807 ± 0.082; p<0.05) compared to control. 
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Figure 3.1 
Western blot analysis of diacylglycerol lipase α (DGL), fatty acid amide hydrolysis 
(FAAH) in male and female rats following 5 days of social stress 
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Figure 3.1:  Western blot analysis of diacylglycerol lipase α (DGL), fatty acid amide 
hydrolysis (FAAH) in male and female rats following 5 days of social stress.  Bands 
shown are representative of one sample obtained from one animal per group.  a.  Western 
blot analysis for DGL expression in protein extracts from the LC showed that DGL 
expression is decreased in male long latency rats compared to control, while DGL 
expression is increased in female short latency rats compared to control.  Additionally, 
female control rats showed significantly less DGL expression compared to males.  b.  
Western blot analysis for FAAH expression in protein extracts from the LC showed no 
significant differences between males and females across phenotypes.  Data represent 
mean ± SEM.  Asterisks indicate a significant difference between groups as determined 
by two-way ANOVA/mixed-effects regression model (* p<0.05). 
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Figure 3.2 
Western blot analysis of corticotropin releasing factor type 1 receptor (CRFr1) in male 
and female rats following 5 days of social stress. 
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Figure 3.2:  Western blot analysis of corticotropin releasing factor type 1 receptor 
(CRFr1) in male and female rats following 5 days of social stress.  Bands shown are 
representative of one sample obtained from one animal per group.  Western blot analysis 
for CRFr1 expression in protein extracts from the LC revealed a significant decrease in 
levels in male and female long latency groups compared to control, and no change 
between short latency groups and control.  Data represent mean ± SEM.  Asterisks 
indicate a significant difference between groups as determined by two-way ANOVA/ 
mixed-effects regression model (* p<0.05). 
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When examining FAAH (Fig. 3.1B), no significant changes in expression levels 
were detected between sexes or phenotypes. FAAH protein expression across sex and 
phenotype was as follows: male control – 0.923 ± 0.030, male long latency 0.762 ±  
0.040, male short latency – 0.815 ± 0.052, female control – 0.714 ± 0.085, female long 
latency – 0.634 ± 0.045, female short latency – 0.825 ± 0.087. 
 
Effects of social stress on CRFr1 expression in the LC 
CRF exerts its effects on LC-NE neurons via CRFr1, which are expressed 
throughout the LC and are very prominent in the peri-LC region (Valentino and Van 
Bockstaele, 2005, Reyes et al., 2008). Western blot analysis revealed that, in addition to 
altering the eCB system, changes in CRFr1 receptor expression were identified across 
phenotypes (Fig. 3.2). CRFr1 levels in LC tissue from both long latency males and 
females were significantly decreased compared to male and female controls (p<0.05), and 
no significant difference between short latency and control groups was detected. Relative 
protein expression for CRFr1 across sex and phenotype was as follows: male controls – 
0.880 ± 0.047, male long latency – 0.684 ± 0.042, male short latency – 0.817 ± 0.052, 
female control – 0.888 ± 0.036, female long latency – 0.678 ± 0.018, female short latency 
0.087 ± 0.042. Decreased CRFr1 expression in the LC of long latency male rats was 
previously identified (Chaijale et al., 2013). A similar trend was found in females, 
confirming that the resilient long latency rats have decreased responsiveness to CRF 
following chronic social stress across both sexes, suggesting one mechanism by which 
long latency rats are protecting themselves from social stress and a resulting increase in 
CRF levels. 
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Discussion 
 Chronic social stress has been shown to differentially alter opioid signaling in the 
LC across long and short latency phenotypes in male rats.  The present study 
demonstrates that the eCB system is also affected following social defeat stress in both 
male and female rats.  Via Western blot analysis, DGL expression was significantly 
decreased in the LC of long latency social defeat male rats compared to control, while 
females showed a significant increase in DGL expression in short latency rats compared 
to control.  Additionally, basal sex differences in DGL levels exist, with females having 
lower expression than males.  No significant change in LC FAAH expression was 
observed across sex or phenotype.  When investigating CRFr1 expression in the LC 
following social stress, males and females showed the same trend: a significant decrease 
in long latency rats compared to control, and no significant change in short latency rats.  
These data confirm that the differences in the eCB system exist between the resilient long 
latency and more vulnerable short latency rats. 
 
Differences in DGL expression across phenotypes 
 DGL is one of the main proteins responsible for the synthesis of eCB 2-AG 
(Castillo et al., 2012).  A decrease in DGL expression would suggest a decrease in 2-AG 
synthesis while, conversely, an increase in DGL expression would suggest an increase in 
2-AG levels.  Based on the data above, male long latency rats have a decrease in DGL 
levels compared to control, and female short latency rats have an increase in DGL levels 
compared to control.  DGL expression across sexes for short latency and long latency 
groups show no significant difference, with long latency rats having higher DGL 
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expression compared to short latency.  This implies short latency rats have more 2-AG in 
the LC compared to long latency, suggesting there is increased eCB signaling in the short 
latency groups.  In regards to the basal sex difference observed in DGL levels in control 
rats, greater expression was observed in males compared to females.  This might suggest 
that the eCB system is primed and ready to combat stress in males, and that females have 
less tonic 2-AG regulation of LC-NE excitability.  Indeed, Krebs-Craft et al. (2010) have 
discovered that males have higher levels of AEA and 2-AG in the amygdala compared to 
males (Craft et al., 2013), confirming region specific sex differences within the eCB 
system. 
 One hallmark characteristic of the short latency group is an inability to attenuate 
HPA axis hyperactivity, while the rats in the long latency group have both decreased 
HPA axis activity as well as a decreased efficacy of CRF in the paraventricular nucleus 
(PVN) of the hypothalamus (Wood et al., 2010).  Studies have found that elevated 
corticosterone levels are responsible for increasing 2-AG (Morena et al., 2016), thus HPA 
axis hyperactivity in short latency rats could be responsible for the heightened DGL 
expression.  Since short latency rats have heightened stress signaling, increased DGL and 
2-AG levels could be an attempt to counteract increased CRF levels and aberrant LC-NE 
activity.  Conversely, long latency rats have developed adaptations in brain regions such 
as the PVN to keep HPA axis and stress levels in balance (Wood et al., 2010); therefore, 
an increase in eCB synthesis within the LC is not necessary to maintain normal LC-NE 
activity. 
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Functional consequences 
Active coping strategies often involve high sympathetic and noradrenergic 
reactivity in response to a stressful stimulus (Fokkema et al., 1995, Walker et al., 2009).  
While hyperactive stress signaling and CRF release in the LC would cause an increase in 
LC-NE activity, this is maladaptive chronically, and can lead to the development of 
psychiatric disorders (Valentino and Van Bockstaele, 2008).  By having a decrease in 
CRFr1 levels and an increase in opioid signaling, resilient long latency rats might be 
protecting themselves from LC-NE hyperactivity (Reyes et al., 2015).  Coupled with 
lower DGL expression, long latency rats exposed to a stressor could have a more 
moderate and appropriate increase in LC-NE activity.  This would allow resilient rats to 
engage in active coping strategies that involve successful cognitive functioning, as a 
robust increase in high phasic low tonic LC-NE activity via CRF can cause problems 
with focused attention and hyperarousal (Valentino and Van Bockstaele, 2008). 
In humans, when chronic stress is not attenuated, pathological changes can lead to 
the development of PTSD and anxiety disorders (Valentino and Van Bockstaele, 2008, 
Wood and Bhatnagar, 2015).  Indeed, HPA hyperactivity and CRF release is often found 
in individuals suffering from major depression (Swaab et al., 2005).  These clinical 
findings correspond with the above observations from social defeat rats, and changes in 
eCB signaling between long latency and short latency groups might be an additional 
mechanism responsible for resilience, further implicating the eCB system as a viable 
target for the treatment of psychological disorders. 
 
 
	   155	  	  
Acknowledgements 
This project was supported by the National Institutes of Health grants DA020129 
to E.J. Van Bockstaele and MH093981 to S. Bhatnagar. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   156	  	  
References 
 
 
Bangasser DA, Valentino RJ (2012) Sex differences in molecular and cellular substrates 
of stress. Cellular and Molecular Neurobiology 32:709-723. 
Billings A, Moos RH (1984) Coping, stress, and social resources among adults with 
unipolar depression. Journal of Personality Social Psychology 46:877-891. 
Bjorkqvist K (2001) Social defeat as a stressor in humans. Physiological Behavior 
73:435-442. 
Carvalho AF, Van Bockstaele EJ (2012) Cannabinoid modulation of noradrenergic 
circuits: Implications for psychiatric disorders. Progress in Neuro-
Psychopharmacology and Biological Psychiatry 38:59-67. 
Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012) Endocannabinoid signaling 
and synaptic function. Neuron 76:70-81. 
Chaijale N, Curtis A, Wood S, Zhang X-Y, Bhatnagar S, Reyes BA, Van Bockstaele EJ, 
Valentino RJ (2013) Social stress engages opioid regulation of locus coeruleus 
norepinephrine neurons and induces a state of cellular and physical opiate 
dependence. Neuropsychopharmacology 38:1833. 
Craft RM, Marusich JA, Wiley JL (2013) Sex differences in cannabinoid pharmacology: 
A reflection of differences in the endocannabinoid system? Life Sciences 92:476-
481. 
Curtis A, Lechner SM, Pavcovich LA, Valentino RJ (1996) Activation of the locus 
coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-
releasing factor: effects on discharge rate, cortical norepinephrine levels and 
cortical electroencephalographic activity. Journal of Pharmacol Experimental 
Therapeutics 281:163-172. 
Curtis A, Leiser SC, Snyder K, Valentino RJ (2012) Predator stress engages 
corticotropin-releasing factor and opioid systems to alter the operating mode of 
locus coeruleus norepinephrine neurons. Neuropharmacology 62:1737-1745. 
Fokkema D, Koolhaas J, van der Gugten J (1995) Individual characteristics of behavior, 
blood pressure, and adrenal hormones in colony rats. Physiological Behavior 
57:857-862. 
	   157	  	  
Hill MN, Patel S, Campolongo P, Tasker JG, Wotjak CT, Bains JS (2010) Functional 
interactions between stress and the endocannabinoid system: from synaptic 
signaling to behavioral output. The Journal of Neuroscience 30:14980-14986. 
Kendler KS, Kessler RC, Walkers EE, MacLean C, Neale MC, Heath AC, Eaves LJ 
(1995) Stressful life events, genetic liability, and onset of an episode of major 
depression in women. American Journal of Psychiatry 152:833-842. 
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, 
Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric 
disorders in the United States. Results from the National Comorbidity Survey. 
Arch Gen Psychiatry 51:8-19. 
Krebs-Kraft D, Hill MN, Hillard CJ, McCarthy M (2010) Sex differences in cell 
proliferation in developing rat amygdala mediated by endocannabinoids has 
implications for social behavior. Proceedings of the National Academy of 
Sciences USA 107:20535-20540. 
Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, Wisniewski 
SR, Balasubramani GK, Trivedi MH, Rush AJ (2005) Gender differences in 
depression: findings from the STAR*D study. Journal of Affective Disorders 
87:141-150. 
McEwen BS (2008) Central effects of stress hormones in health and disease: 
understanding the protective and damaging effects of stress and stress mediators. 
European Journal of Pharmacology 583:174-185. 
Miczek K (1979) A new test for aggression in rats without aversive stimulation: 
differential effects of d-amphetamine and cocaine. Psychopharmacology 60:253-
259. 
Morena M, Patel S, Bains JS, Hill MN (2016) Neurobiological interactions between 
stress and the endocannabinoid system. Neuropsychopharmacology 41:80-102. 
Reich C, Taylor M, McCarthy M (2009) Differential effects of chronic unpredictable 
stress on hippocampal CB1 receptors in male and female rats. Behavioural Brain 
Research 203:264-269. 
	   158	  	  
Reyes BA, Valentino RJ, Van Bockstaele EJ (2008) Stress-induced intracellular 
trafficking of corticotropin-releasing factor receptors in rat locus coeruleus 
neurons. Endocrinology 149:122-130. 
Reyes BA, Zitnik G, Foster C, Van Bockstaele EJ, Valentino RJ (2015) Social stress 
engages neurochemically-distinct afferents to the rat locus coeruleus depending 
on coping strategy. eNeuro 2:1-12. 
Sgoifo A, Koolhaas J, Musso E, De Boer S (1999) Different sympathovagal modulation 
of heart rate during social and nonsocial stress episodes in wild-type rats. 
Physiology & Behavior 67:733-738. 
Swaab D, Bao A, Lucassen P (2005) The stress system in the human brain in depression 
and neurodegeneration. Ageing Research Reviews 4:141-194. 
Valentino RJ, Van Bockstaele EJ (2005) Functional interactions between stress 
neuromediators and the locus coeruleus-norepinephrine system. Techniques in the 
Behavioral and Neural Sciences 15:465-486. 
Valentino RJ, Van Bockstaele EJ (2008) Convergent regulation of locus coeruleus 
activity as an adaptive response to stress. European Journal of Pharmacology 
583:194-203. 
Veenema A, Meijer O, De Kloet E, Koolhaas J (2003) Genetic selection for coping style 
predicts stressor susceptiblity. Journal of Neuroendocrinology 15:256-267. 
Walker F, Masters L, Dielenberg R, Day T (2009) Coping with defeat: acute 
glucocorticoid and forebrain responses to social defeat vary with defeat episode 
behavior. Neuroscience 162:244-253. 
Wood S, Bhatnagar S (2015) Resilience to the effects of social stress: evidence from 
clinical and preclinical studies on the role of coping strategies. Neurobiology of 
Stress 1:164-173. 
Wood S, Walker H, Valentino RJ, Bhatnagar S (2010) Individual differences in reactivity 
to social stress predict susceptibility and resilience to a depressive phenotype: role 
of corticotropin-releasing factor. Neuroendocrinology 151:1795-1805. 
Wyrofsky RR, McGonigle P, Van Bockstaele EJ (2015) Drug discovery strategies that 
focus on the endocannabinoid signaling system in psychiatric disease. Expert 
Opinion on Drug Discovery 10:17-36. 
	   159	  	  
Wyrofsky RR, Reyes BAS, Van Bockstaele EJ (2017) Co-localization of the cannabinoid 
type 1 receptor with corticotropin-releasing factor-containing afferents in the 
noradrenergic nucleus locus coeruleus: implications for the cognitive limb of the 
stress response. Brain Structure & Function 1-17. 
 	  
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   160	  	  
	  	  
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   161	  	  
Overall Conclusions 
Through numerous techniques, the experiments presented in this thesis greatly 
improve our understanding of the CB1r role in the LC.  First, the functional consequences 
of CB1r deletion on LC-NE activity across sexes were determined.  CB1r-KO caused a 
significant increase in noradrenergic indices in male mice compared to WT: KO mice had 
an increase in LC-NE excitability, input resistance, TH expression within the LC, and NE 
levels in the mPFC.  These noradrenergic indices were not significantly different 
following CB1r deletion in female mice.  Western blot analyses of LC tissue from male 
and female CB1r/CB2r-KO mice also highlighted several sex differences.  Male 
CB1r/CB2r-KO mice showed a significant increase in CRF expression and in NET 
expression compared to male WT mice, while female CB1r/CB2r-KO mice showed a 
significant increase in α2-AR expression compared to female WT mice, and these 
adaptations might play a role in the resulting dysregulation of LC-NE activity that occurs 
in male but not female CB1r-KO mice.  Second, while 300 nM CRF was capable of 
increasing LC-NE excitability in WT brain slices from both male and female mice, LC-
NE neurons from CB1r-KO mice were not affected by 300 nM CRF bath application, 
which could be due to other cellular adaptations that have occurred in the CB1r-KO mice.  
Third, direct anatomical evidence has been provided for CB1r modulation of CRF-
containing afferents.  Via immunofluorescence and immunoelectron microscopy, co-
localization between CB1r and the CRF peptide in both the core and peri-LC was 
detected, suggesting that CB1r activation by endogenous and exogenous cannabinoids 
could produce an effect on CRF release in the LC and subsequent LC-NE neuronal 
activity.  Finally, Western blot analysis of LC tissue from social defeat animals showed 
	   162	  	  
male long latency rats had decreased expression of the eCB synthesizing enzyme DGL 
compared to control, while female short latency rats had higher levels compared to 
control, highlighting differences in the eCB system between resilient and vulnerable rats 
across sexes.  Additionally, control males had higher DGL expression compared to 
control females, suggesting a sex difference in basal eCB tone in the LC.  These studies 
combined demonstrate the importance of proper CB1r signaling in the LC, especially in 
males where deletion results in aberrant LC-NE excitability, and provide another 
mechanism by which the eCB system can modulate stress circuitry. 
 
Research Implications Across Studies 
 Studies examining CB1r in other brain regions have demonstrated the importance 
of the eCB system in regulating various aspects of the stress response.  From CB1r in the 
paraventricular nucleus of the hypothalamus and eCB involvement in the negative 
feedback loop of the HPA axis (Patel et al., 2004, Hill and McEwen, 2009, Hill and 
Tasker, 2012), to activation of CB1r in the amygdala via fluctuating levels of eCB to help 
control the fear response when a stressor is not present (Hill et al., 2009, Gunduz-Cinar et 
al., 2013), this system has repeatedly been identified as a key modulator of stress 
signaling.  The new data presented above provide further evidence for the importance of 
the eCB system in modulating the stress response, specifically within the LC.  Global 
lifetime deletion of CB1r in males causes an increase in CRF within the LC, which 
supports previous findings that CB1r-KO mice have heightened HPA axis activity.  
However, an increase in LC-NE excitability and a subsequent increase in NE efflux in the 
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mPFC demonstrate that CB1r deletion also significantly affects the cognitive limb of the 
stress response. 
 
Role of eCB System in LC-NE Activity 
CB1r mRNA and protein expression have been localized within the LC 
(Herkenham et al., 1991, Mailleux and Vanderhaeghen, 1992, Matsuda et al., 1993, 
Derbenev et al., 2004).  Additionally, electron microscopy studies have shown that CB1r 
are found on presynaptic axon terminals that synapse with NE-producing LC neurons as 
well as post-synaptically in somatodendritic processes of LC cells (Scavone et al., 2010).  
The presence of CB1r on LC-NE neurons is functional, as indicated by 
electrophysiological studies showing that CB1r agonists and FAAH inhibitors increase 
the basal firing rate of LC-NE cells, c-Fos expression of LC neurons, and NE efflux in 
the mPFC (Gobbi et al., 2005, Oropeza et al., 2005, Mendiguren and Pineda, 2006, 
Muntoni et al., 2006, Page et al., 2008).  Additionally, there is tonic eCB production in 
the LC, as sole application of a CB1r antagonist is capable of decreasing LC-NE activity 
(Muntoni et al., 2006, Carvalho and Van Bockstaele, 2012).  Interestingly, the LC 
appears to be under biphasic regulation of the eCB system, as other studies have found 
that systemic administration of rimonabant, a CB1r antagonist, increases NE levels in the 
mPFC and PVN (Tzavara et al., 2001, Tzavara et al., 2003), and low levels of THC can 
cause a decrease in NE release from synaptosomes (Poddar and Dewey, 1980).  
Therefore, it appears that the eCB system serves to modulate the LC-NE system to 
maintain an optimal level of activity. In support of this, our laboratory has recently 
demonstrated a reduction in basal mPFC neuronal excitability in CB1r-KO mice, caused 
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by desensitization of the normally excitatory mPFC α2-adrenoceptors (ARs) (Reyes et 
al., 2017).  This indicates that without a functioning eCB system, aberrant LC-NE 
activity is observed, where CB1r-KO mice have increased LC-NE activity, resulting in 
mPFC α2-AR desensitization, and subsequent decreased mPFC output (Fig. 3).   
Additionally, when LC-NE neurons are excited via potassium chloride (KCl) bath 
application, CB1r agonist pre-treatment is capable of attenuating the KCl-induced 
increases in LC-NE firing (Mendiguren and Pineda, 2007).  These data suggest that the 
eCB system might function to prevent over-activation of LC-NE neurons. 
Since CRF release in the LC increases LC-NE excitability and activity, it is 
tempting to speculate that the eCB system can serve to attenuate these CRF-induced 
increases as well (Curtis et al., 1996).  Indeed, the immunofluorescence studies 
performed in chapter 2 demonstrated that CB1r are co-localized with CRF in the rat LC.   
Additionally, using Phaseolus Vulgaris Leucoagglutinin (PHAL) as an anterograde tracer 
injected into the amygdala, CB1r are directly positioned to regulate CRF release from 
amygdalar limbic afferents.  Immunoelectron quantification has confirmed that CB1r are 
localized both pre- and post-synaptically with respect to CRF in both the core and peri-
LC and in both excitatory and inhibitory synapses.  These findings provide an anatomical 
substrate for direct eCB modulation of CRF.  Because aberrant NE release in the mPFC 
contributes to the development of stress-induced psychiatric disorders, eCB modulation 
of CRF release in the LC during stress could play a role in the anxiolytic effects of CB1r 
agonists. 
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Figure 3 
Schematic depicting alterations to LC-mPFC microcircuit in male CB1r-KO mice. 
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Figure 3: Schematic depicting alterations to LC-mPFC microcircuit in male CB1r-
KO mice. A. The nucleus paragigantocellularis (PGi) and paraventricular nucleus of the 
hypothalamus (PVN) provide excitatory/glutamatergic (green neurons) input and the 
nucleus prepositus hypoglossi (PrH) provides inhibitory/GABAergic (red neurons) to the 
locus coeruleus (LC) core, while the amygdala (CNA) provides excitatory/glutamatergic 
input to the peri-LC. These afferents can also release corticotropin-releasing factor 
(CRF), as indicated by the green arrows. Additionally, GABAergic interneurons are 
present in the LC. Cannabinoid type 1 receptors (CB1r) have been localized to excitatory 
and inhibitory synapses in the core and peri-LC, providing a mechanism for eCB 
modulation of limbic and autonomic projections, suggesting that deletion of CB1r could 
result in dysregulation of neurotransmitter and CRF release in the LC. Indeed, male 
CB1r-knock out (KO) mice have a significant increase in NE levels in the medial 
prefrontal cortex (mPFC) compared to wild type (WT), resulting in the desensitization 
and decreased expression of α2-adrenoceptors. B. In vitro whole-cell patch clamp 
recordings reveal that male CB1r-KO mice have increased LC-NE excitability compared 
to WT, which corresponds with the increase in mPFC NE levels. Additionally, male 
CB1r-KO mice have a decrease in mPFC cortical neuron excitability, likely resulting 
from desensitization of excitatory mPFC α2-adrenoceptors. Traces are examples of 
neuronal excitability, as would be measured by counting the number of action potentials 
that occur during application of increasing current pulses. 
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Working Model of eCB Regulation of LC-NE Activity 
 CB1r have been localized to CRF-containing afferents from the amygdala, and 
their presynaptic distribution in the peri-LC suggests that they might be capable of 
attenuating CRF release via activation by endogenous or exogenous cannabinoids.  Based 
on our collective data, we propose the following model for eCB regulation of LC-NE 
neuronal activity.  Initially, acute stress exposure causes release of CRF into the LC, from 
a variety of brain regions, but predominantly from amygdalar afferents (Fig. 4A).  CRF 
then binds to CRFr1 on LC-NE somatodendritic processes, causing postsynaptic 
depolarization and an increase in LC-NE activity and NE release in the mPFC.  This 
depolarization and influx in intracellular calcium levels stimulates an increase in DGL 
activity, causing the synthesis and release of the eCB 2-AG (Fig. 4B).  2-AG retrogradely 
crosses the synaptic cleft to bind to presynaptic CB1r, which have been localized to 
amygdalar-CRF afferents, where its activation leads to a decrease in CRF release and 
subsequent attenuation of LC-NE activity.  However, under conditions of chronic stress 
in vulnerable subpopulations, such as short latency females in our social stress model, we 
have found an increase in DGL expression.  This could present a problem when stressors 
are no longer present, as the increased DGL levels could lead to an increase in 2-AG 
synthesis, even when a stressor is not present.  While eCBs are capable of attenuating 
LC-NE excitability, overexpression of eCBs have been shown to also increase basal LC-
NE activity.  Therefore, hyperactivity of the eCB system following chronic stress might 
lead to activation of CB1r at other neighboring synapses in the LC, such as inhibitory 
interneurons, where CB1r have also been localized (Fig. 4C).  This disinhibition onto LC 
dendrites  would  cause an  increase in  LC-NE  activity,  and  aberrant  NE release  in the  
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Figure 4 
Working model for eCB modulation of LC following chronic stress. 
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Figure 4:  Working model for eCB modulation of LC following chronic stress.  
Cannabinoid type 1 receptor (CB1r) has been localized to excitatory and inhibitory 
corticotropin-releasing factor (CRF) afferents in the locus coeruleus (LC), and 
anterograde tract tracing has found CB1r specifically on excitatory amygdalar-CRF 
afferents, the main source of CRF to the LC. A. Following a stressor, CRF is released in 
the LC, where it binds to corticotropin-releasing factor receptor type 1 (CRFr1).  This 
causes postsynaptic depolarization of LC-norepinephrine (NE) neurons, leading to an 
increase in activity and NE efflux in the medial prefrontal cortex (mPFC). B. CRF-
induced depolarization and influx in intracellular calcium (Ca2+) stimulates 
diacylglycerol lipase (DGL) to synthesize and release 2-arachidonlyglycerol (2-AG) into 
the synaptic cleft. 2-AG then crosses the synapse and binds to CB1r. This inhibits the 
continued release of CRF, attenuating the CRF-induced increases in LC-NE activity and 
NE efflux, and helping to diminish the stress response. C. Chronic stress, especially in 
vulnerable female subpopulations, results in high DGL expression. Increased DGL would 
suggest greater production of 2-AG, which could bind to CB1r on neighboring synapses, 
causing inhibition of GABAergic interneurons and non-CRF releasing afferents. This 
dysregulation synaptic activity and disinhibition could further excite LC-NE neurons can 
cause aberrant NE release in the mPFC, and could contribute to the increased propensity 
for females to develop stress-induced psychiatric disorders. 
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mPFC could contribute to anxiety and depressive-like behaviors.  As females are known 
to be more susceptible to stress-induced psychiatric disorders, a significant increase in 
LC DGL expression following chronic stress in vulnerable female populations might be 
contributing to the disparity in prevalence of PTSD and depression. 
 
Sex Differences in eCB Regulation of LC-NE Activity 
The studies performed in chapter 1 demonstrate that CB1r deletion differentially 
affects male and female LC neurons.  Using in vitro slice electrophysiology, Western 
blotting, and ELISA analysis, we discovered that CB1r-KO caused a significant increase 
in noradrenergic indices in male mice compared to WT: male KO mice had an increase in 
LC-NE excitability, input resistance, tyrosine hydroxylase (TH) expression within the 
LC, and NE levels in the mPFC (Fig. 3).  These noradrenergic indices were not altered 
following CB1r deletion in female mice.  Western blot analyses of LC tissue from male 
and female CB1r/CB2r-KO mice also highlighted several sex differences.  Male 
CB1r/CB2r-KO mice showed a significant increase in CRF expression and in NET 
expression compared to male WT mice, while female CB1r/CB2r-KO mice showed a 
significant increase in α2-AR expression compared to female WT mice, and these 
adaptations might play a role in the resulting dysregulation of LC-NE activity that occurs 
in male but not female CB1r-KO mice.  Additionally, we tested LC-NE activity in 
response to CRF under conditions of CB1r deletion.  While 300 nM CRF was capable of 
increasing LC-NE excitability in WT brain slices from both male and female mice, LC-
NE neurons from CB1r-KO mice were not affected by 300 nM CRF bath application.  
This could be attributed to cellular adaptations observed in the CB1r-KO mice, such as 
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increased α2-AR signaling in female KO mice, saturation of CRFr1 in male KO mice 
resulting from their increased endogenous CRF levels, or alterations to CRFr1 trafficking 
or synthesis.  This shows the importance of the eCB system in maintaining normal LC-
NE excitability and responsiveness to stress signaling. 
At first, the lack of change in LC-NE activity of CB1r-KO females compared to 
WT females was surprising, given that females have heightened stress signaling and HPA 
axis activity following stressors such as restraint stress compared to males (Buynitsky 
and Mostofsky, 2009).  However, further exploration into existing literature supports the 
notion that CB1r-KO might have less of an effect on stress circuitry in females.  Roberts 
et al. (2014) have discovered that female CB1r-KO mice do not show the same increase  
in circulating corticosterone levels 30 minutes after restraint stress that male CB1r-KO 
mice show, in part due to an increase in capacity for corticosteroid-binding globulin to 
bind corticosterone and reduce free circulating levels (Roberts et al., 2014).  Another 
study shows that acute administration of a CB1r antagonist produces a more robust 
increase in HPA activity in male rats, while females show significantly less of an increase 
following treatment (Atkinson et al., 2010).  Additionally, sex differences in the eCB 
system, such as an increased cannabinoid self-administration rate (Fattore et al., 2007, 
Fattore et al., 2009) and lower CB1r density in several brain regions in female mice 
compared to males (Rodriguez de Fonseca et al., 1994), implicate a reduced eCB tone in 
females.  In regards to the amygdala, studies have found a decrease in 2-AG and AEA 
levels that correspond with decreased expression of their metabolizing enzymes (Krebs-
Craft et al., 2010, Craft et al., 2013).  The Western blot analysis in chapter 3 provides 
evidence basal differences in LC eCB levels across sex, with female rats have 
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significantly less DGL expression in the LC than males.  Less DGL would correspond 
with a decrease in 2-AG synthesis, suggesting the female LC is under less tonic 
regulation by the eCB system.  Taken together, discovering that female CB1r-KO mice 
do not show an increase in LC-NE excitability does in fact corroborate with other studies 
suggesting that female mice undergo compensatory changes to counteract the effect of 
long-term global CB1r deletion on stress responses. 
 
Future directions 
 Perhaps one of the most intriguing findings from these experiments is that CRF-
induced increases in LC-NE excitability are lost in CB1r-KO mice.  As mentioned in 
chapter 2, Western blot analyses should be performed in order to further investigate if a 
possible up-regulation of other anti-stress systems, such as the opioid or NPY systems, 
could be responsible for the lack of response to CRF in the LC.  Changes in CRFr1 levels 
in CB1r-KO mice should also be determined, as a significant decrease in male CB1r-KO 
mice could be responsible for a decreased effect of CRF on LC-NE excitability.  
Furthermore, we know that stressors cause differential trafficking of CRFr1 in males 
versus females, with females having an increase in membrane bound CRFr1 while males 
promote internalization (Bangasser et al., 2010, Valentino et al., 2013).  Immunoelectron 
microscopy studies would show whether CB1r-KO males, facing a chronic increase in 
CRF levels in the LC, have continued internalization of CRFr1, and whether female 
CB1r-KO mice have altered CRFr1 trafficking compared to WT females. 
 While chapter 2 was successful in providing anatomical evidence for CB1r 
localization to CRF axon terminals in the LC, these studies were only performed in 
	   173	  	  
males.  Given the known sex differences in both stress circuitry and the eCB system 
(Craft et al., 2013, Valentino et al., 2013, Castelli et al., 2014), it would be useful to 
investigate whether females have a different pattern of CB1r localization than males.  
Since CB1r-KO females did not show an increase in LC-NE excitability, perhaps they 
have less CB1r localized to CRF-containing afferents or greater receptor internalization 
compared to males.  Future immunoelectron microscopy studies could shed light on this 
possibility.  Additionally, data from chapter 3 shows that, within the LC, females have a 
significantly lower DGL expression compared to males.  Subsequent ELISA studies 
could be performed on LC tissue to confirm basal sex differences in eCB levels. 
 Finally, the working model proposed above for eCB modulation of CRF-induced 
activation of LC-NE neurons could be tested via whole-cell patch clamp 
electrophysiology experiments.  Brain sections from male and female WT mice could be 
excised as described in chapter 1 methods.  Before CRF bath application, pretreatment 
with a CB1r agonist or FAAH inhibitor would demonstrate whether the eCB system 
could attenuate the effects of CRF on LC-NE cells. 
 
Practical applications 
Effects of cannabinoids on fear and PTSD 
In addition to dysregulation of cannabinoid-adrenergic signaling, problems with 
cannabinoid-amygdalar signaling also plays a key part in the development of PTSD 
(Jovanovic and Ressler, 2010, Wyrofsky et al., 2015).   Understanding the effects of 
cannabinoids in the amygdala is of paramount importance when investigating the LC, as 
the LC is heavily targeted by both glutamatergic and CRF-containing afferents from 
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amygdala (Van Bockstaele et al., 1996, Reyes et al., 2011, Wyrofsky et al., 2017). 
A direct role for eCB modulation of the emotional components of amygdalar 
function has been observed in animal studies. Classical associative fear conditioning and 
extinction behavioral models show that eCB levels are increased in the amygdala during 
the extinction session; however, these increases were not observed during the initial fear 
condition, and fear behaviors persisted longer in the extinction sessions in CB1r KO mice 
compared to WT mice (Marsicano et al., 2002). Rats exposed to a footshock followed by 
situational reminders, which is a potential model for PTSD, exhibit impaired extinction of 
the traumatic memory and increased CB1r levels in the hippocampus (CA1) and PFC, 
and these alterations were prevented by WIN 55,212-2 administration following exposure 
to the traumatic event (Korem and Akirav, 2014). Combined with the results from other 
studies, it has been concluded that amygdalar-eCB signaling is critical for both within- 
and between-session habituation and adaption of fear-related behaviors (Marsicano et al., 
2002, Kamprath et al., 2006). These data suggest that the eCB system is essential for 
regulating amygdalar function and that the amygdala is a nucleus where eCB signaling 
can affect both neuroendocrine and stress adaptation behaviors (Hill et al., 2010b).  
In addition to affecting fear-related behaviors, the eCB system is also involved in 
the consolidation, retrieval, and extinction of emotionally charged and distressing 
memories (Fig. 5) (Atsak et al., 2012). As previously mentioned, glucocorticoids that are 
released following a stressor can stimulate eCB synthesis, which in turn inhibits 
GABAergic neurotransmission. This disinhibition of GABAergic projections from the 
BLA to the LC results in increased NE release and its subsequent binding to β-ARs, 
causing  the consolidation  of  stressful  and  potentially  traumatic  memories  (Hill et al.,  
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Figure 5 
Schematic diagram depicting cannabinoid-adrenergic interactions in stress-integrative 
circuitry. 
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Figure 5:  Schematic diagram depicting cannabinoid-adrenergic interactions in 
stress-integrative circuitry. The basolateral complex of the amygdala (BLA) has been 
implicated in the consolidation of emotionally arousing experiences and involves 
glucocorticoid-mediated increases in eCB release and interactions with norepinephrine 
(NE) (Campolongo et al., 2009). (1) eCBs are posited to increase BLA activity by 
decreasing GABAergic neurotransmission (Duvarci and Pare, 2007). (2) Disinhibition of 
GABAergic interneurons results in an increase of glutamatergic signaling in the central 
nucleus of the amygdala (CeA), a source of excitatory and CRF-containing afferents to 
the LC (Valentino and Van Bockstaele, 2008). (3) Activation of the LC via amygdalar 
CRF and glutamate causes an increase in noradrenergic signaling and NE release in 
postsynaptic targets, such as the prefrontal cortex (PFC). Given that the PFC represents a 
critical region in mediating the extinction of traumatic/aversive memories, treatments 
involving the eCB system that target this region may help alleviate symptoms of anxiety 
disorders by increasing extinction of such memories. For example, (4) CBs have been 
shown to inhibit monoamine oxidase (MAO), representing another mechanism in which 
CB signaling can regulate NE levels. (5) Targeting GABAergic projections to the L with 
CB ligands can potentially modulate LC afferent activity to the PFC. Achieving the 
proper balance in frontal cortical activity by targeting cannabinoid-adrenergic 
interactions may result in enhancing extinction of aversive memories and diminish 
anxiety-like behaviors that are precipitated by stress. 
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2010b). Administration of WIN 55,212-2 or glucocorticoid receptor antagonist RU-486 
into the BLA before exposure to a stressful stimuli prevented the enhancement in 
memory consolidation that is normally observed (Ramot and Akirav, 2012). Since stress 
also leads to rapid increases in FAAH levels, FAAH inhibitors prevent the degradation of 
AEA, which in turn promotes long-term fear extinction in animal models via CB1r 
binding in the BLA and provides protection against stress-induced alterations to eCB 
signaling (Gunduz-Cinar et al., 2013). It has been suggested that since eCBs are released 
within the BLA during fear extinction, the resulting eCB-dependent negative feedback on 
the HPA axis is critical for the extinction of traumatic memories (Marsicano et al., 2002, 
de Bitencourt et al., 2013). Therefore, compounds that enhance the eCB system could 
serve as therapeutics for PTSD. 
 
Therapeutic potential for the treatment of psychiatric disorders 
The ability of the eCB system to modulate both noradrenergic neurotransmission 
and the HPA axis makes it a potentially attractive therapeutic target for the treatment of 
numerous psychiatric disorders, which involve abnormal function of these systems.  As 
described earlier in this review, there is an extensive body of preclinical data 
demonstrating that various compounds and manipulations that increase CB signaling 
produce effects in behavioral assays that are predictive of therapeutic efficacy.  Although 
several CB compounds have been evaluated in clinical trials for non-psychiatric disorders 
such as obesity and pain, it is only recently that some of these compounds have begun to 
be tested for psychiatric disorders including schizophrenia, PTSD, and depression (Table 
2) (Fraser, 2009, Leweke et al., 2012).  While only a limited number of studies have 
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released information on the results of their trials, some of them seem particularly 
promising.  For example, CBD resulted in relief from psychotic symptoms in acute 
schizophrenic patients that was comparable to a potent antipsychotic while resulting in 
fewer side effects. In a study of PTSD, nabilone, a synthetic cannabinoid, greatly 
improved the quality of sleep and decreased the number of daytime flashbacks in 
treatment-resistant patients (Fraser, 2009).  Nabilone also significantly improved PTSD-
associated insomnia, chronic pain, and nightmares in a retrospective study of 104 
mentally ill men (Cameron et al., 2014).  A second study found that THC treatment, 
twice a day over the course of 3 weeks, decreased the number of nightmares and 
increased sleep quality in 10 patients suffering from chronic PTSD (Shalev et al., 2013). 
PTSD patients are plagued with debilitating flashbacks of a horrific event, potentially due 
to dysfunctional retrieval and extinction of emotional memories (Nemeroff et al., 2006, 
Akirav, 2013).  These results are consistent with clinical studies showing that many 
individuals afflicted with PTSD self-medicate with cannabis to help alleviate their 
symptoms (Passie et al., 2012).  Cannabis use is correlated with both the onset and 
severity of PTSD symptoms (Cougle et al., 2011, Potter et al., 2011).  Since it is known 
that the eCB system is involved in these processes and that people suffering from PTSD 
often self-medicate with cannabis, other compounds that increase eCB signaling could 
prove to be therapeutic as well. 
The eCB and noradrenergic systems are significantly and dynamically impacted 
by stress (Cassens et al., 1980, Flugge et al., 2004, Gorzalka et al., 2008, Hill and 
McEwen, 2010, Shinba et al., 2010) and noradrenergic transmission is responsible for 
cannabinoid-induced activation of the HPA axis (McLaughlin et al., 2009).  Under 
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conditions of acute stress, NE is increased centrally and peripherally (Cassens et al., 
1980, Abercrombie and Jacobs, 1987, Page and Valentino, 1994, Valentino et al., 1997, 
Ferry et al., 1999, Nestler et al., 1999, Sands et al., 2000) while the eCB system tonically 
constrains activation of neural circuits, including the HPA axis (Gorzalka et al., 2008, 
Steiner and Wotjak, 2008).  However, disrupted noradrenergic and eCB signaling is 
associated with an inability to adapt to chronic stress (Nestler et al., 1999, Wong et al., 
2000, Flugge et al., 2004, Hill and Gorzalka, 2004, Gorzalka et al., 2008, Hill et al., 
2008).  Previous studies from our group indicate a different consequence to the regulation 
of NE by cannabinoids under stress conditions.  Specifically, stress-induced increases in 
cortical NE levels are significantly attenuated by prior treatment with a cannabinoid 
receptor agonist suggesting complex actions of cannabinoids on noradrenergic circuitry 
that vary under basal versus stress conditions.  One working model posits that, under 
basal conditions, decreased signaling of presynaptically distributed CB1r localized to 
noradrenergic afferents contribute to local increases in cortical NE and AR 
desensitization.  Under conditions of stress where NE levels are elevated, increased 
release of eCB from cortical neurons attenuates presynaptic release of NE potentially 
leading to AR sensitization. 
There is significant potential for establishing cannabinoid-adrenergic interactions 
as a novel target in the development of improved treatment strategies for stress-induced 
anxiety.  The pathophysiology underlying anxiety disorders, and specifically PTSD, may 
be related to an inability to extinguish aversive memories (Lehner et al., 2009).  Increased 
salience of aversive memories due to activation of limbic circuits and poor cognitive 
inhibition/flexibility due to decreased cortical activity may contribute to the behavioral 
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expression of anxiety.  Understanding the cellular mechanism responsible for extinction 
of fear memories may provide the basis for more effective forms of clinical treatment of 
anxiety.  Patients with PTSD suffer from recurrent retrieval of traumatic memories in the 
form of context-induced flashbacks and repeated nightmares.  Repeated re-consolidation 
of fear memories in limbic circuits and inability to extinguish fear memories (Jovanovic 
and Ressler, 2010) are thought to underlie the pathophysiology of PTSD.  Consolidation 
of emotionally arousing memories involves, in part, noradrenergic circuits targeting the 
amygdala (McGaugh et al., 1996, Ferry et al., 1999), while extinction of memory is 
dependent on the mPFC (Mueller et al., 2008).  Pharmacological manipulation of AR 
systems has provided symptomatic relief in PTSD patients (Taylor et al., 2008, Byers et 
al., 2010), suggesting that therapeutic improvement may result, in part, from attenuation 
of signaling of sensitized ARs.  Moreover, the cannabinoid receptor agonist, nabilone, 
has recently been reported to be effective in management of symptoms of PTSD (Fraser, 
2009).  Taken with recent evidence that the eCB and noradrenergic systems interact in 
stress-related memory consolidation (Fig. 5) (Campolongo et al., 2009, Hill and 
McEwen, 2010), targeting interactions between these two systems may represent a novel 
approach for the treatment of stress-induced anxiety disorders.  Elucidating reciprocal 
interactions between the cannabinoid-adrenergic systems in stress-integrative circuits is 
vital for demonstrating that interaction of the two is important in modulating stress-
induced anxiety and extinction of conditioned fear.  Given that the PFC represents a 
critical region in mediating the extinction of traumatic/aversive memories, treatments that 
target this region may help alleviate symptoms of anxiety disorders by increasing 
extinction of such memories.  Achieving the proper balance in frontal cortical activity by 
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targeting cannabinoid-adrenergic interactions may result in enhancing extinction of 
aversive memories and diminish anxiety-like behaviors that are precipitated by stress. 
The increasing availability of different classes of compounds that target discrete 
aspects of the eCB system provides a unique opportunity to more thoroughly evaluate the 
importance of cannabinoid-adrenergic interactions on anxious behaviors in both 
preclinical and clinical studies.  As mentioned earlier, the preliminary results obtained 
with the synthetic cannabinoid nabilone as well as the natural cannabinoid THC and 
cannabis itself for the treatment of PTSD have been very promising.  As females have a 
higher propensity to develop PTSD and anxiety disorders, understanding sex differences 
in the cellular mechanisms that underlie cannabinoid and noradrenergic dysregulation 
following stressors is of great importance.  Chapters 1 and 3 have revealed important sex 
differences in the eCB system within the LC.  Electrophysiology results suggest that 
CB1r deletion has less of an effect in female rodents compared to males, as male CB1r-
KO mice showed a significant increase in LC-NE excitability compared to WT, but no 
change was observed in females.  Western analysis of social defeat tissue show a 
significant reduction in basal DGL levels in female rats compared to males, suggesting 
that females have less tonic eCB signaling than males.  Therefore, removal of eCB 
signaling might have less profound of an effect on female LC-NE activity, and eCB-
targeting therapeutics might affect males and females differently.  This is in line with 
analyses performed on the adverse effects of CB1r antagonist rimonabant, which 
suggested that the odds ratio for developing anxiety and depression following treatment 
was the largest in males aged 35-38 (Pi-Sunyer et al., 2006, Nissen et al., 2008).  Future 
studies should be aimed at investigating the effectiveness of eCB-targeting compounds at 
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treating stress-induced psychiatric disorders across sexes, in hopes of finding better 
therapeutic interventions for those suffering from anxiety, depression, and PTSD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   183	  	  
 
 
 
 
 
REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   184	  	  
Abercrombie E, Jacobs B (1987) Single-unit response of noradernergic neurons in the 
locus coeruleus of freely moving cats. Journal of Neuroscience 7:2844-2848. 
Adams P, Constanti A, Brown D, Clark R (1982) Intracellular Ca2+ activates a fast 
voltage-sensitive K+ current in vertebrate sympathetic neurones. Nature 296:746-
749. 
Ahn K, Mahmoud MM, Kendall DA (2012) Allosteric modulator ORG27569 induces a 
CB1 cannabinoid receptor high affinity agonist binding state, receptor 
internalization and Gi-independent ERK1/2 activation. Journal of Biological 
Chemistry 287:12070-12082. 
Akirav I (2013) Cannabinoids and glucocorticoids modulate emotional memory after 
stress. Neuroscience and Biobehavioral Reviews. 
Andrade R, Aghajanian GK (1984) Locus coeruleus activity in vitro: intrinsic regulation 
by a calcium-dependent potassium conductance but not alpha 2-adrenoceptors. 
Journal of Neuroscience 4:161-170. 
Aso E, Ozaita A, Valdizan EM, Ledent C, Pazos A, Maldonado R, Valverde O (2008) 
BDNF impairment in the hippocampus is related to enhanced despair behavior in 
CB1 knockout mice. Journal of Neurochemistry 105:565-572. 
Aston-Jones G, Cohen JD (2005) An integrative theory of locus coeruleus-
norepinephrine function: adaptive gain and optimal performance. Annual Review 
of Neuroscience 28:403-450. 
Atkinson H, Leggett J, Wood S, Castrique E, Kershaw Y, Lightman SL (2010) 
Regulation of the hypothalamic-pituitary-adrenal axis circadian rhythm by 
endocannabinoids is sexualy diergic. Endocrinology 151:3720-3727. 
Atsak P, Hauer D, Campolongo P, Schelling G, McGaugh JL, Roozendaal B (2012) 
Glucocorticoids interact with the hippocampal endocannabinoid system in 
impairing retrieval of contextual fear memory. Proceedings of the National 
Academy of Sciences of the United States of America 109:3504-3509. 
Bacci A, Huguenard JR, Prince DA (2004) Long-lasting self-inhibition of neocortical 
interneurons mediated by endocannabinoids. Nature 431:312-316. 
	   185	  	  
Bambico FR, Katz N, Debonnel G, Gobbi G (2007) Cannabinoids elicit antidepressant-
like behavior and activate serotoninergic neurons through the medial prefrontal 
cortex. The Journal of Neuroscience 27:11700-11711. 
Bangasser DA, Curtis A, Reyes BA, Bethea TT, Parastatidis I, Ischiropoulos H, Van 
Bockstaele EJ, Valentino RJ (2010) Sex differences in corticotropin-releasing 
factor receptor signaling and trafficking: potential role in female vulnerability to 
stress-related psychopathology. Molecular Psychiatry 15:877-904. 
Bangasser DA, Reyes BA, Piel D, Garachh V, Zhang X-Y, Plona Z (2013) Increased 
vulnerability of the brain norepinephrine system of females to corticotropin-
releasing factor overexpression. Molecular Psychiatry 18:166. 
Bangasser DA, Valentino RJ (2012) Sex differences in molecular and cellular substrates 
of stress. Cellular and Molecular Neurobiology 32:709-723. 
Barna I, Zelena D, Arszovszki AC, Ledent C (2004) The role of endogenous 
cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in 
vitro studies in CB1 receptor knockout mice. Life Sciences 75:2959-2970. 
Befort K (2015) Interactions of the opioid and cannabinoid systems in reward: insights 
from knockout studies. Frontiers in Pharmacology 6. 
Berridge CW, Waterhouse BD (2003) The locus coeruleus-noradrenergic system: 
modulation of behavioral state and state-dependenge cognitive processes. Brain 
Research Review 43:33-84. 
Billings A, Moos RH (1984) Coping, stress, and social resources among adults with 
unipolar depression. Journal of Personality Social Psychology 46:877-891. 
Birnbaum S, Gobeske K, Auerbach J, Taylor J, Arnsten A (1999) A role for 
norepinephrine in stress-induced cognitive deficits: a-1-adrenoceptor mediation in 
the prefrontal cortex. Biological Psychiatry 46:1266-1274. 
Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A, Appendino G, 
Saturnino C, Martin B, Razdan RK, Di Marzo V (2006) Development of the first 
potent and specific inhibitors of endocannabinoid biosynthesis. Biochimica et 
Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1761:205-212. 
Bjorkqvist K (2001) Social defeat as a stressor in humans. Physiological Behavior 
73:435-442. 
	   186	  	  
Blankman JL, Simon GM, Cravatt BF (2007) A comprehensive profile of brain enzymes 
that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chemical Biology 
14:1347-1356. 
Brusco A, Tagliaferro PA, Saez T, Onaivi ES (2008) Ultrastructural localization of 
neuronal brain CB2 cannabinoid receptors. Annals of the New York Academy of 
Sciences 1139:450-457. 
Buynitsky T, Mostofsky D (2009) Restraint stress in biobehavioral research: recent 
developments. Neuroscience and Biobehavioral Reviews 33:1089-1098. 
Byers M, Allison K, Wendel C, Lee J (2010) Prazosin versus quetiapine for nighttime 
posttraumatic stress disorder symptoms in veterans: an assessment of long-term 
comparative effectiveness and safety. Journal of Clinical Psychopharmacology 
30:225-229. 
Cameron C, Watson D, Robinson J (2014) Use of a synthetic cannbinoid in a correctional 
population for posttraumatic stress disorder-related insomnia and nightmares, 
chronic pain, harm reduction, and other indications: a retrospective evaluation. 
Journal of Clinical Psychopharmacology 5:559-564. 
Campolongo P, Roozendaal B, Trezza V, Hauer D, Schelling G, McGaugh JL, Cuomo V 
(2009) Endocannabinoids in the rat basolateral amygdala enhance memory 
consolidation and enable glucocorticoid modulation of memory. Proceedings of 
the National Academy of Sciences of the United States of America 106:4888-
4893. 
Carvalho AF, Mackie K, Van Bockstaele EJ (2010) Cannabinoid modulation of limbic 
forebrain noradrenergic circuitry. European Journal of Pharmacology 31:286-301. 
Carvalho AF, Van Bockstaele EJ (2012) Cannabinoid modulation of noradrenergic 
circuits: Implications for psychiatric disorders. Progress in Neuro-
Psychopharmacology and Biological Psychiatry 38:59-67. 
Cassens G, Roffman M, Kuruc A, Orsulak P, Schildkraut J (1980) Alterations in brain 
norepinephrine metabolism induced by environmental stimuli previously paired 
wtih inescapable shock. Science 209:1138-1140. 
Castelli M, Fadda P, Casu A, Spano M, Casti A, Fratta W, Fattore L (2014) Male and 
female rats differ in brain cannabinoid CB1 receptor density and function and in 
	   187	  	  
behavioural traits predisposing to drug addiction: effect of ovarian hormones. 
Current Pharmaceutical Design 20. 
Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012) Endocannabinoid signaling 
and synaptic function. Neuron 76:70-81. 
Cathel AM, Reyes BA, Wang Q, Palma J, Mackie K, Van Bockstaele EJ, Kirby LG 
(2014) Cannabinoid modulation of alpha2 adrenergic receptor function in rodent 
medial prefrontal cortex. European Journal of Neuroscience 40:2014. 
Chaijale N, Curtis A, Wood S, Zhang X-Y, Bhatnagar S, Reyes BA, Van Bockstaele EJ, 
Valentino RJ (2013) Social stress engages opioid regulation of locus coeruleus 
norepinephrine neurons and induces a state of cellular and physical opiate 
dependence. Neuropsychopharmacology 38:1833. 
Cohen H, Liu T, Kozlovsky N, Kaplan Z, Zohar J, Mathe A (2012) The neuropeptide Y 
(NPY)-ergic system is associated with behavioral resilience to stress exposure in 
an animal model of post-traumatic stress disorder. Neuropsychopharmacology 
37:350-363. 
Cossu G, Ledent C, Fattore L, Imperato A, Bohme G, Parmentier M, Fratta W (2001) 
Cannabinoid CB 1 receptor knockout mice fail to self-administer morphine but 
not other drugs of abuse. Behavioral Brain Research 118:61-65. 
Cota D (2008) The role of the endocannabinoid system in the regulation of the 
hypothalamic-pituitary-adrenal axis activity. Journal of Neuroendocrinology 
20:35-38. 
Cougle JR, Bonn-Miller MO, Vujanovic AA, Zvolensky MJ, Hawkins KA (2011) 
Posttraumatic stress disorder and cannabins use in a nationally representative 
sample. Psychology of Addictive Behaviors 25:554-558. 
Craft RM, Marusich JA, Wiley JL (2013) Sex differences in cannabinoid pharmacology: 
A reflection of differences in the endocannabinoid system? Life Sciences 92:476-
481. 
Curtis A, Bello NT, Valentino RJ (2001) Evidence for functional release of endogenous 
opioids in the locus ceruleus during stress termination. The Journal of 
Neuroscience 21:1-5. 
	   188	  	  
Curtis A, Lechner SM, Pavcovich LA, Valentino RJ (1996) Activation of the locus 
coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-
releasing factor: effects on discharge rate, cortical norepinephrine levels and 
cortical electroencephalographic activity. Journal of Pharmacol Experimental 
Therapeutics 281:163-172. 
Curtis A, Leiser SC, Snyder K, Valentino RJ (2012) Predator stress engages 
corticotropin-releasing factor and opioid systems to alter the operating mode of 
locus coeruleus norepinephrine neurons. Neuropharmacology 62:1737-1745. 
de Bitencourt R, Pamplona FA, Takahashi RN (2013) A current overview of 
cannabinoids and glucocorticoids in facilitating extinction of aversive memories: 
potential extinction enhancers. Neuropharmacology 64:389-395. 
Devane WA, Dysarz III FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination 
and characterization of a cannabinoid receptor in rat brain. Molecular 
Pharmacology 34:605-613. 
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griggin G, Gibson D, 
Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a 
brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949. 
Di Marzo V (2011) Endocannabinoid signaling in the brain: biosynthetic mechanisms in 
the limelight. Nature Neuroscience 14:9-15. 
Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its 
therapeutic exploitation. Nature Reviews Drug Discovery 3:771-784. 
Duvarci S, Pare D (2007) Glucocorticoids enhance the excitability of principal 
basolateral amygdala neurons. Journal of Neuroscience 27:4482-4491. 
Fattore L, Fadda P, Fratta W (2009) Sex differences in the self-administration of 
cannabionids and other drugs of abuse. Psychoneuroendocrinology 34:S227-
S236. 
Fattore L, Spano M, Altea S, Angius F, Fadda P, Fratta W (2007) Cannabinoid self-
administration in rats: sex differences and the influence of ovarian function. 
British Journal of Pharmacology 152. 
	   189	  	  
Ferry B, Roozendaal B, McGaugh JL (1999) Role of norepinephrine in mediating stress 
hormone regulation of long-term memory storage: a critical involvement of the 
amygdala. Biological Psychiatry 46:1140-1152. 
Fisar Z (2010) Inhibition of monoamine oxidase activity by cannabinoids. Naunyn-
Schmiedeberg Archives of Pharmacology 381:563-572. 
Flugge G, Van Kampen M, Mijnster M (2004) Perturbations in brain monoamine systems 
during stress. Cell Tissue Research 315:1-14. 
Fokkema D, Koolhaas J, van der Gugten J (1995) Individual characteristics of behavior, 
blood pressure, and adrenal hormones in colony rats. Physiological Behavior 
57:857-862. 
Fraser GA (2009) The use of a synthetic cannabinoid in the management of treatment-
resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neuroscience 
& Therapeutics 15:84-88. 
Gamage TF, Ignatowska-Jankowska BM, Wiley JL, Abdelrahman M, Trembleau L, 
Greig IR, Thakur GA, Tichkule R, Poklis J, Ross RA, Pertwee RG, Lichtman AH 
(2014) In-vivo pharmacological evaluation of the CB1-receptor allosteric 
modulator Org-27569. Behavioral Pharmacology 25:182-185. 
Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active 
constituent of hashish. Journal of the American Chemical Society 86:1646-1647. 
Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano M, 
Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, 
Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and 
modulation of brain monoaminergic transmission by blockade of anandamide 
hydrolysis. Proceedings of the National Academy of Sciences of the United States 
of America 102:18620-18625. 
Goddard AW, Ball SG, Martinez J, Robinson MJ, Yang CR, Russell JM, Shekhar A 
(2010) Current perspectives of the roles of the central norepinephrine system in 
anxiety and depression. Depression and Anxiety 27:339-350. 
Gong J-P, Onaivi ES, Ishiguro H, Liu Q-R, Tagliaferro PA, Brusco A, Uhl GR (2006) 
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain 
Research 1071:10-23. 
	   190	  	  
Gorzalka BB, Hill MN, Hillard CJ (2008) Regulation of endocannabinoid signaling by 
stress: implications for stress-related affective disorders. Neuroscience 
Biobehavioral Reviews 32:1152-1160. 
Green B, Kavanagh D, Young R (2003) Being stoned: a review of self-reported cannabis 
effects. Drug and Alcohol Review 22:453-460. 
Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A (2013) Amygdala FAAH and 
anandamide: mediating protection and recovery from stress. Trends in 
Pharmacological Science 34:637-644. 
Handa R, Burgess L, Kerr J, O'Keefe J (1994) Gonadal steroid hormone receptors and 
sex differences in the hypothalamo-pituitary-adrenal axis. Hormones and 
Behavior 28:464-476. 
Handa R, Weiser M (2014) Gonadal steroid hormones and the hypothalamo-pituitary-
adrenal axis. Frontiers in Neuroendocrinology 35:197-220. 
Hauer D, Kaufmann I, Strewe C, Briegel I, Campolongo P, Schelling G (2013) The role 
of glucocorticoids, catecholamines and endocannabinoids in the development of 
traumatic memories and posttraumatic stress symptoms in survivors of critical 
illness. Neurobiology of Learning and Memory 1-7. 
Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, Egawa T, Kitamura Y, 
Uchida N, Nishimura R, Egashira N, Iwasaki K, Fujiwara M (2008) Cannabidiol 
potentiates the pharmacological effects of Delta(9)-tetrahydrocannabinol via 
CB(1) receptor-dependent mechanism. Brain Research 1188:157-164. 
Heilig M (2004) The NPY system in stress, anxiety and depression. Neuropeptides 
38:213-224. 
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC 
(1990) Cannabinoid receptorl localization in brain. Proceedings of the National 
Academy of Sciences of the United States of America 87:1932-1936. 
Herman JP, Ostrander MM, Mueller NK, Figueiredo H (2005) Limbic system 
mechanisms of stress regulation: hypothalamo-pituitary-adrenocortical axis. 
Progress in Neuro-Psychopharmacology and Biological Psychiatry 29:1201-1213. 
	   191	  	  
Hill MN, Carrier E, Ho W, Shi L, Patel S, Gorzalka BB, Hillard CJ (2008) Prolonged 
glucocorticoid treatment decreases cannabinoid CB1 receptor density in the 
hippocampus. Hippocampus 18:221-226. 
Hill MN, Gorzalka BB (2004) Enhancement of anxiety-like responsiveness to the 
cannabinoid CB(1) receptor agonist HU-210 following chronic stress. European 
Journal of Pharmacology 499:291-295. 
Hill MN, Gorzalka BB (2009) The endocannabinoid system and the treatment of mood 
and anxiety disorders. CNS Neurological Disorders and Drug Targets 8:451-458. 
Hill MN, McEwen BS (2009) Endocannabinoids: the silent partner of glucocorticoids in 
the synapse. Proceedings of the National Academy of Sciences 106:4579-4580. 
Hill MN, McEwen BS (2010) Involvement of the endocannabinoid system in the 
neurobehavioral effects of stress and glucocorticoids. Progress in 
Neuropsychopharmacology & Biological Psychiatry 34:791-797. 
Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT-Y, Gray JM, Hillard CJ, 
Gorzalka BB, Viau V (2010a) Endogenous cannabinoid signaling is essential for 
stress adaptation. Proceedings of the National Academy of Sciences 107:9406-
9411. 
Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ, Gorzalka BB 
(2009) Suppression of amygdalar endocannabinoid signalling by stress 
contributes to activation of the hypothalamic-pituitary-adrenal axis. 
Neuropsychopharmacology 34:2733-2745. 
Hill MN, McLaughlin RJ, Pan B, Fitzgerald ML, Roberts CJ, Lee TT-Y, Karatsoreos IN, 
Mackie K, Viau V, Pickel VM, McEwen BS, Liu Q-s, Gorzalka BB, Hillard CJ 
(2011) Recruitment of prefrontal cortical endocannabinoid signaling by 
glucocorticoids contributes to termination of the stress response. The Journal of 
Neuroscience 31:10506-10515. 
Hill MN, Patel S, Campolongo P, Tasker JG, Wotjak CT, Bains JS (2010b) Functional 
interactions between stress and the endocannabinoid system: from synaptic 
signaling to behavioral output. The Journal of Neuroscience 30:14980-14986. 
	   192	  	  
Hill MN, Tasker JG (2012) Endocannabinoid signaling, glucocorticoid-mediated negative 
feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience 
204:5-16. 
Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ, Reynet C, Wong 
Kai In P (2007) PSNCBAM-1, a novel allosteric antagonist at cannbinoid CB1 
receptors with hypophagic effects in rats. British Journal of Pharmacology 
152:805-814. 
Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB, 
Mann JJ, Arango V (2004) Upregulation of CB1 receptors and antagonist-
stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed 
suicide victims. Molecular Psychiatry 9. 
Insel T (2008) Assessing the economic costs of serious mental illness. The American 
Journal of Psychiatry 165:663-665. 
Jedema H, Grace A (2004) Corticotropin-releasing hormone directly activates 
noradrenergic neurons of the locus coeruleus recorded in vitro. Journal of 
Neuroscience 24:9703-9713. 
Jentsch JD, Andrusiak E, Tranm A, Bowers Jr MB, Roth RH (1997) Delta-9-
tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization 
and impairs spatial working memory in the rat: blockade of dopaminergic effects 
with HA966. Neuropsychopharmacology 16:426-432. 
Johnston TG, Kelly CB, Stevenson MR, COoper SJ (1999) Plasma norepinephrine and 
prediciton of outcome in major depressive disorder. Biological Psychiatry 
46:1253-1258. 
Jovanovic T, Ressler KJ (2010) How the neurocircuitry and genetics of fear inhibition 
may inform our understanding of PTSD. American Journal of Psychiatry 
167:648-662. 
Kamprath K, Marsicano G, Tang J, Monory K, Bisogno T, Di Marzo V, Lutz B, Wotjak 
CT (2006) Cannabinoid CB1 receptor mediates fear extinction via habituation-
like processes. Journal of Neuroscience 26:6677-6686. 
	   193	  	  
Kask A, Rago L, Harro J (1998) Anxiolytic-like effect of neuropeptide Y (NPY) and 
NPY 13-36 microinjected into vicinity of locus coeruleus in rats. Brain Research 
788:345-348. 
Kendler KS, Kessler RC, Walkers EE, MacLean C, Neale MC, Heath AC, Eaves LJ 
(1995) Stressful life events, genetic liability, and onset of an episode of major 
depression in women. American Journal of Psychiatry 152:833-842. 
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, 
Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric 
disorders in the United States. Results from the National Comorbidity Survey. 
Arch Gen Psychiatry 51:8-19. 
Kirilly E, Hunyady L, Bagdy G (2013) Opposing local effects of endocannbinoids on the 
activity of noradrenergic neurons and release of noradrenaline: relevance for their 
role in depression and in the actions of CB1 receptor antagonists. Biological 
Psychiatry 120:177-186. 
Klimek V, Stockmeier C, Overholser J, Meltzer HY, Kalka S, Dilley G, Ordway G 
(1997) Reduced levels of norepinephrine transporters in the locus coeruleus in 
major depression. Journal of Neuroscience 17:8451-8458. 
Korem N, Akirav I (2014) Cannabinoids prevent the effects of a footshock followed by 
situational reminders on emotional processing. Neuropsychopharmacology. 
Korf J, Aghajanian GK, Roth RH (1973) Increased turnover of norepinephrine in the rat 
cerebral cortex during stress: role of the locus coeruleus. Neuropharmacology 
12:933-938. 
Krebs-Kraft D, Hill MN, Hillard CJ, McCarthy M (2010) Sex differences in cell 
proliferation in developing rat amygdala mediated by endocannabinoids has 
implications for social behavior. Proceedings of the National Academy of 
Sciences USA 107:20535-20540. 
Le Foll B, Gorelick DA, Goldberg SR (2009) The future of endocannabinoid-oriented 
clinical research after CB1 antagonists. Psychopharmacology 205:171-174. 
Lee A, Rosin D, Van Bockstaele EJ (1998a) a 2A-adrenergic receptors in the rat nucleus 
locus coeruleus: subcellular localization in catecholaminergic dendrites, 
astrocytes, and presynaptic axon terminals. Brain Research 795:157-169. 
	   194	  	  
Lee A, Rosin D, Van Bockstaele EJ (1998b) Ultrastructural evidence for prominent 
postsynaptic localization of a2c-adrenergic receptors in the catecholaminergic 
dendrites in the rat nucleus locus coeruleus. The Journal of Comparative 
Neurology 394:218-229. 
Lee KS, Conigrave KM, Patton GC, Clough AR (2009) Cannabis use in remote 
Indigenous communities in Australia: endemic yet neglected. Medical Journal of 
Australia 190:228-229. 
Lehner M, Wilslowska-Stanek A, Plaznik A (2009) Extinction of emotional response as a 
novel approach of pharmacotherapy of anxiety disorders. Psychiatria Polska 
43:639-653. 
Leonard BE, Myint A (2009) The psychoneuroimmunology of depression. Human 
Psychopharmacology 24:165-175. 
Leweke FM, Piomelli D, Muhl D, Gerth CW, Hoyer C, Klosterkotter J, Hellmich M, 
Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates 
psychotic symptoms of schizophrenia. Translational Psychiatry 2:1-7. 
Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavon FJ, Serrano AM, 
Selley DE, Parsons LH, Lichtman AH, Cravatt BF (2009) Selective blockade of 
2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. 
Nature Chemical Biology 5:37-44. 
Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, Wisniewski 
SR, Balasubramani GK, Trivedi MH, Rush AJ (2005) Gender differences in 
depression: findings from the STAR*D study. Journal of Affective Disorders 
87:141-150. 
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, 
Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B (2002) The 
endogenous cannabinoid system controls extinction of aversive memories. Nature 
481:530-534. 
Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Involvement of 
CB1 cannabinoid receptors in emotional behavior. Psychopharmacology 159:379-
387. 
	   195	  	  
May LT, Leach K, Sexton PM, Christopoulos A (2007) Allosteric modulation of G 
protein-coupled receptors. Annual Review of Pharmacology and Toxicology 
47:1-51. 
McEwen BS (2008) Central effects of stress hormones in health and disease: 
understanding the protective and damaging effects of stress and stress mediators. 
European Journal of Pharmacology 583:174-185. 
McGaugh JL, Cahill L, Roozendaal B (1996) Involvement of the amygdala in memory 
storage: interaction with other brain systems. Proceedings of the National 
Academy of Sciences of the United States of America 93:13508-13514. 
McLaughlin RJ, Hill MN, Gorzalka BB (2009) Monoaminergic neurotransmission 
contributes to cannabinoid-induced activation of the hypothalamic-pituitary-
adrenal axis. European Journal of Pharmacology 624:71-76. 
Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher 
A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, 
Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present 
in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 
50:83-90. 
Mendiguren A, Pineda J (2006) Systemic effect of cannabinoids on the spontaneous 
firing rate of locus coeruleus neurons in rats. European Journal of Pharmacology 
534:83-88. 
Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F (2013) Endocannabinoid system 
and mood disorders: Priming a target for new therapies. Pharmacology & 
Therapeutics 138:18-37. 
Miczek K (1979) A new test for aggression in rats without aversive stimulation: 
differential effects of d-amphetamine and cocaine. Psychopharmacology 60:253-
259. 
Morena M, Patel S, Bains JS, Hill MN (2016) Neurobiological interactions between 
stress and the endocannabinoid system. Neuropsychopharmacology 41:80-102. 
Morilak DA, Frazer A (2004) Antidepressants and brain monoaminergic systems: a 
dimensional approach to understanding their behavioral effect in depression and 
anxiety disorders. International Journal of Neuropsychopharmacology 7:193-218. 
	   196	  	  
Mueller D, Cahill SP (2010) Noradrenergic modulation of extinction learning and 
exposure therapy. Behavioral Brain Research 208:1-11. 
Mueller D, Porter JT, Quirk GJ (2008) Noradrenergic signaling in infralimbic cortex 
increases cell excitability and strengthens memory for fear extinction. The Journal 
of Neuroscience 28:369-375. 
Muntoni AL, Pillolla G, Melis M, Perra S, Gessa GL, Pistis M (2006) Cannabinoids 
modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus 
noradrenergic neurons. European Journal of Pharmacology 23:2385-2394. 
Murataeva N, Mackie K, Straiker A (2012) The CB2-preferring agonist JWH015 also 
potently and efficaciously activates CB1 in autaptic hippocampal neurons. 
Pharmacological Research 66:437-442. 
Navarro HA, Howard JL, Pollard GT, Carroll FI (2009) Positive allosteric modulation of 
the human cannabinoid (CB1) receptor by RTI-371, a selective inhibitor of the 
dopamine transporter. British Journal of Pharmacology 156:1178-1184. 
Navarro M, Carrera M, Fratta W, Valverde O, Cossu G, Fattore L, Chowen J, Gomez R, 
Del Arco I, Villanua M, Maldonado R (2001) Functional interaction between 
opioid and cannabinoid receptors in drug self-administration. Journal of 
Neuroscience 21:55344-55350. 
Nemeroff B, Bremner JD, Foa EB, Mayberg HS, North CS, Stein MB (2006) 
Posttraumatic stress disorder: a state-of-the-science review. Journal of Psychiatric 
Research 40:1-21. 
Nestler E, Aghajanian GK (1997) Molecular and cellular basis of addiction. Science 
278:58-63. 
Nestler E, Alreja M, Aghajanian GK (1999) Molecular control of locus coeruleus 
neurotransmission. Biological Psychiatry 46:1131-1139. 
Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, 
Huang Y (2013) Elevated brain cannabinoid CB receptor availability in post-
traumatic stress disorder: a positron emission tomography study. Molecular 
Psychiatry 18:1034-1040. 
Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres 
JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, 
	   197	  	  
Hu B, Bhatt DL, Lincoff AM, Tuzcu EM (2008) Effect of rimonabant on 
progression of atherosclerosis in patients with abdominal obesity and coronary 
artery disease: the STRADIVARIUS randomized controlled trial. JAMA 
299:1547-1560. 
Okamoto Y, Wang J, Morishita J, Ueda N (2007) Biosynthetic pathways of the 
endocannabinoid anandamide. Chemistry & Biodiversity 4:1842-1857. 
Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, Perchuk A, Mora Z, 
Tagliaferro PA, Gardner E, Brusco A, Akinshola BE, Hope B, Lujilde J, Inada T, 
Iwasaki S, Macharia D, Teasenfitz L, Arinami T, Uhl GR (2008) Brain neuronal 
CB2 cannabinoid receptors in drug abuse and depression: from mice to human 
subjects. PLoS One 3. 
Oropeza VC, Page ME, Van Bockstaele EJ (2005) Systemic administration of WIN 
55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Research 
1046:45-54. 
Osmanovic S, Shefner S (1993) Calcium-activated hyperpolarization in rat locus 
coeruleus neurons in vitro. Journal of Physiology 469:89-109. 
Page ME, Oropeza VC, Sparks SE, Qian Y, Menko AS, Van Bockstaele EJ (2007) 
Repeated cannabinoid administration increases indices of noradrenergic activity 
in rats. Pharmacology, Biochemistry, and Behavior 86:162-168. 
Page ME, Oropeza VC, Van Bockstaele EJ (2008) Local administration of a cannabinoid 
agonist alters norepinephrine efflux in the rat frontal cortex. Neuroscience Letters 
431:1-5. 
Page ME, Valentino RJ (1994) Locus coeruleus activation by physiological challenges. 
Brain Research Bulletin 35:557-560. 
Pamplona FA, Ferreira J, Menezes de Lima J, Octavio, Duarte FS, Bento AF, Forner S, 
Villarinho JG, Bellocchio L, Wotjak CT, Lerner R, Monory K, Lutz B, Canetti C, 
Matias I, Calixto JB, Marsicano G, Guimaraes MZP, Takahashi RN (2012) Anti-
inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 
cannabinoid receptor. Proceedings of the National Academy of Sciences 
109:21134-21139. 
	   198	  	  
Parolaro D, Realini N, Vigano D, Guidali C, Rubino T (2010) The endocannabinoid 
system and psychiatric disorders. Experimental Neurology 224:3-14. 
Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH (2012) Mitigation of post-
traumatic stress symptoms by Cannabis resin: a review of the clinical and 
neurobiological evidence. Drug Testing and Analysis 4:649-659. 
Patel KD, Hillard CJ (2003) Cannabinoid-induced fos expression within A10 
dopaminergic neurons. Brain Research 963:15-25. 
Patel S, Kingsley PJ, Mackie K, Marnett LJ, Winder DG (2009) Repeated homotypic 
stress elevates 2-arachidonoylglycerol levels and enhanves short-term 
endocannabinoid signalling at inhibitory synapses in basolateral amygdala. 
Neuropsychopharmacology 34:2699-2709. 
Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004) Endocannabinoid 
signaling negatively modulates stress-induced activation of the hypothalamic-
pituitary-adrenal axis. Endocrinology 145:5431-5438. 
Pattij T, Wiskerke J, Schoffelmeer A (2008) Cannabinoid modulation of executive 
functions. European Journal of Pharmacology 585:458-463. 
Pertwee RG (2012) Lipoxin A4 is an allosteric endocannabinoid that strengthens 
anandamide-induced CB1 receptor activation. Proceedings of the National 
Academy of Sciences 109:20781-20782. 
Pi-Sunyer F, Aronne L, Heshmati H, Devin J, Rosenstock J (2006) Effect of rimonabant, 
a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in 
overweight of obese patients: RIO-North America: a randomized controlled trial. 
JAMA 295:761-775. 
Pietrzak RH, Gallezot J, Ding Y, Henry S, Potenza M, Southwick SM, Krystal J, Carson 
R, Neumeister A (2013) Association of posttraumatic stress disorder with reduced 
in vivo norepinephrine transporter availability in the locus coeruleus. JAMA 
Psychiatry 70:1199-1205. 
Piscitelli F, Ligresti A, La Regina G, Coluccia A, Morera L, Allara M, Novellino E, Di 
Marzo V, Silvestri R (2012) Indole-2-carboxamides as allosteric modulators of 
the cannabinoid CB1 receptor. Journal of Medicinal Chemistry 55:5627-5631. 
	   199	  	  
Poddar MK, Dewey WL (1980) Effects of cannabinoids on catecholamine uptake and 
release in hypothalamic and striatal synaptosomes. Journal of Pharmacol 
Experimental Therapeutics 214:63-67. 
Potter CM, Vujanovic AA, Marshall-Berenz EC, Bernstein A, Bonn-Miller MO (2011) 
Posttraumatic stress and marijuana use coping motives: the mediating role of 
distress tolerance. Journal of Anxiety Disorders 25:437-443. 
Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, 
McIntosh L, Goodwin G, Walker G, Westwood P, Marrs J, Thomson F, Cowley 
P, Christopoulos A, Pertwee RG, Ross RA (2005) Allosteric modulation of the 
cannabinoid CB1 receptor. Molecular Pharmacology 68:1484-1495. 
Rabinak CA, Angstadt M, Sripada CS, Abelson JL, Liberzon I, Milad MR, Phan KL 
(2013) Cannabinoid facilitation of fear extinction memory recall in humans. 
Neuropharmacology 64:396-402. 
Ramot A, Akirav I (2012) Cannabinoid receptors activation and glucocorticoid receptors 
deactivation in the amygdala prevent the stress-induced enhancement of a 
negative learning experience. Neurobiology of Learning and Memory 97:393-401. 
Reich C, Taylor M, McCarthy M (2009) Differential effects of chronic unpredictable 
stress on hippocampal CB1 receptors in male and female rats. Behavioural Brain 
Research 203:264-269. 
Reilly D, Didcott P, Swift W, Hall W (1998) Long-term cannabis use: characteristics of 
users in an Australian rural area. Addiction 93:837-846. 
Reyes BA, Carvalho AF, Vakharia K, Van Bockstaele EJ (2011) Amygdalar peptidergic 
circuits regulating noradrenergic locus coeruleus neurons: linking limbic and 
arousal centers. Experimental Neurology 230:96-105. 
Reyes BA, Drolet G, Van Bockstaele EJ (2008a) Dynorphin and stress-related peptides in 
rat locus coeruleus: contribution of amygdalar efferents. The Journal of 
Comparative Neurology 508:663-675. 
Reyes BA, Valentino RJ, Van Bockstaele EJ (2008b) Stress-induced intracellular 
trafficking of corticotropin-releasing factor receptors in rat locus coeruleus 
neurons. Endocrinology 149:122-130. 
	   200	  	  
Reyes BA, Zitnik G, Foster C, Van Bockstaele EJ, Valentino RJ (2015) Social stress 
engages neurochemically-distinct afferents to the rat locus coeruleus depending 
on coping strategy. eNeuro 2:1-12. 
Reyes BAS, Carvalho AF, Szot P, Kalamarides DJ, Wang Q, Kirby LG, Van Bockstaele 
EJ (2017) Cortical adrenoceptor expression, function and adaptation under 
conditions of cannabinoid receptor deletion. Experimental Neurology 292:179-
192. 
Reyes BAS, Rosario JC, Piana PMT, Van Bockstaele EJ (2009) Cannabinoid modulation 
of cortical adrenergic receptors and transporters. Journal of Neuroscience 
Research 87:3671-3678. 
Reyes BAS, Szot P, Sikkema C, Cathel AM, Kirby LG, Van Bockstaele EJ (2012) Stress-
induced sensitization of cortical adrenergic receptors following a history of 
cannabinoid exposure. Experimental Neurology 236:327-335. 
Roberts CJ, Stuhr KL, Hutz MJ, Raff H, Hillard CJ (2014) Endocannabinoid signaling in 
hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of 
indirect agonists and comparison of male and female mice. Pharmacology 
Biochemistry and Behavior 117:17-24. 
Rodriguez de Fonseca F, Cebeira M, Martin M, Fernandez-Ruiz J (1994) Cannabinoid 
receptors in rat brain areas: sexual differences, fluctuations during estrous cycle 
and changes after gonadectomy and sex steroid replacement. Life Sciences 54. 
Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, 
Pertwee RG (1999) Agonist-inverse agonist characterization at CB1 and CB2 
cannabinoid receptors of L759633, L759656 and AM630. British Journal of 
Pharmacology 126:665-672. 
Saito VM, Wotjak CT, Moreira FA (2010) Pharmacological exploitation of the 
endocannabinoid system: new perspectives for the treatment of depression and 
anxiety disorders? Revista Brasileira de Psiquiatria 32:S7-S14. 
Sands S, Strong R, Corbitt J, Morilak DA (2000) Effects of acute restraing stress on 
tyrosine hydroxylase mRNA expression in locus coeruleus of Wistar and Wistar-
Kyoto rats. Molecular Brain Research 75:1-7. 
	   201	  	  
Sara SJ (2009) The locus coeruleus and noradrenergic modulation of cognition. Nature 
Reviews Neuroscience 10:211-223. 
Scavone JL, Mackie K, Van Bockstaele EJ (2010) Characterization of cannabinoid-1 
receptors in the locus coeruleus: relationship with mu-opioid receptors. Brain 
Research 1312:18-31. 
Schwarcz G, Karajgi B, McCarthy R (2009) Synthetic d-9-tetrahydrocannabinol 
(Dronabinol) can improve the symptoms of schizophrenia. Journal of Clinical 
Psychopharmacology 29:255-258. 
Serova L, Tillinger A, Alaluf M, Laukova M, Keegan K, Sabban E (2013) Single 
intranasal neuropeptide Y infusion attenuates development of PTSD-like 
symptoms to traumatic stress in rats. Neuroscience 236:298-312. 
Services TDoHH (2009) HCUP facts and figures: Statistics on hospital-based care in the 
United States. 
Sgoifo A, Koolhaas J, Musso E, De Boer S (1999) Different sympathovagal modulation 
of heart rate during social and nonsocial stress episodes in wild-type rats. 
Physiology & Behavior 67:733-738. 
Shalev A, Roitman P, Mechoulam R (2013) Pilot open label trial on oral absorbable 
delta9-THC for chronic PTSD. Israel Society for Biological Psychiatry abstract 
book Hagoshrim, Israel; 2013. 
Shinba T, Ozawa N, Yoshii M, Yamamoto K (2010) Delayed increase of brain 
noradrenaline after acute footshock stress in rats. Neurochemical Research 35. 
Southwick SM, Bremner JD, Rasmusson A, Morgan III CA, Arnsten A, Charney DS 
(1999) Role of norepinephrine in the pathophysiology and treatment of 
posttraumatic stress disorder. Biological Psychiatry 46:1192-1204. 
Steiner H, Bonner TI, Zimmer A, Kitai S, Zimmer A (1999) Altered gene expression in 
striatal projectio neurons in CB1 cannabinoid receptor knockout mice. 
Proceedings of the National Academy of Sciences USA 5786-5790. 
Steiner MA, Wanisch K, Monory K, Marsicano G, Borroni E, Bachli H, Holsboer F, Lutz 
B, Wotjak CT (2008) Impaired cannabinoid receptor type 1 signaling interferes 
with stress-coping behavior in mice. Pharmacogenomics Journal 8:196-208. 
	   202	  	  
Steiner MA, Wotjak CT (2008) Role of the endocannabinoid system in regulation of the 
hypothalamic-pituitary-adrenocortical axis. Progress in Brain Research 170:397-
432. 
Sugiura T (2009) Physiological roles of 2-arachidonoylglycerol, an endogenous 
cannabinoid receptor ligand. Biofactors 35:88-97. 
Swaab D, Bao A, Lucassen P (2005) The stress system in the human brain in depression 
and neurodegeneration. Ageing Research Reviews 4:141-194. 
Taylor H, Freeman M, Cates M (2008) Prazosin for treatment of nightmares related to 
posttraumatic stress disorder. American Journal of Health-System Pharmacology 
65:716-722. 
Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007) 
Cannabidiol displays unexpectidly high potency as an antagonist of CB1 and CB2 
receptor agonists in vitro. British Journal of Pharmacology 150:613-623. 
Tjoumakaris SI, Rudoy CA, Peoples J, Valentino RJ, Van Bockstaele EJ (2003) Cellular 
interactions between axon terminals containing endogenous opioid peptides or 
corticotropin-releasing factor in the rat locus coeruleus and surrounding dorsal 
pontine tegmentum. The Journal of Comparative Neurology 466:445-456. 
Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin J, Nomikos G 
(2003) The CB1 receptor antagonist ST141716A selectively increases 
monoaminergic neurotransmission in the medial prefrontal cortex; implications 
for therapeutic actions. British Journal of Pharmacology 138:544-553. 
Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos G (2001) The 
cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine 
outflow in the rat anterior hypothalamus. European Journal of Pharmacology 
426:R3-4. 
Uriguen L, Perez-Rial S, Ledent C, Palomo R, Manzanares J (2004) Impaired action of 
anxiolytic drugs in mice deficient in cannabinoid CB1 receptors 
Neuropharmacology 46:966-973. 
U.S. National Institutes of Health (2008) Evaluation of the antipsychotic efficacy of 
cannabidiol in acute schizophrenic psychosis (CBD-CT1). University of Cologne. 
Bethesda, MD: National Library of Medicine (US). Available at: 
	   203	  	  
http://clinicaltrials.gov/show/NCT00628290. NLM Identifier: NCT00628290. 
[Last accessed 7 July 2014]. 
U.S. National Institutes of Health (2010) Efficacy and Safety of AVE1625 as a Co-
treatment With Antipsychotic Therapy in Schizophrenia (CONNECT). U.S. 
Sanofi. Bethesda, MD: National Library of Medicine (US). Available at: 
http://clinicaltrials.gov/ct2/show/NCT00439634. NLM Identifier: NCT00439634. 
[Last accessed 7 July 2014]. 
U.S. National Institutes of Health (2012) Add on Study on d9-THC Treatment for 
Posttraumatic Stress Disorders (PTSD) (THC_PTSD). Hadassah Medical 
Organization, Bethesda, MD. National Library of Medicine (US). Available at: 
http://clinicaltrials.gov/show/NCT00965809. NLM Identifier: NCT00965809. 
[Last accessed 3 March 2016]. 
U.S. National Institutes of Health (2013a) Evaluation Study of New Compounds With 
Potential Use in Schizophrenia (EICAS). Central Institute of Mental Health, 
Mannheim. Bethesda, MD: National Library of Medicine (US). Available at: 
http://clinicaltrials.gov/ct2/show/NCT00916201. NLM Identifier: NCT00916201. 
[Last accessed 7 July 2014]. 
U.S. National Institutes of Health (2013b) An Eight-week Study of SSR411298 as 
Treatment for Major Depressive Disorder in Elderly Patients (FIDELIO). Sanofi. 
Bethesda, MD: National Library of Medicine (US). Available at: 
http://clinicaltrials.gov/ct2/show/NCT00822744. NLM Identifier: NCT00822744. 
[Last accessed 7 July 2014]. 
U.S. National Institutes of Health (2014a) A study of GWP42003 as an adjunctive 
therapy in the first line treatment of schizophrenia or related psychotic disorder. 
GW Pharmaceuticals Ltd. Bethesda, MD. National Library of Medicine (US). 
Available at: http://clinicaltrials.gov/show/NCT02006628. NLM Identifier: 
NCT02006628. [Last accessed 7 July 2014]. 
U.S. National Institutes of Health (2014b) Integrated CBT for Cannabis Dependence 
With Co-occurring Anxiety Disorders. Louisiana State University and A&M 
College. Bethesda, MD: National Library of Medicine (US). Available at: 
	   204	  	  
http://clinicaltrials.gov/ct2/show/NCT01875796. NLM Identifier: NCT01875796. 
[Last accessed 7 July 2014]. 
U.S. National Institutes of Health (2014c) A Randomized Study of Sativex on Cognitive 
Function and Mood: Multiple Sclerosis Patients. GW Pharmaceuticals Ltd. 
Bethesda, MD: National Library of Medicine (US). Available at: 
http://clinicaltrials.gov/ct2/show/NCT01964547. NLM Identifier: NCT01964547. 
[Last accessed 7 July 2014]. 
Valentino RJ, Bangasser DA, Van Bockstaele EJ (2013) Sex-biased stress signaling: the 
corticotropin-releasing factor receptor as a model. Molecular Pharmacology 
83:737-745. 
Valentino RJ, Curtis A, Page ME, Pavcovich LA, Florin-Lechner S (1997) Activation of 
the locus coeruleus brain noradrenergic system during stress: circuitry, 
consequences, and regulation. Advances in Pharmacology 42:781-784. 
Valentino RJ, Van Bockstaele EJ (2005) Functional interactions between stress 
neuromediators and the locus coeruleus-norepinephrine system. Techniques in the 
Behavioral and Neural Sciences 15:465-486. 
Valentino RJ, Van Bockstaele EJ (2008) Convergent regulation of locus coeruleus 
activity as an adaptive response to stress. European Journal of Pharmacology 
583:194-203. 
Van Bockstaele EJ, Bajic D, Proudfit H, Valentino RJ (2001) Topographic architecture of 
stress-related pathways targeting the noradrenergic locus coeruleus. Physiology & 
Behavior 73:273-283. 
Van Bockstaele EJ, Chan J, Pickel VM (1996) Input from central nucleus of the 
amygdala efferents to pericoerulear dendrites, some of which contain tyrosine 
hydroxylase immunoreactivity. Journal of Neuroscience 45:289-302. 
Van Bockstaele EJ, Colago EEO, Valentino RJ (1998) Amygdaloid corticotropin-
releasing factor targets locus coeruleus dendrites: substrate for the coordination of 
emotional and cognitive limbs of the stress response. Journal of 
Neuroendocrinology 10:743-757. 
	   205	  	  
Van Bockstaele EJ, Peoples J, Valentino RJ (1999) Anatomic basis for differential 
regulation of the rostrolateral peri-locus coeruleus region by limbic afferents. 
Biological Psychiatry 46:1352-1363. 
Van Bockstaele EJ, Saunders A, Commons KG, Liu XB, Peoples J (2000) Evidence for 
coexistence of enkephalin and glutamate in axon terminals and cellular sites for 
functional interactions of their receptors in the rat locus coeruleus. The Journal of 
Comparative Neurology 417:103-114. 
Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, 
Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, 
Patel KD, Sharkey KA (2005) Identification and functional characterization of 
brainstem cannabinoid CB2 receptors. Science 310:329-332. 
Veenema A, Meijer O, De Kloet E, Koolhaas J (2003) Genetic selection for coping style 
predicts stressor susceptiblity. Journal of Neuroendocrinology 15:256-267. 
Velez CN, Johnson J, Cohen PA (1989) A longitudinal analysis of selected risk factors 
for childhood psychopathology. Journal of the American Academy of Child and 
Adolescent Psychiatry 28:861-864. 
Viveros MP, Marco EM, Llorente R, Lopez-Gallardo M (2007) Endocannabinoid system 
and synaptic plasticity: implications for emotional responses. Neural Plasticity 
2007. 
Walker F, Masters L, Dielenberg R, Day T (2009) Coping with defeat: acute 
glucocorticoid and forebrain responses to social defeat vary with defeat episode 
behavior. Neuroscience 162:244-253. 
Wang H, Lupica CR (2014) Release of endogenous cannabinoids from ventral tegmental 
area dopamine neurons and the modulation of synaptic processes. Progress in 
Neuro-Psychopharmacology and Biological Psychiatry 52:24-27. 
Warner M, Reyes BA, Van Bockstaele EJ (2016) Cellular substrates for interactions 
between neuropeptide Y (NPY) and corticotropin-releasing factor (CRF) in the rat 
locus coeruleus. Society for Neuroscience poster. 
Williams J, North R (1984) Opiate receptor interactions on single locus coeruleus 
neurons. Molecular Pharmacology 26. 
	   206	  	  
Williams J, North R, Shefner S, Nishi S, Egan T (1984) Membrane properties of rat locus 
coeruleus neurons. Neuroscience 13:137-156. 
Witkin J, Tzavara E, Nomikos G (2005) A role for cannabinoid CB1 receptors in mood 
and anxiety disorders. Behavioral Pharmacology 16:315-331. 
Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, Karp B, McCutcheon 
IE, Geracioti Jr TD, DeBellis MD, Rice KC, Goldstein DS, Veldhuis JD, 
Chrousos GP, Oldfield EH, McCann SM, Gold PW (2000) Pronounced and 
sustainged central hypernoradrenergic function in major depression with 
melancholic features: relation to hypercortisolism and corticotropin-releasing 
hormone. Proceedings of the National Academy of Sciences of the United States 
of America 97:325-330. 
Wood S, Bhatnagar S (2015) Resilience to the effects of social stress: evidence from 
clinical and preclinical studies on the role of coping strategies. Neurobiology of 
Stress 1:164-173. 
Wood S, Walker H, Valentino RJ, Bhatnagar S (2010) Individual differences in reactivity 
to social stress predict susceptibility and resilience to a depressive phenotype: role 
of corticotropin-releasing factor. Neuroendocrinology 151:1795-1805. 
Wyrofsky RR, McGonigle P, Van Bockstaele EJ (2015) Drug discovery strategies that 
focus on the endocannabinoid signaling system in psychiatric disease. Expert 
Opinion on Drug Discovery 10:17-36. 
Wyrofsky RR, Reyes BAS, Van Bockstaele EJ (2017) Co-localization of the cannabinoid 
type 1 receptor with corticotropin-releasing factor-containing afferents in the 
noradrenergic nucleus locus coeruleus: implications for the cognitive limb of the 
stress response. Brain Structure & Function 1-17. 
Zafar H, Pare W, Tejani-Butt SM (1997) Effect of acute or repeated stress on behavior 
and brain norepinephrine system in Wistar-Kyoto (WKY) rats. Brain Research 
Bulletin 44:289-295. 
Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased 
mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout 
mice. Proceedings of the National Academy of Sciences USA 96:5780-5785. 
 
	   207	  	  
 
 
 
 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   208	  	  
APPENDIX A: Permission for Reuse from Taylor & Francis 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
	   209	  	  
Appendix B: Permission for Reuse from Springer Nature 
 
 
 
 
 
